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Multidrug resistant (MDR) cancers often become resistant to pharmacologically and
structurally diverse drugs by overexpressing members of the family of ATP Binding Cassette
(ABC) transporters. These membrane pumps protect normal cells by actively exporting a large
range of toxins out of the cells. Classic MDR is often correlated with the overexpression of three
well-studied mammalian ABC transporters: P-glycoprotein (P-gp), Breast Cancer Resistant
Protein (BCRP), and Multidrug Resistant Protein 1 (MRP1).
P-gp is the most studied ABC transporter, and the search for P-gp inhibitors as cotherapeutics to combat MDR has had little success after decades of studies. We previously used
high-throughput in silico ligand docking studies and identified drug-like compounds that reversed
MDR in human cancers cell lines. Other compounds were more recently found that also reversed
MDR in cancer cells, but interestingly, not all of them were recognized in the biochemical ATPase
inhibition assays

1, 2

. One reason why the biochemical screens did not identify these compounds

may be that the mouse P-gp homolog used in the biochemical test may be sufficiently different
from human P-gp, making the mouse protein non-representative. We have established methods to
successfully incorporate P-gp into membrane nanodiscs with high recovery yields and increases
in activity and stability. The human MDR1-clone initially available in our lab exhibited low protein
v

yield during purification making it undesirable for further experimentation. A newly constructed
MDR1 clone, codon-optimized for expression in P. pastoris, was transformed into regular (GS115)
and high expression (PichiaPinkTM) Pichia pastoris systems in attempts to obtain higher protein
yield to proceed with further experiments. Both new P. pastoris strains containing human MDR1
failed to express P-gp. Finally, P. pastoris cells expressing the human wild-type MDR1 P-gp were
provided by Dr. Ina L. Urbatsch (Texas Tech University Health Science Center). The enzyme was
successfully purified in our lab. To improve the overall enzymatic activity of P-gp, several lipid
activation tests and assembly into nanodisc with different lipid content were tested for the
optimized activity improvement of the protein. P-gp reconstituted into nanodiscs were used to
evaluate the potential of our newly discovered drug-like compound to serve as inhibitors of human
P-gp ATP hydrolysis activity.
Here we also reported our attempts to optimize the expression and purification of BCRP
from Pichia pastoris cells.
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CHAPTER 1
BACKGROUND

1.1 ABC transporters and their role in multidrug resistance in cancer cells
Multidrug resistance (MDR) is an important phenomenon of significant medical
consequence in the chemotherapeutic treatment of cancer. It has been linked to the failure of
chemotherapy, poor prognosis, and reduced survival rates in patients with several cancer types 310

In MDR, the cancer cells become resistant to pharmacologically and structurally diverse
drugs 3, 9, 11-13, often by overexpressing members of a family of membrane pump proteins. These
resistances may be inherent or acquired 9, 10, 14; in that some cancers may develop from tissues that
naturally express high levels of particular membrane pumps and other cancers that have been
exposed to one cytotoxic agent develop cross-resistance to a great range of structurally and
functionally unrelated compounds by the induction of expression of particular membrane pumps
8, 10, 12, 15

.

MDR can also occur as an intrinsically stable change within the cell, altering the drug’s
cellular target or increasing repair of the drug-induced damage or activating detoxifying systems
such as cytochrome P450

12, 16

. Other examples of MDR are the malignant transformation that

results in defective apoptotic pathways

12, 16-18

. These MDRs are potentially achieved without

previous chemotherapeutic agent exposure 10, 12 (figure 1).

1

The above-mentioned membrane pump proteins usually are responsible for protecting
normal cells from xenobiotic attack by exporting a large range of toxins out of the cell.
Unfortunately, in tumor cells, overexpression of these pumps causes MDR by preventing the
accumulation of cytotoxic drugs in cells 8, 19 by the action of these energy-dependent unidirectional
drug efflux pumps.

Figure 1. 1: Cellular mechanisms of multidrug resistance (MDR)12
Classic MDR is frequently associated with overexpression of the best-studied mammalian
ATP Binding Cassette (ABC) transporter, P-glycoprotein (P-gp), the product of the MDR1 gene
in humans. P-gp is constitutively expressed in various normal human tissues implying an important
role in excreting xenobiotics and metabolites. For this reason, it also results in the increased efflux
of chemotherapeutics from cancer cells derived from these tissues 12, 15, 19-23.
1.2 The role of P-glycoprotein in cancer multidrug resistance (MDR)
P-glycoprotein is responsible for transporting chemotherapeutic drugs and other
hydrophobic compounds outward across the plasma membrane in an ATP-dependent process

2

24-

27

. One of the most interesting features of P-gp is that it can recognize and transport drugs with a

wide array of chemical structures, including a large variety of hydrophobic compounds with
neutral or positive charge 3, 20, 21, 28.
P-gp in humans is a 170-kD plasma membrane protein of 1280 amino acid residues,
expressed from the multidrug resistance protein 1 (MDR1) gene, as a member of the ABC
transporter family, subclass ABCB1 3, 22, 29, 30. A molecular model of P-gp protein generated in
our lab is shown in figure 1a

31

.

P-gp exists as a single polypeptide that contains two

transmembrane domains (TMDs), with six transmembrane α-helices each, and two nucleotide
binding domains (NBDs). It can be seen as divided into two relatively symmetrical halves
connected by a linker peptide and presenting a TMD1-NDB1-TMD2-NBD2 topology (Fig. 1 b) 12,
32-37

. The drug binding sites (DBS) for transport substrates are formed by the interaction of the

residues from the helices 4, 5, 6 from TMD1 and 9, 10, 11, and 12 from TMD2 37-44.

3

Figure 1. 2: The P-glycoprotein structure
(a) A molecular model of P-glycoprotein generated by McCormick JW, Vogel PD, Wise JG.
Biochemistry 2015 31. On the left, NBD is open to the inside of the cell conformation, while the
TMDs are closed to the outside. On the right, the NBDs are in closed conformation while the
TMDs are wide open to the outside. In red and blue solid spheres, two P-gp substrates are shown
that seem ready to be released from the proteins on the extracellular side of the cell. (b) Topological
model of P-gp showing the two homologous halves, each with a TMD containing six TM helices
and one NBD. From Sharom et al., 201136.

The NBDs and the TMDs of P-gp and other ABC transporters appear to undergo very large
conformational changes during the catalytic cycle 45-52. Based on crystal structures of homologs in
various conformations 45, 53-55, targeted molecular dynamics studies of human P-gp were performed
by Wise

33

to elucidate catalytically relevant structures of P-gp and its conformational changes.

Transitions from conformations wide open to the cytoplasm to conformations wide open to the
extracellular space were studied 33. Some previous structural models showed closed NBD dimers
with nucleotides bound at each site while the TMDs are opened to the exterior of the cell 54-56. At
the same time, in nucleotide-free structures, the TMDs are disengaged and sometimes widely
separated. According to Senior & Bhagat

57

, two non-simultaneous ATP hydrolysis events are

needed to transport one drug molecule. Firstly, the binding of the transport substrate to the
transmembrane regions stimulates the ATPase activity of P-gp, which then causes the

4

conformational change that releases the substrate

58

. Then the hydrolysis at the second ATP site

reset the transporter allowing it to bind substrate again and completing one catalytic cycle
the studies by Wise

33

59

. In

, the coupled movement of NBDs and TMDs observed may support the

hypothesis that ATP hydrolysis is stimulated in the presence of drugs that are transported.
According to previous studies
drug transport

51, 52, 61-63

60, 61

, inactivation of one NDB blocks the ATP hydrolysis and the

, suggesting that P-gp requires the energy from ATP binding and

hydrolysis in both NBDs to drive drug transport across the membrane

33, 60, 64, 65

. McCormick et

al.. 31 used the chemotherapeutic daunorubicin and the antihypertensive agent verapamil, both Pgp substrates, in simulation experiments to observe transport substrate movements cytoplasmic to
extracellular positions. Although both drugs were docked within the cytoplasmic leaflet part of the
cell membrane, there was a preferred binding of each substrate to different subsites within the drug
binding domain (DBD) of P-gp in the open to the cytoplasmic conformation: Daunorubicin
preferentially bound to residues on TM helices 1, 2, 3, 6, and 11 and verapamil mainly used
residues on TM helices 4, 5, 6, 7, 8 and 12. The two different drug transport pathways observed
in these experiments suggested that there was not only one single defined path of contact that
drives a transport substrate out of the cell 31. The understanding of the catalytic mechanism of Pgp is critical to the development of inhibitors that might overcome the MDR 33.
P-gp has been investigated as a pharmacological target for improving cancer treatment
since its discovery. For a review, see 66. Inhibiting P-gp as a method to reverse MDR in cancer
patients has been studied extensively, but despite three decades of effort, it has had relatively little
success 3.
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1.3 The search for P-glycoprotein inhibitors
P-gp requires ATP-hydrolysis in the NBDs to catalyze the transport of a broad range of
compounds across the plasma membrane and out of the cell

28

. Although transport substrate

appears to bind to multiple binding sites within the TMDs, most of the P-gp substrates are
hydrophobic, suggesting that partitioning into the lipid membrane may be a rate-limiting step for
the interaction of a substrate with the active site of P-gp 67.
Many P-gp inhibitors previously identified as potential co-therapeutics for MDR diseases,
described in Binkhathlan

3, 9, 16

, have failed in clinical trials

3, 16

. Many of these inhibitors were

found to compete for binding with the drug transport substrate in the DBDs of P-gp as its transport
substrate. For this reason, high concentrations are needed for efficacy, likely contributing to
toxicities that limited the success in clinical trials

16

. Besides these problems, several of these

agents were also good substrates for CYP3A enzymes, the most abundant group of the cytochrome
P450 (CYP) metabolizing enzymes responsible for catalyzing many reactions involved in drug
metabolism. This characteristic would likely alter the pharmacokinetics of other drugs, i.e., coadministered cancer chemotherapeutics 3, 68, 69.
Many studies have shown that drug binding to the TMDs stimulates ATP hydrolysis in the
NBDs 33, 64, 65, 70. Since substrate transport is ATP dependent, inhibition of the power source of the
transporter is thought to stop the catalytic cycle preventing the efflux pump-out activity. Brewer
et al.. 70 hypothesized that molecules that strongly interact with ATP binding domains of P-gp or
disrupt nucleotide binding but do not bind well to the DBDs would make better drug leads for
inhibiting P-gp reversing MDR than those previously investigated.
Identifying potential inhibitors that would interact with the NBDs of P-gp, the targeted
molecular dynamics techniques mentioned previously 33, were used to visualize structural changes

6

in human P-gp during its transition from one conformational state to another during the catalytic
transport cycle. One specific conformation of P-gp that corresponded to a structural conformation
of P-gp where the NBDs are fully engaged, and the DBDs were partially open outward was initially
chosen as a protein target for docking analysis

70

. In general, docking studies can predict the

preferred orientation of one molecule towards a macromolecule when they are bound to each other
to form a stable complex 71. High-throughput computational screens of a very large database of
drug-like molecules from the ZINC website 72, 73 were employed to identify the best predicted hit
compounds for the in silico docking experiments 70. Using this new computational hit discovery
approach, with the chosen human P-gp structural conformation, ~ 300 compounds were identified
that were predicted to bind preferentially to the NBD but not well to the DBD of P-gp

70

. Initially,

35 of these compounds (numbered 11-45) were purchased and tested in in vitro biochemical assays
for the capability to stimulate or inhibit ATP hydrolysis activity by purified P-gp 70. These steadystate assays utilized a coupled enzyme assay described in

74

and adopted 96 well format as

described in 70.
The spectroscopic activity assay for ATP hydrolyzing enzymes described in 70, 74, 75 couples
the hydrolysis of ATP by P-gp to the oxidation of NADH to NAD+ through reactions of pyruvate
kinase (PK) and lactate dehydrogenase (LDH). This assay was adapted from

74

. ATP hydrolysis

by P-gp was stimulated by the transport substrate verapamil, a calcium channel blocker. Verapamil
inhibits the P-gp catalyzed transport of other substrates by competing for the transport cycles 3.
Low levels of P-gp unstimulated ATP hydrolysis (basal activity) can be observed with hydrolysis
assays performed in the absence of transportable substrates. In Brewer et al. 70, compounds that
did not stimulate basal ATP hydrolysis and inhibited verapamil-stimulated ATPase activity were
further analyzed. Four of the 35 compounds initially tested (compounds 19, 29, 34, and 45)

7

achieved the desirable condition of inhibiting verapamil stimulated ATP hydrolysis by P-gp 70. In
contrast, they did not stimulate basal hydrolysis rates at either ATP concentrations tested,
suggesting no interactions with DBDs 70.
Electron spin resonance (ESR) studies were then performed to confirm whether these four
compounds interacted with the NBDs of P-gp 70. ESR is a very sensitive spectroscopic technique
that detects species with unpaired electrons, taking advantage of their magnetic moments. Its
surroundings modify the magnetic behavior of the electron. Biological samples usually lack
paramagnetic species, and so they are silent in ESR spectroscopy. Fortunately, this lack of
naturally occurring radicals allows the site-specific attachment of stable radicals, spin-labels (SL),
as reporter groups to larger molecules and have been used by our group to study multidrug
resistance proteins

75, 76

. The method is highly sensitive to conformational changes occurring

within the vicinity of these spin-labels, thus providing important information about the structural
environment of the label and dynamic conformation processes during substrate binding and often
during enzymatic turnovers 75-78. Titration experiments using a spin-labeled analog of ATP 79 were
used in

70

in equilibrium binding studies to determine whether the compounds affected ATP

binding to P-gp. Undefined mixtures of spin-labeled ATP and spin-labeled ADP are called SLANP. The protein-bound SL-ANP and free SL-ANP have different well-resolved ESR spectra
allowing the measurement of the concentration of the protein-bound SL-ANP and the dynamics
and conformational properties of P-gp under compound inhibition conditions
studies in

70

70, 76

. The ESR

showed that compounds 19, 34, and 45 indeed affected nucleotide binding by P-gp

and, together with inhibitor docking results, suggested that the inhibitors interacted directly with
P-gp close to the nucleotide-binding sites. Compound 29 did not affect nucleotide binding but still

8

caused inhibition of ATP hydrolysis, possibly by blocking crucial conformational transitions of
the enzyme 70.
The evaluation of these four P-gp inhibitors to elucidate their potential as pharmaceutical
lead compounds was reported in 80. The intrinsic cytotoxicity and ability to re-sensitize an MDR
prostate cancer cell line were assessed. Compounds 29, 34, and 45 restored paclitaxel sensitivity
in the MDR prostate cancer cell line 80. These compounds were also shown to reverse MDR caused
by P-gp over-expression in ovarian and colon cancer cell lines (unpublished). The success of these
inhibitors in cell culture demonstrated that the in silico subtractive screening methods employed
and the subsequent biochemical and biophysical evaluation have great potential to identify
potential drug-like compounds as P-gp inhibitors. In work not yet published (manuscript in
preparation), additional compounds from enhanced in silico screens demonstrated a similar
reversal of MDR in prostate cancer cell lines. However, some of these compounds did not affect
ATP hydrolysis when assayed using mouse P-gp (encoded by the mouse MDR3 gene) that had all
cysteines mutated to alanines (cysteine-less protein). This mouse P-gp is significantly more stable
than the human homolog

81

, and its expression in yeast and subsequent purification was well

established in the lab.
Co-crystal structures and molecular dynamics studies, with or without substrates and
inhibitors, have provided a glimpse of the interactions between some bound inhibitors and the drug
binding sites 33, 45. Still, much work remains for a full understanding of the molecular mechanism
of drug export. For this reason, large-scale production of the fully functional protein is essential
82

.
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1.4 Rationale
The search for P-gp inhibitors as co-therapeutics to combat MDR has had relatively little
success despite decades of effort. High-throughput in silico ligand docking studies were used by
us to identify a number of drug-like compounds as potential inhibitors 70. Biochemical assays
74, 76, 83

70,

using purified P-gp provide important information regarding the mechanism of inhibition

and have been used as a primary screen in our drug discovery process.
After the successful reversal of the multidrug resistance phenotype in human cell culture
assays using molecules identified by these procedures

80

, biochemical assays, previously made

using the mdr3 cysteine-less mouse P-gp, need to be performed also in MDR1 human P-gp
incorporated into nanodiscs. We hypothesize that the comparison between results obtained with
these two P-gp variants will help elucidate whether important differences between mouse and
human P-gp exist and how these differences might affect the interpretation of previous results.
Interestingly, not all the compounds that reversed MDR in cell culture were recognized in
these biochemical screens using the mouse P-gp (Chen et al., unpublished). One difficulty in these
studies was to stabilize and maintain the activity of the protein in the presence of our potential
inhibitors. We, therefore, established methods to incorporate mouse P-gp into lipid nanodiscs
85

84,

, providing a native-like phospholipid bilayer environment. The reconstitution of this P-gp (the

cysteine-less mouse P-gp mutant, “mdr3-Cl”) into nanodiscs resulted in enhanced ATPase activity
and increased stability of the enzyme. We predict that similar stabilization by nanodiscs can be
achieved using human MDR1 P-gp. In this project, we show the attempts to establish protocols to
reconstitute human P-gp into nanodiscs. Human MDR1 P-gp is well known for its great instability
when removed from its native environment. Elucidating methods for its stabilization (i.e.,
incorporation into membrane nanodiscs) will enable more accurate analysis of P-gp inhibitors that
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may reverse MDR in cancer chemotherapies. Here we also report the evaluation of the potential
of our previously discovered drug-like compounds to serve as inhibitors of human P-gp ATP
hydrolysis activity.
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CHAPTER 2
PURIFICATION AND EXPRESSION OF P-GLYCOPROTEIN MUTANTS IN THE YEAST
PICHIA PASTORIS

2.1 Introduction
The most studied of the ABC transporters is P-glycoprotein (P-gp). P-gp is expressed in
many tissues throughout the human body3-10 and is known to export a diverse range of chemicals
and toxins from the cell, preventing chemotherapeutics from accumulating to the concentration
required to kill cancer cells9-13, 23. The search of P-gp inhibitors as co-therapeutics to combat MDR
has had little success so far in producing clinically applicable drugs11, 14-16. In our lab, we had
previously used high-throughput in silico docking studies using a molecular model of the human
P-gp. We were able to identify drug-like compounds that reversed MDR in human cancers 1, 70, 80.
Expression of P-gp in the yeast Pichia pastoris in a biologically active form was previously
reported by others and our previous works45, 63, 70, 76, 86 87. Brewer et al.70 were able to test the
inhibitory effect of those initial compounds on the ATPase hydrolysis activity by purified mouse
P-gp. At the same time, assays of MDR-reversal of a prostate cancer cell line were made by Follit
et al. 80, and assays in an ovarian cancer cell line were performed by Nanayakkara 1. More recently,
computationally identified compounds were shown to reverse MDR in cancer cells and needed to
be biochemically tested on isolated P-gp (McCormick et al., unpublished).
For the biochemical evaluation of the newly found compounds, relatively large amounts of
active purified protein are needed. Membrane proteins have been a challenge to study mainly
12

because the requirement of their solubilization to maintain the target protein in a stable and
functionally active state allows purification, biochemical and biophysical assays, and structure
determination85.
Previous works reported differences in P-gp ATPase hydrolysis activity in the absence or
the presence of lipids 86. As native membrane proteins are found embedded in a lipid environment,
this variation observed on the ATPase activity of purified P-gp could be due to different intrinsic
lipid content on different preparations.
Traditionally, membrane proteins have been solubilized using detergents to form mixed
detergent-protein-lipid micelles. Detergents, however, are often protein denaturants and can
destabilize the protein. In addition, the presence of excess micelles potentially interferes with many
assay procedures 84, 85, 88, 89. Membrane proteins can also require specific types of phospholipids
to maintain active function, making detergent micelles a poor membrane mimetic 84, 85.
Liposome’s preparations have been used to incorporate membrane proteins90. However,
liposomes are large and often form unstable aggregates and are difficult to prepare with precisely
controlled characteristics. Another issue is that membrane proteins can insert into liposomes in
two different orientations, and surfaces facing the lumen of the vesicle will likely be inaccessible
to ligands

84, 85

. Many membrane proteins interact with ligands or other proteins on one or both

sides of the membrane 84; with liposome preparations, as much as half of the proteins of interest
(assuming random orientation of the protein in the membrane) will have little or no possibility to
interact with other molecules and ligands. For this reason, mixed-micelles or liposomes do not
always provide the ideal environment for active membrane proteins.
Nanodiscs are soluble disk-shaped nanoscale phospholipid bilayers which self-assemble
with integral membrane proteins for biophysical, enzymatic, or structural investigations. In
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nanodisc preparation, when detergent is removed, the target proteins assemble with phospholipids
and an encircling amphipathic protein belt formed by two units of a protein called membrane
scaffold protein (MSP) (fig. 1). The diameter of the MSP belt will control the overall nanodisc size
84, 85, 89

.
The resultant nanodiscs allow solubilization of membrane proteins and offer advantages

over liposomes or detergent micelles not only in terms of size and stability, but the native-like
phospholipid bilayer environment also provides ready access to both sides of the phospholipids.
This novel tool gives means to investigate dynamics and molecular mechanisms between the
protein and membranes, besides protein and its substrate 85.

Figure 2.1: Schematic view of nanodisc assembly.
Modified from 91. Nanodisc assemble from a mixture of detergent/phospholipid micelles and MSP
upon removal of the detergent 92.
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2.1 Results
2.1.1 Mouse P-gp purification and nanodisc assembly optimization
In our lab, we have an Mdr3 cysteine-less clone that expresses relatively large amounts of
the protein. We obtained the GS115 P. pastoris strains expressing human cysteine-less mdr1 from
Dr. Alan E. Senior (University of Rochester Medical Center, Rochester, New York).
We established methods to incorporate this mouse P-gp into lipid nanodiscs 84, 85 providing
the native-like phospholipids bilayer environment to stabilize purified enzyme for our drug finding
and mechanistic studies (Chen and de Oliveira et al., manuscript in preparation).
The purification of the P-gp transporter encoded by the modified, cysteine-less mouse
MDR3 gene was previously optimized and is described in 70, 75. Further optimizations provided a
high yield of a relatively pure enzyme from the cysteine-less mouse P-gp (Fig. 2a) suitable for its
assembly into nanodiscs (Fig. 2b).
To increase the stability of the P-gp mutants for biochemical and biophysical analyses, we
have established methods to incorporate (mouse) P-gp into membrane nanodisc successfully and
were able to reconstitute the P-gp mouse cysteine-free mutant into membrane nanodiscs as
described in 84, 93.
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Figure 2. 2: “Cysteine-free” mouse P-gp (mdr3 Cl) nanodisc assembly and activity summary.
(a) SDS-PAGE Coomassie blue-stained from purified MDR3Cl. Lane 1: purified mouse MDR3Cl
P-gp. Lane 2: PageRuler™ Plus Prestained Protein Ladder, 10 to 250 kDa
(ThermoFisher Scientific TM ). (b) SDS-PAGE Coomassie blue-stained from purified MDR3Cl
assembled into Nanodisc (two different preparations - Nano 1 and Nano 2). Lanes 1 and 7: Flowthrough recovered, concentrated, and 8 µl were applied for PAGE analysis. Lanes 2 and 6: Column
Wash was recovered, concentrated, and 8 µl was applied for the PAGE analysis. Lanes 3 and 5:
Final elution containing the purified mouse P-gp assembled into nanodiscs was recovered,
concentrated, and 1µl was applied for the PAGE analysis. Lane 4: Spectra™ Multicolor Broad
Range Protein Ladder PageRuler™, 10 to 260 kDa (ThermoFisher Scientific TM ). Excess
of MSP can be observed on the bottom of the gel.
The reconstitution of mouse mdr3 cysteine-less P-gp mutant into nanodiscs resulted in
enhanced ATPase activity, and increased stability of the enzyme showed in Table 1. The maximum
protein reconstitution yield of the purified mouse P-gp into nanodiscs was 82%, the amount of Pgp that was assembled into nanodisc from the initial P-gp presented on the assembly mix (P-gp in
micelles, MSP and L-alpha-phosphatidylcholine). The specific activity increased by 10-fold for
stimulated activity (Table 1). ATP hydrolysis activity summary in Table 1 is presented as a
representative example of progressively optimized reconstitution experiments.
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Table 2. 1: ATP hydrolysis activity summary.

Nanodisc Mdr3Cl activity assay summary
P-glycoprotein

Basal Activity

Drug Stim. activity

(nmol/min/mg)

(nmol/min/mg)

-

18

110

P-gp in nanodiscs 1

74%

490

830

P-gp in nanodiscs 2

82%

570

1190

P-gp yield
preparations
P-gp in micelles

2.1.2 Human MDR1 cysteine less purification
We obtained the GS115 P. pastoris strains expressing human cysteine-less MDR1 from
Dr. Alan E. Senior (University of Rochester Medical Center, Rochester, New York).
Our original purification procedures

70, 75, 76, 86

that had been optimized for mouse mdr3

cysteine-less P-gp were unfortunately not as efficient when applied to the isolation of human P-gp
from our existing MDR1 Cl clone (Fig. 3). P-gp losses were observed during all purification steps
(Figs. 3a and 3b). Even after increased solubilization cycles, the same pattern of enzyme losses
were observed. Changes in the Ni-NTA equilibration buffer and solubilization buffer (pH 7.4 to
8) were made to increase His-tag/Ni-NTA affinity, but this also did not have much effect on P-gp
yield.
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Figure 2. 3: Human “cysteine-less” P-gp (MDR1 Cl) purification steps.
(a) SDS-PAGE Coomassie blue-stained from two MDR1Cl purifications. Lanes 1 and 7: Flowthrough recovered, concentrated, and 8 µl were applied for PAGE analysis. Lanes 2 and 6: Column
Wash was recovered, concentrated, and 8 µl was applied for the PAGE analysis. Lanes 3 and 5:
Final elution containing the purified human cysteine less P-gp was recovered, concentrated, and
1µl was applied for the PAGE analysis. Lane 4: Spectra™ Multicolor Broad Range Protein Ladder
PageRuler™, 10 to 260 kDa (ThermoFisher Scient ific TM ). (b) Western blot analysis from
each fraction of the purification steps, 10ug protein/well, C219 anti-P-gp antibody (ALX-801-002
– Enzo Life Science). Lane 1: Elution 1. Lane 2: Elution 2. Lane 3: Column wash 1. Lane 4:
Column wash 2. Lane 5: Flow-through 1. Lane 6: Flow-through 2.
After several attempts, the best results were achieved after increasing the detergent/lipid
ratio during the first solubilization step. The modified pH of the elution buffer was also maintained.
One hypothesis why poor purification was achieved was that the affinity to the histidine tag on Pgp for the Ni-NTA resin used was weak. To test this hypothesis, HisPur cobalt resin (Thermo
Fischer Scientific) was used instead of Ni-NTA. The cobalt-chelated resin performed better than
Ni-NTA Agarose (Qiagen), presenting somewhat cleaner protein after the second wash was
applied, as assessed by the SDS-PAGE Coomassie blue gel (see figure 4). Western blot analysis
indicated that both resins did not result in significant enzyme loss during purification steps.
18

However, HisPurTM Cobalt resin (Thermo Fischer Scientific) seemed to result in somewhat cleaner
protein in fewer steps (in case of additional washes were necessary) than what was achieved by
Ni-NTA agarose (Qiagen).

HisPur

Ni-NTA 1

2

3

4

TM

Cobalt -

5

6

7

Elu

2º wash

8

260
140
100
70
50

FT

1º wash

1

2

2º wash
3

Elu
4

6

7

1º wash

FT

8

Figure 2. 4: MDR1 Cl P-gp purification Ni-NTA resin versus Cobalt resin.
(a) SDS-PAGE Coomassie blue-stained from two MDR1Cl purifications using different gel resin:
On the left is Ni_NTA agarose (Qiagen), on the right is HisPurTM Cobalt resin (ThermoFisher
ScientificTM). Lanes 1 and 9: Flow-through recovered, concentrated, and 3 µl were applied for
PAGE analysis. Lanes 2 and 8: Column Wash 1 was recovered, concentrated, and 3 µl were applied
for the PAGE analysis. Lanes 3 and 7: Column Wash 2 was recovered, concentrated, and 3 µl were
applied for the PAGE analysis. Lanes 4 and 6: Final elution containing the purified human cysteine
less P-gp was recovered, concentrated, and 3 µl was applied for the PAGE analysis. Lane 5:
Spectra™ Multicolor Broad Range Protein Ladder PageRuler™, 10 to 260 kDa
(ThermoFisher Scientific TM ). (b) Western blot analysis from each fraction of the purification
steps, 10ug protein/well, C219 anti-P-gp antibody. Each lane is correspondent with the lane
presented on the Coomassie blue gel above.
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However, even after the improvements of the purification procedure, still, more wash steps
would be needed to obtain acceptably pure protein at reasonable overall protein yields for further
biochemical studies of the protein. It seemed clear that the clone available in our lab was not
providing enough starting material of the human P-gp to proceed with nanodisc assembly. Further
modifications were made during all the steps starting from yeast growth to protein purification to
obtain higher expression of this transporter. Still, none was successful enough to yield sufficient
human P-gp for nanodisc incorporation. However, it seemed to us that the lack of success in this
task made it necessary to investigate the construction of a more optimized MDR1 clone to achieve
protein yields high enough for biochemical evaluation.

2.3 Methods and materials
2.3.1 Growth of P. pastoris mouse MDR3CL P-gp and human MDR1CL P-gp:
Cells were grown using the methods previously described in

70, 75, 76, 86

. In short, a single

colony of the modified yeast strain grown on a Minimal Dextrose (MD) agar plate (1.34% Yeast
Nitrogen Base (YNB), 4x10-5% Biotin, 2% dextrose, 15g agar/L) was inoculated into 10 ml of
liquid Minimal Glycerol (MG) medium (1.34% YNB, 1% glycerol, 4x10-5% Biotin) and incubated
at 28oC with shaking to OD600 of ~2.0 (18h). After 16-18 hours, this 10 ml was added to 1 liter of
MG medium in a 2-liter Fernbach flask. Incubation at 28oC with shaking to OD600 of 2.0 to 4.0
was continued (~18h), then the cultures were centrifuged in sterile bottles (4000 rpm for 20 min at
23oC). Protein production was induced by switching the carbon source of the medium from
glycerol to methanol. The cells pellets were resuspended in 1 liter of Minimal Methanol (MM)
medium (1.34% YNB, 4x10-5% Biotin, 0,5% v/v methanol) in 2-liter Fernbach flasks covered with
cheesecloth. Incubation continued for 72h with the addition of methanol (1% v/v) at 24 and 48
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hours. The pH was adjusted to ~6.0 at these times. Cells were collected by centrifugation at 4000
x g for 10 min at 4oC and resuspended in ice-cold “homogenization buffer” (0.33 M sucrose, 0.3
M Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 2 mM DTT, 100 mM 6-aminocaproic acid) at
a concentration of 1g wet cells/ml buffer. The cells were stored at -80oC.
2.3.2 Microsome preparation from yeast cells:
Microsomes were prepared essentially as described in 86, with the modifications made in
70, 75, 76

. Frozen cells were rapidly thawed by incubating the frozen cells in a water bath set at 28-

30oC for ~10 min, swirling the bottle's content to equilibrate the temperature. All further steps
were performed at 4oC or on ice. Protease inhibitors were added once the cell suspension was
thawed as follow: 2 µg/ml pepstatin A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 350 µg/ml
PMSF (phenylmethylsulfonyl fluoride), and 10 µl/ml DTT (dithiothreitol). All the cells were
transferred to a chilled bead beater apparatus that was filled to top with “buffer A1” (30% v/v
glycerol, 50 mM Tris-HCl, pH 8, 125 mM NaCl, 10 mM imidazole) supplemented with DTT (10
µl/mL) Cells were mechanically disrupted by using 0.5 mm glass beads in a bead-beater (BioSpec)
for a total of 14 minutes. The bead-beater was attached to a jacketed chamber filled with an icesalt mixture that helped maintain the lower temperature. Cell disruption was performed in 7 cycles
of 2 minutes bead beating alternated with 6 minutes with the bead-beater “off” to allow cells to
cool down. This method helped solve the problem of overheated samples due to the high heat
output of the bead-beater motor. The homogenate was then centrifuged for 30 minutes at 10,000
rpm (at Beckman J21-M equipped with a JA-20 rotor), and the pellet was discarded. These steps
removed unbroken cells, nuclei, and mitochondrial fractions. The supernatant was centrifuged at
45,000 rpm (at Beckman Optima LE-80K equipped with Ti70 or Ti55.2) for 45 min at 4oC. After
this ultracentrifugation, the supernatant contained cytoplasmic protein and was discarded. The
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resulting pellet containing the microsomes was resuspended in “wash buffer” (20% v/v glycerol,
50 mM Tris-Cl, pH 7.4 at 4oC, and protease inhibitors – 1 mM PMSF, 1 mM DTT, Pepstatin A,
Leupeptin, and Chymostatin as above). The microsomes were recentrifuged at 45,000 rpm at
Beckman Optima LE-80K equipped with Ti 70 or Ti 55.2) for 45 min at 4oC. The supernatant was
discarded, and the pellet was resuspended initially using a paintbrush then by ten strokes by hand
in a Potter-Elvehjem Teflon pestle homogenizer in 30 ml of “buffer A1” plus protease inhibitors
as before). The microsomes were then frozen at -80oC.
2.3.3 P-gp Purification:
Purification of the transporter protein was performed essentially as described in 70, 75, 76, 86,
which successfully resulted in highly enriched mouse (mdr3-Cl) P-gp in mixed micelles. The
microsomes were quickly thawed in a circulating water bath set at 28-30oC and then eluted to a
final concentration of 4mg microsomal protein/ml with “buffer A2” (20% v/v glycerol, 50 mM
Tris-HCl, pH 8.0 at 4oC, 50 mM NaCl, 10 mM imidazole, plus protease inhibitors as follow: 2
µg/ml pepstatin A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 1 mM PMSF). Further dilution of
the sample to a final concentration of 2 mg microsomal protein/mL was achieved by adding a
volume of buffer A2 equal to a total volume of the first dilution supplemented with 1.2% (w/v) ndodecyl-β-D-maltoside, DDM (Inalco), and 0.02% (w/v) lyso-phosphatidylcholine, Lyso-PC
(Lipoid GmbH). DDM and lyso-PC were added to facilitate micelle formation, providing a more
native-like environment during the purification process. Sonication of samples at 4oC for 4 cycles
of 5 minutes each in an ultrasonic bath filled with ice/water, interspersed with 5 minutes incubation
in an ice bucket on a rocking platform, was performed to allow protein solubilization. The
suspension was then centrifuged at 20,000 rpm for 30 min at 4oC (Beckman Optima LE-80K
equipped with Ti 70 or Ti 55.2 rotors) to remove insoluble material. The supernatant was then
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applied to the pre-equilibrated Ni-NTA agarose resin (Qiagen) column at a ratio of 100 mg
microsomal protein per 1ml packing resin (one bed volume). The chromatography gel and
solubilized protein solution were mixed and incubated for 10 minutes before the column was
poured. The flow-through was ~2ml/min. The resin with bound P-gp was washed first with 20
bed-volumes of “Column wash buffer 1” (20 % glycerol (v/v), 50 mM Tris-HCl, pH 7.5 @ 4oC,
50 mM NaCl, 20 mM Imidazole, supplemented with 5 µL 20% (w/v) DDM/mL buffer; 1µL 10 %
(w/v) lyso-PC/mL buffer), followed by 10 bed-volume of “Column Wash buffer 2” (20 % glycerol
(v/v), 50 mM Tris-HCl, pH 7.5 @ 4oC, 50 mM NaCl, 40 mM Imidazole, supplemented with 5 µL
20% (w/v) DDM/mL buffer; 1 µL 10 % (w/v) lyso-PC/mL buffer). For both washes, the flowthrough was ~1ml/min. P-gp was then eluted with 3 bed-volumes of Elution buffer (20 % glycerol
(v/v), 50 mM Tris-HCl, pH 7.5 @ 4oC, 50 mM NaCl, 300 mM Imidazole, supplemented with 5
µL 20% (w/v) DDM/mL buffer; 1µL 10 % (w/v) lyso-PC/mL buffer) with a ~0.5 ml/min flow
rate. All eluted protein was collected for the next step. To obtain concentrated P-gp, the elution
fraction from the Ni-NTA column was concentrated 70- to 100-fold using Amicon centrifugal
filters (Amicon/Millipore Corp., catalog number UFC910008) a molecular mass cutoff of 100,000
Da. This procedure enriched both protein and micelles and ensured retained solubilization of the
membrane protein, resulting in concentrated, enriched, and solubilized protein for use in nanodisc
assembly. The protein was aliquoted in 40µl aliquots, ready to be used in nanodisc assembly, and
stored at -80oC.
2.3.4 Nanodisc Assembly and Recovery 84, 85:
P-gp in mixed detergent micelles obtained during protein purification was assembled with
Membrane Scaffold Protein (clone available in our lab expressed on BL21 (DE3) E. coli strain),
L-alpha-phosphatidylcholine (L-α-PC – Sigma-Aldrich), using assembly mix buffer solution of 50
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mM Tris-CL (pH 8). The detergent was removed using Bio-beads SM, HisPur Ni-NTA
chromatography was used to isolate nanodiscs, using “start buffer” (20% (v/v) glycerol, 50 mM
Tris-CL pH 7.5 at 4oC, 50 mM NaCl), and elution buffer (20% (v/v) glycerol, 50 mM Tris-Cl pH
7.5 at 4oC, 50 mM NaCl, 300 mM imidazole).
2.3.5 Assays of ATPase activity – Coupled-enzyme assay 70:
The activity assay for ATP hydrolyzing enzymes developed by Vogel & Steinhart 74 was
well established and adapted to medium-high-throughput conditions on 96-well plates 70. The assay
couples the hydrolysis of ATP by P-gp to the oxidation of NADH to NAD+ through the reaction
of pyruvate kinase and lactate dehydrogenase. The desired amount of Pgp (10 µg or more) was
added to 1 ml of cocktail (50 mM Tris-Cl, pH 8, 24 mM MgSO4, 1.94 mM PEP, 20 mM KCl,
0.058 mg/ml Pyruvate kinase (PK), 0.028 mg/ml Lactate Dehydrogenase (LDH), 0.13 mM NADH,
0.4 M ATP) +/- 150 µM verapamil in DMSO (the same volume DMSO alone was added to the
control reaction when verapamil was added to the protein samples) at 37oC. ATP hydrolysis was
recorded as absorbance decrease at 340 nm (ε=6300 M-1 cm-1), using a BioTek plate reader
(BioTek, Winooski, VT).

2.4 Discussion
Several studies 82, 86 as well as our lab have reported on the expression of P-gp in the yeast
Pichia pastoris and purified the protein in what was assumed to be a fully biologically active form.
P. pastoris yeast grows to very high densities in fermenter cultures, often providing ample source
material.
Biochemical assays using purified P-gp provide important information regarding the
mechanism of inhibition and have been used as primary screens in our drug finding process.
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In our previous work 70, the purified mouse mdr3-Cl P-gp variant in micelles was used to
identify the first set of MDR reversing compounds and investigate the mechanism underlying the
inhibition. We have successfully tested the effect of potential P-gp inhibitors on P-gp ATPase
hydrolysis activity.
As demonstrated by others 86, the intrinsic lipid content of each preparation could interfere
with the ATPase hydrolysis activity of P-gp, which we hypothesize could change the way such
inhibitors would affect P-gp ATPase activity. With this idea in mind, we have established methods
to incorporate successfully (mouse) P-gp into membrane nanodisc (fig. 2b), with a recovery yield
of P-gp reconstituted in nanodiscs around 82%, a dramatic increase in the specific basal activity
of the enzyme and up to 10-fold increase on the specific substrate stimulated activity showing a
significant increase in stability (table 1).
This successful approach brought us an optimistic possibility of testing more compounds
that were being computationally screened at that time. Some of these newly found compounds
were found to reverse MDR in cancer cells but were not recognized the same way in the
biochemical screenings (Chen et al., unpublished). One reason why the biochemical assay did not
identify these compounds may be that even though human and mouse P-gp share about 87%
identity in amino acid sequence, there may still be sufficient differences between the two proteins
that may prevent a mouse mdr3-Cl from faithfully reporting on inhibitor action on the human
protein45, 61, 82, 87.
Our next approach was to replace the mouse mdr3-Cl P-gp for a human MDR1 cysteineless variant also available in the lab. Since we were previously able to optimize the procedures for
the purification of mouse cysteine-less P-gp (mdr3-Cl) with a high yield and high purity and also
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able to improve the yield of its reconstitution into nanodiscs with enhanced ATPase activity and
increased stability, we decided to repeat our successful protocol this time.
Unfortunately, the same procedures did not show the same efficacy on the human MDR1
cysteine-less clone available in our lab (Fig. 3). After a series of modifications of the procedure
which attempted to optimize conditions for human P-gp purification (altered detergent ratios, pH
of the chromatography buffer, testing of affinity His-tag- binding to Ni- versus Co resins), and
even after all modification and finally no significant loss of the protein during the purification,
each preparation presented very modest final protein yield available from this clone that would not
support the amount of purified transporter needed for the nanodisc assembly and the following
biochemical assays (Fig. 4). The low protein yield during purification made it undesirable for
further experimentation. Bai et al.

82

suggested that codon usage bias may be one of the factors

leading to inefficient translation in Pichia, thereby limiting protein production. A codon usage
adjusted sequence of mouse P-gp-encoding mdr3 gene resulted in a significant increase in P-gp
expression 82. A high protein expression system seemed desirable to provide the required protein
yield to proceed with these studies. We hypothesize that a gene for human P-gp that has been
optimized for translation in Pichia pastoris will allow higher levels of protein expression than
observed using human DNA sequences for P-gp.
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CHAPTER 3
THE CHALLENGES OF LARGE-SCALE PRODUCTION AND PURIFICATION OF THE
ABC TRANSPORTER P-GLYCOPROTEIN (P-gp) IN THE YEAST, PICHIA PASTORIS.

3.1 Introduction
3.1.1 Recombinant P-glycoprotein
Over the last decades, researchers have learned how to manipulate DNA to identify, move
and place genes into a variety of organisms other than its original source organism and have used
these techniques mainly to produce proteins that were difficult to otherwise obtain 94, 95.
Escherichia coli has been the “factory” of choice for the expression of many proteins. Still,
as it is a prokaryote, it lacks the intracellular organelles and their associated post-translational
modification activities of eukaryotes. The endoplasmic reticulum and the Golgi apparatus are
responsible for posttranslational modifications of many eukaryotic proteins (such as glycosylation)
that may be important for protein function. For this reason, researchers have also turned to
eukaryotic yeast species for protein production 94, 95.
Pichia pastoris is a yeast, and therefore a eukaryote offers many of the advantages of
eukaryotic expression systems, such as protein processing and folding and the availability of
posttranslational modifications. Pichia pastoris can use methanol as its sole carbon source. The
utilization of methanol in the absence of glucose or glycerol induces expression from the alcohol
oxidase (AOX1) promoter, causing the expression of the gene that codes for the alcohol oxidase.
This enzyme catalyzes the first step in the metabolism of methanol94-99. This transcriptional control

of expression of alcohol oxidase has been used to genetically link the expression of a protein of
choice in several readily available expression systems.
Despite these advantages, a series of limitations and disadvantages of the P. pastoris
system have been gradually uncovered over the last 20 years:
1) The expression vectors designed to integrate into the Pichia chromosome may enable
stable expression but with very low transformation efficiencies because the vector must
both enter the cell and integrate into specific locations in the host chromosome, both of
which are inherently inefficient processes 94, 100-103.
2) Proteases are secreted in the medium during Pichia fermentation, allowing the
degradation of the desired protein 102.
3) After the transformation of P. pastoris, lower expression levels than desired may be
observed in the transformants 102.
4) Most of the alcohol oxidase activity in the cell is attributable to the AOX1 gene. Still,
in some transformants, a second gene, AOX2, may be used, which is harder to induce
using methanol at a much slower rate 82, 104-106.
Previously, we had expressed different versions of human P-gp and a mouse homologous
protein in Pichia pastoris (Invitrogen, GS115 strain 98) and purified the protein in a biochemically
active form. This yeast grows to very high densities in fermenter or flask cultures providing ample
cellular material. However, the modest expression level of the human variant of this integral
membrane protein still presented undesirably low yields in protein production in several previous
works 75, 76.
Bai et al. 82 suggested that codon usage bias may be one of the factors leading to inefficient
translation in Pichia, thereby limiting protein production. In the mentioned study, a codon usage
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adjusted sequence of mouse P-gp-encoding mdr3 gene resulted in a significant increase in P-gp
expression. We hypothesize that a gene for human P-gp optimized for translation in Pichia pastoris
would allow higher protein expression levels than observed using human DNA sequences for Pgp.

3.1.2 The PichiaPinkTM system:
To overcome the disadvantages of low protein expression, a new P. pastoris system called
PichiaPinkTM has been reported 94, 98, 99. This new system based on Pichia pastoris is suggested for
high-level (g/liter) and large scale (1000+ liter) production of recombinant proteins 98 and supplies
a new and efficient way to screen high-expression transformants 94, 98.
The strains in the PichiaPinkTM system contain a full deletion of the ADE2 gene 94, 98, 107109

and are unable to grow in the absence of adenine (ADE2 auxotroph). The ADE2 gene encodes

phosphoribosylaminoimidazole carboxylase, an enzyme that catalyzes the sixth step in the de novo
biosynthesis of purine nucleotides 94, 98, 107-110. The host PichiaPinkTM strain is an ade2 knockout
and is autotrophic for adenine. Insufficient transformation or integration of ADE2 encoding vector
DNA then results in the accumulation of red-colored purine precursors in the vacuoles of the cells.
Colonies with low levels of the integrated vector will be pink or red, while colonies with higher
levels of integration of ADE2 will appear white

110, 111

. The available PichiaPinkTM plasmids

include the wildtype ADE2 gene for complementation, ensuring high stability of transformants
after chromosomal integration and easy identification when selected in minimal media lacking
adenine. They also contain convenient restriction sites for cloning of the gene of interest under the
control of the AOX1 promoter 94, 98, 108, 109. The chromosomal integration of the gene of interest in
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this system also ensures clonal stability during scale-up for protein expression when rich media
are employed.
To reduce the impact of proteases and the need for heavy protease inhibitor use, three
protease knockout strains are available for use along with a protease normal Pichia strain. These
strains include a pep4 knockout, which prevents it from synthesizing protease A, a prb1 knockout,
which prevents it from synthesizing protease B, and a pep4 prb1 double knockout

98, 112

. These

strains should allow for screening of transformant-integrant with minimal P-gp protein degradation
and may help conserve expensive protease inhibitors that have been normally required.
The system includes a choice between two cloning vectors with different ADE2 promoter
strengths, pPink-HC and pPink-LC (high and low-copy number expression). The promoter
deletion in the HC vector decreases the expression of the ADE2 gene product, necessitating
additional copies for adequate complementation and loss of the red phenotype. Again, the color
of the colonies will indicate relative expression levels of the protein of interest since the colony
color depends on the copy number of the integrated plasmid 98.
Furthermore, in the expression plasmids of this system, only the AOX1 promoter is used to
drive expression of the gene of interest encoding the desired heterologous protein, avoiding the
adverse influence of the AOX2 promoter observed in some earlier vectors 98.
With all these combined advantageous features of the PichiaPinkTM vectors (figure 3.1),
we hoped to achieve the desired high expression from our recombinant MDR1 yeast strain.
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Figure 3 1: PichiaPink cloning vectors pPink vectors.
pPink-LC and pPink-HC vectors, including the ADE2 gene for complementation, AOX1 promoter
(AOX1p), and the restriction endonucleases sites for EcoRI and KpnI in their multiple cloning
sites98.
3.1.3 The Pichia pastoris GS115 strain
GS115 is a mutant strain of P. pastoris that contains a defective histidinol dehydrogenase
(his4) that prevents histidine synthesis113. GS115 His- cannot grow on a minimal medium unless
it is supplemented with histidine. A plasmid vector containing the wild-type HIS4 gene would
work as a selective marker of mutants on a minimal medium.
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Figure 3 2: Restriction map of the plasmid pHIL-D2

In this system, depending on the plasmid of choice, there is a different integration process99.
Transformation of the GS115 P. pastoris cells with linearized pHIL-D2 (figure 3.2) favors gene
replacement from a double crossover event between the AOX1 promoter and the 3’ AOX1 regions
of the vector and genome (figure 3.3), causing a complete removal of the AOX1 coding region.
The loss of the AOX1 gene results in the Muts (Methanol utilization slow) strain that exhibits poor
growth on a minimal medium containing methanol as the sole carbon source. With pHIL
containing the wild-type HIS4, the resulting phenotype of successful recombinants will be His+
and Muts. With two different markers (His and Mut), the chances of identifying and select
successful recombinants are higher than if the selection was based on one marker.
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Figure 3 3: Gene replacement at AOX1 in GS115 – image reproduced by the manual (Invitrogen)

3.2 Results
3.2.1 Cloning human P-gp into the PichiaPinkTM system
Previous work has shown that codon optimization of MDR3 P-gp resulted in increased
protein yield82. The new MDR1 clone was designed with optimized codon usage for translation in
P. pastoris was commercially synthesized and cloned by using in-house programs at GenScript,
Piscataway, NJ. The codon optimization was assessed using the “Graphical Codon Usage
Analyzer” at http://gcua.schoedl.de/.
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Figure 3 4: Schematic view of the codon-optimized MDR1 gene, MDR1-subsites2.
A Kozak sequence was incorporated on the 5’end of the reading frame, while EcoRI and KpnI
restriction sites were incorporated at each end of the construct. Single unique sites for Pstl, Xmal,
Apal, and SalI were incorporated, allowing cloning of subsections of the gene. The DNA was
synthesized using standard Gibson assembly methods.

The optimized MDR1 gene sequence that encodes for the human P-gp protein sequence
(figure 3.4) was designed with a strong Kozak sequence on the 5’end of the reading frame, and
EcoRI and KpnI restriction sites were incorporated at each end of the construct for force cloning
into pUC57 (figure 3.5) and pPink vectors (figure 3.1). In addition, four internal unique restriction
sites for Pstl, XmaI, Apal, and SalI were incorporated into the P-gp DNA sequence by silent
mutations that together with unique 5’EcoRI and 3’KpnI sites allow the subcloning of 5 (five)
approximately equal-sized subsections of the gene for facile troubleshooting and mutagenesis.
After these design elements were incorporated in the sequence, the DNA was synthesized by
GenScript using standard Gibson assembly methods114. pUC57 was used as a cloning vector for
this initial DNA construct (figure 3.5, left panel). Transformation into CopyCutterTM EPI400TM
Electrocompetent E.coli (EPICENTRE)

115

allowed replication of the multicopy pUC57–MDR1

plasmid (figure 3.5, right panel).
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Figure 3 5: pUC57 DNA plasmids
pUC57 plasmid (2710 bps - GenScript) and pUC57-MDR1-subsites2 plasmid (6576 bps)

The initial growth of the E. coli strain containing the pUC57-MDR1-subsites2 plasmid in
attempts to isolate the multicopy plasmid failed (figure 3.6 b). Difficulties in the replication and
maintenance of MDR1 gene sequences in E. coli, especially on high copy number plasmids, have
been observed by us previously. The E. coli strain containing the pUC57-MDR1-subsites2 plasmid
was allowed to grow, and the plasmid was prepared according to the ZymoTM Plasmid Miniprep
protocol (Zymo Research).

These preparations were then digested with the restriction

endonucleases EcoRI and KpnI. It was possible to see faint bands of our desired 3866 bps insert
size (figure 3.6 c). Still, it was clear that it would not be possible to obtain the desired amount of
DNA to proceed with these traditional cloning approaches.
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Figure 3 6: pUC57-MDR1 subsites2 plasmids
(a) Comparison of GeneRuler (GR) 1 Kb DNA ladder (ThermoFisher ScientificsTM) and
Supercoiled (SC) DNA ladder (NEB). (b) Plasmid preparation after different induction growth
conditions in EPI400 E. coli Electrocompetent strain. Lane 1: GeneRuler (GR) 1 Kb DNA ladder
(ThermoFisher ScientificsTM); Lane 2: pUC57-MDR1-subsites2 plasmid after use induction
solution; Lane 3: pUC57-MDR1-subsites2 plasmid IPTG induced; Lane 4 and 5: pUC57-MDR1subsites2 plasmid uninduced. (c) Restriction endonuclease digestions - EcoRI/KpnI – pUC57MDR1-subsites2. Lane 1: plasmid pUC57-MDR1-subsites2 uncut (6576 bps). The correct plasmid
size is shown with a dashed arrow. See (a) for Supercoiled (SC)DNA ladder (NEB); Lane 2:
pUC57-MDR1-subsites2 single cut KpnI; Lane 3: pUC57-MDR1-subsites2 double-cut
EcoRI/KpnI top arrow presents the 3866 bps insert, bottom arrow presents the 2710 bps plasmid
pUC57; Lane 4: GeneRuler (GR) 1 Kb DNA ladder (ThermoFisher ScientificsTM).

The MDR1-subsite2 DNA (3866 bps) was then amplified by polymerase chain reaction
(PCR) using M13 universal primers (figure not shown) in attempts at salvaging the synthesized
gene. In experiments aimed at cloning the insert DNA directly into pPink vectors, the PCR product
of these reactions was digested with EcoRI and KpnI for insertion into the pPink plasmids. The
vector DNA was 5’ dephosphorylated by Shrimp Alkaline Phosphatase (rSAP) (New England
Biolabs). EcoRI/KpnI cut PCR fragment was then ligated into the pPink plasmid
dephosphorylated, double-cut DNA before transformation into E. coli DH5α and NEB Stable
strains (figure 3.7).
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Figure 3 7 – pPinkHC vector/MDR1-subsites 2 insert ligation attempts.
(A) schematic representation of the ligation experiment attempts. (B) Ligation 5:1 PCR product
using AOX1for and CYC1rev pPink primers and Hot Start Taq2X Master Mix (NEB).

The first cloning attempt used a 3:1 insert/vector ratio and the quick ligation kit from New
England Biolabs. After transformation into NEB® Stable competent E. coli high-efficiency cells,
no ampicillin-resistant transformants were observed (figure 3.7 a, top). A second ligation attempt
was made with a 3:1 insert/vector ratio, and the ligated product was then used to transform not
only the Stable E. coli high-efficiency competent cells (NEB) but also NEB® 5-alpha Competent
E. coli to test whether the previous ligation/transformation result was due a strain dependence
issue. There was no growth of transformants on NEB® 5-alpha Competent E. coli plates except for
the LB agar plate ‘cells only’ control showing there was good viability of the cells. There were
few small colonies growing on NEB® Stable competent E. coli high-efficiency cells in the
experimental plates (figure 3.7 a, middle). These colonies were inoculated in Luria-Bertani (LB)
broth media with ampicillin for overnight cultures followed by plasmid preparations the next day
performed according to the ZymoTM Plasmid Miniprep protocol (Zymo Research). The
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preparations were size screened in a 0.6% agarose gel electrophoresis, and the plasmids presented
a pattern similar to the one presented by the pPink vector-only control (figure not shown).
A third attempt was made using a 5:1 insert/vector ratio, and the transformation was made
again in NEB® Stable competent E. coli high-efficiency cells. PCR amplified the ligation mixture
to assess whether the desired construct was present in the ligation using primers complementary
to vector DNA that flanked the insert. A very faint band was observed on agarose gel after
electrophoresis of the PCR samples (figure 3.7 b), suggesting that the desired ligation product was
present. The yield of desired product was likely not sufficient to the success of the experiment,
however, since most of the subsequently isolated transformed plasmids were again almost identical
in size to the vector-only control, ~ 7,732 bps, instead of the 11,585-bps predicted for the
successful vector insert (figure 3.8). In control experiments with dephosphorylated vector DNA
subjected to ligation, no transformants were observed, suggesting that the dephosphorylation
performed before the ligation successfully prevented the vector self-ligation.
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Figure 3 8: Plasmid prep from NEB® Stable competent E. coli high-efficiency cells /pPinkHCMDR1 or pPINKLC-MDR1.
The top gels are pPinkLC-MDR1, and the bottom gels are pPinkHC-MDR1 (except on the bottom
right pPinkLC-MDR1 #4.5. The first number indicates the colony's plate, and the second number
shows the number of the colony picked.

Additional transformation experiments were performed, and the plasmid preparations of
pPinkHC-MDR1 show DNA rearrangements after transformation into the E. coli strain NEB
StableTM (figure 3.8). Control vector pPinkHC only makes it clear that the plasmid size is almost
identical to the vector only in most of the preps. λ DNA/HindIII Marker DNA ladder and
Supercoiled DNA ladder on the left side. (Add expected size for the correct plasmid).
The difficulties in obtaining the correct pPinkHC-MDR1 plasmid made us believe that the
full MDR1-subsites2 DNA sequence could be potentially toxic. We then decided to start the
subcloning of the MDR1-subsites2 DNA fragment to find a more stable way to combine the MDR1
DNA sequence and the plasmid cloning vector.
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As we did not know which fragment or combination of fragments could cause the
rearrangements, each section was tested separately to investigate the problem.
The gene sequence MDR1-subsites2 was designed to contain 4 internal unique restriction
sites, allowing 5 subsections of MDR1. The first step was to cut each subsection with their
correspondent enzyme restriction to separate the sections and then clone each one into a puc57
clone vector with transformation into E. coli strain. This way, we could study each sequence and
fix it, if necessary, before combining all subsections to continue the attempts to clone the whole
insert.
Using the MDR1-subsite2 DNA (3866 bps) that was amplified by PCR earlier, the
restrictions enzyme applied to separate the subsections were: EcoRI-HF (NEB)/PstI (Fermentas)
for the subsection A (~773 bps), PstI/XmaI (NEB) for the subsection B (~938 bps), XmaI/ApaI
(NEB) for the subsection C (~814 bps), ApaI/SalI (NEB) for the subsection D (~789 bps) and SalIKpnI-HF (NEB) for the subsection E (~640 bps). All subsections were sequence-verified before
proceeding with the next step. Vector pUC57 was treated with the same enzyme restriction for
each subsection to perform vector/subsection ligation reaction (NEB Quick T4 Ligation kit).
Before the ligation reaction, the plasmid vector was also dephosphorylated to prevent self-ligation.
Ligated vector/MDR1 subsection plasmid was attempted to be transformed into different
E. coli strains. Plasmids with the subsections A, C, D, and E were successfully transformed into
the NEB DH5α E. coli strain (figure 3.9 b). In contrast, the plasmid containing subsection B could
only be transformed into the SURE Supercompetent E. coli cells (Agilent technologies) (figure 3.9
c). Sequences were again sent for verification since we needed to track for DNA sequence
rearrangements, and they were all sequence verified.
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To reassemble the subsections, the attempt was to combine subsections A, B, and C first
(MDR1 ABC), then subsections D and E (MDR1 DE). MDR1 ABC and MDR1 DE were ligated
with the pUC57 vector separately and transformed into DH5α E. coli (Figures 3.9 d and 3.9 e).
After successful transformation, a large growth and a larger scale plasmid preparation
(ZymoPure midiprep protocol) were performed to obtain enough material for the next steps. The
plasmids were then digested to isolate the MDR1 ABC and MDR1 DE fragments for the following
ligation reaction.

Figure 3 9: MDR1 Subcloning - pUC57-MDR1 subsections A-E and subsections assembly.
(a) Comparison of GeneRuler (GR) 1 Kb DNA ladder (ThermoFisher ScientificsTM) and
Supercoiled (SC) DNA ladder (NEB). (b) Plasmid preparations of pUC57-MDR1 subsections A,
C-E from NEB5-alpha High Competent cellsTM (undigested). Lane 1: GeneRuler (GR) 1 Kb, Lane
2: pUC57 cloning vector; Lane 3: pUC57-MDR1-A (3350 bps); Lane 4: pUC57-MDR1-C (3517
bps); Lane 5: pUC57-MDR1-D (3497 bps); Lanes 6: pUC57-MDR1-E (3306 bps), all plasmid
preparations uncut. (c) Plasmid preparation pUC57-MDR1-B from SURE 2 Supercompetent
cellTM Lane 1: GeneRuler (GR) 1 Kb; Lane 2: pUC57 cloning vector uncut; Lane 3: pUC57MDR1-B lower band (3638 bps). (d) Plasmid preparation of pUC57-MDR1-ABC. Lane 1:
GeneRuler (GR) 1 Kb; Lane 2: pUC57 cloning vector uncut; Lanes 3: pUC57-MDR1-ABC.
MDR1-ABC verified by sequencing. (e) Plasmid preparation of pUC57-MDR1-DE. Lane 1:
GeneRuler (GR) 1 Kb; Lane 2: pUC57 cloning vector uncut; Lanes 3: pUC57-MDR1-DE. The
MDR1-DE was verified by sequencing.
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The ligation reaction was successful, and after transformation into SURE 2
Supercompetent cellsTM (figure 3.10 b, lane 6), the PCR product from pPinkHC-MDR1 (figure
3.10 c) was sent to sequencing, where we were able to verify the full MDR1 sequence. The
plasmid was then linearized by SpeI single digestion (figure 3.10 d) for electroporation into all
four PichiaPinkTM strains. The linearized pPinkHC-MDR1 vector (figure 3.10 d) was desalted by
ethanol precipitation and electroporated into electrocompetent PichiaPink cells.

Figure 3 10: Plasmid preparations of pPinkHC-MDR1 ABC+DE from SURE 2 Supercompetent
cellsTM for electroporation into Pichia pastoris.
(a) Left: λ DNA/HindIII Marker DNA ladder; right: comparison of GeneRuler (GR) 1 Kb DNA
ladder (ThermoFisher ScientificsTM) and Supercoiled (SC) DNA ladder (NEB). (b) Lane 1: λ
DNA/HindIII markerTM; Lane 2: pPinkHC vector uncut; Lane 3-6: Uncut plasmids pPinkHC
MDR1 A-E #1-4. Lane 6 sequence verified. (c) PCR product from pPinkHC-MDR1 –
AOX1/CYC1 primers. Lane 1: GeneRulerTM 1 Kb DNA ladder, Lane 2: pcr product of pPinkMDR1 ABC+DE (~3930 bps). (d) pPinkHC-MDR1 ABC+DE SpeI single digestion for
electroporation in Pichia pastoris. Lane 1: λ DNA/HindIII markerTM; Lane 2: pPinkHC-MDR1
3.10 SpeI cut (11516 bps); Lane 3: pPinkHC-MDR1 3.10 #1 uncut (11516 bps).

Recombinants exhibiting His+, Muts phenotype were selected, and small-scale cultures were
grown to confirm the correct DNA insert into the yeast genomic DNA. The cells were lysed, and
the DNA was cleaned and purified before proceeding to the PCR reaction, where it was confirmed
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successful integration of the MDR1 DNA sequence into the genomic DNA of the PichiaPinkTM
strains (figure 3.11).

Figure 3 11: PCR screening from PichiaPink strains MDR1 lysates.
(A) Pichia 1 + MDR1: Lane 1: PCR reaction control C – plasmid pPinkHC-MDR1 was used as
DNA template (PCR product ~4046 bps); Lane 2: 1Kb GeneRuler DNA ladder; Lane 3: PichiaPink
strain 1 cells only + pPinkHC-MDR1 plasmid (+); Lane 4: PichiaPink strain 1 cells only (-); Lanes
5-10: PichiaPink strain 1 cells + MDR1 colonies 1.1-1.6. (B) PichiaPink strain 2 + MDR1: Lane
1: PCR reaction control C – plasmid pPinkHC-MDR1 was used as DNA template (PCR product
~4046 bps); Lane 2: 1Kb GeneRuler DNA ladder; Lane 3: PichiaPink strain 2 cells only +
pPinkHC-MDR1 plasmid (+); Lane 4: PichiaPink strain 2 cells only (-); Lanes 5-10: PichiaPink
strain 2 cells + MDR1 colonies 2.1-2.6. (C) PichiaPink strain 3 + MDR1: Lane 1: PCR reaction
control C – plasmid pPinkHC-MDR1 was used as DNA template (PCR product ~4046 bps); Lane
2: 1Kb GeneRuler DNA ladder; Lane 3: PichiaPink strain 3 cells only + pPinkHC-MDR1 plasmid
(+); Lane 4: PichiaPink strain 3 cells only (-); Lanes 5-10: PichiaPink strain 3 + MDR1 colonies
3.1-3.6. (D) PichiaPink strain 4 + MDR1: Lane 1: PCR reaction control C – plasmid pPinkHCMDR1 was used as DNA template (PCR product ~4046 bps); Lane 2: 1Kb GeneRuler DNA
ladder; Lanes 3-8: PichiaPink strain 4 cells + MDR1 colonies 4.1-4.6; Lane 9: PichiaPink strain 4
cells only + pPinkHC-MDR1 plasmid (+); Lane 10: PichiaPink strain 4 cells only (-).
To ensure that MDR1 DNA was correctly integrated into the Pichia genome, genomic
DNA was extracted and amplified by PCR using PichiaPinkTM plasmids (AOX1/CYC1) and
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MDR1 internal primers (MDR1_int1for/MDR1_int6rev). We also performed single digestions of
the PCR products with the internal XmaI restriction site (figure 3.12). All tests confirmed that the
correct MDR1 DNA sequence was successfully integrated into the PichiaPinkTM strains.

Figure 3 12: Integration genomic DNA tests
(A) GeneRuler (GR) 1 Kb DNA ladder (ThermoFisher ScientificsTM); (B) left: MDR1 PCR
product cut by XmaI enzymatic digestion. Right: PCR products from genomic DNA with
PichiaPinkTM and MDR1 primers.
A single colony from a plate of transformants from each PichiaPinkTM strain was selected for
small-scale cultures for P-gp expression verification. The cells were first inoculated in glycerolbased media for 24 hours, and then the medium was switched to a methanol-based medium for 72
hours to allow protein expression. Crude membrane extracts were prepared (mini microsome
preparations described in the methods), and P-gp expression was thought to be achieved through
immunoblot analysis (figure 3.13 b) using the monoclonal antibody C219 (Enzo Life Sciences).
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Figure 3 13: MDR1 expression after DNA integration into the yeast genome.
(A) Pilot expression – top: PAGE Coomassie blue staining; bottom: Western Blot: C219 anti-Pgp antibody. Colony code and strain are listed on the top of each well. (B) Comparison pilot sample
1.2 and the MDR1 cysteine-less control – top PAGE Coomassie blue staining; bottom: western
blot using C219 anti-P-gp antibody.

Previous work using the human cysteine-less P-gp (MDR1 Cl – chapter 2) an aliquot of
one of the past preparation of MDR1 Cl was used as control on the immunobloting assay variant
with the new cloned human P-gp wild-type (figure 3.13). The signal from MDR1 Cl was observed
to appear slightly higher in the gel than the pilot culture 1.2 (PichiaPink-MDR1 strain 1); however,
the difference could be due to differences in the protein glycosylation. According to previous
success using this antibody, we confirmed human P-gp (MDR1) expression in the small-scale
cultures (figure 3.13 A, bottom panel). Larger cultures were then prepared as referred to in the
Methods and Materials section. Aliquots were taken over time to track P-gp expression levels
during the yeast growth time after the methanol-based medium was applied. The cultures were
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harvested, mini microsome preparations were made on the aliquots for expression analysis, and
microsome preparations were made from the larger cultures to break the cells and access the
membranes.
To check the quality of the microsome preparations, aliquots of each fraction were taken
for analysis (figure 3.14).

Figure 3 14: MDR1 microsome prep analysis.
Lane 1: Spectra ladder 10-260 kDa; Lane 2: final microsome pellet; Lane 3: supernatant 3; Lane
4: supernatant 2; Lane 5: pellet 1 (unbroken cells)

From immunoblotting analysis, we observed that the fractions of supernatants 2 and 3, after
ultracentrifugation at 45,000 rpm, still presented P-gp, while the last microsomal fraction showed
almost no P-gp. Changes in the glycerol content from the buffer used on these fractions were
made, but it did not change the outcome presented the first time.
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Next, we wanted to test if any cross-reactivity of the antibody would give us a false positive
on the P-gp expression on our pilot cultures. For this, we used a blot from a culture that expresses
BCRP (Breast Cancer Resistance Protein) but not P-gp (figure 3.15).

Figure 3 15: Antibody cross-reactivity test
Left panel: immunoblot for BCRP expression on PichiaPink strains using B1- anti ABCG2
(BCRP). Right panel: the same immunoblot using now C219 anti-P-gp antibodies.

Cross-reactivity of C219 antibody on PichiaPinkTM membrane was detected on the BCRP
immunoblotting. The same test was repeated using PichiaPinkTM cells only control
(electroporated without plasmid), resulting in the same signal around 130 kDa (data not shown).
The data showed we did not have P-gp expression initially, even though the correct MDR1 DNA
sequence was integrated into the PichiaPinkTM genome.

3.2.2 MDR1 cloning into GS115 Pichia pastoris strain
The difficulties of expression of MDR1 in Pichia PinkTM made us try to use the optimized
MDR1 DNA sequence in our already known P. pastoris host strain GS115.
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Our lab only had the pHIL-E556C-MDR1 plasmid containing another recombinant P-gp
(gifted by Dr. Alan E. Senior – University of Rochester Medical Center, Rochester, New York).
The solution was to remove the original P-gp insert from pHIL to insert back our new version.
To achieve this, we used the restriction sites for SacII and XhoI on pHIL-E556C-MDR1(figure
3.16 c) to remove the E556C-MDR1 sequence to obtain the pHIL cloning vector. We developed
adapter primers mdr1-pink-to-hil for/mdr1-pink-to-hil-rev to include both restriction sites before
and after the MDR1 sequence (figure 3.16 a and b) from the pPinkHC-MDR1 plasmid.

Figure 3 16: insert vector preparation for cloning in Pichia GS115.
(A) Sequence of the adapter primers mdr1-pink-to-hil for/rev; (B) MDR1 insert removed from
PichiaPink-MDR1 plasmid digested with SacII and Xhol; (C) pHIL-E556C plasmid before MDR1
E556C sequence removal – circled in red SacII and Xhol restriction sites.

The codon-optimized MDR1 gene was removed from the PichiaPink-MDR1 plasmid to be
cloned into the Pichia pastoris GS115 cloning vector pHIL. Restriction enzyme digestions were
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performed to confirm if the correct MDR1 sequence was removed from the original vector before
insertion into the host vector, pHIL (figure 3.17).

Figure 3 17: MDR1 pink-to-hil - Screening steps to remove MDR1 sequence from pPinkHCMDR1 plasmid to insert into the pHIL cloning vector.
(A) Lane 1: pHIL-E566c plasmid uncut; Lane 2 (1 kb GeneRuler); Lane 3 pHIL-MDR1 final
plasmid. (B) PCR products from plasmid pHIL-MDR1 using pHIL primers 1 and 2, and MDR1
internal primer #5 and pHIL reverse primers. (C) pHIL-MDR1 restriction enzyme digestion using
MDR1 internal sites: EcoRI, ApaI
Both insert MDR1, and the plasmid pHIL-E556C were double digested with the restriction
enzymes, SacII and XhoI to generate complementary ends. After removing the MDR1 DNA
sequence from the PichiaPinkTM plasmid, the insert was ligated into a pHIL cloning vector and
transformed into Sure 2 competent cellsTM (Agilent/Stratagene). The plasmid was then linearized
with NotI (figure 3.18) and desalted before integration into Pichia GS115 cells. Integration was
achieved through electroporation.
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Figure 3 18: Plasmid preparation for electroporation in Pichia pastoris GS115 by restriction
enzyme digestion.
(A) NotI digestion 1 hour – Lane 1: λ DNA/ HindIII marker; Lane 2: MAXIprep pHIL-MDR1
uncut (12113 bps); Lane 3: NotI digestion pHIL-MDR1 (9233 bps) and smaller fragment (2880
bps); Lane 4 Gene ruler 1kb DNA ladder. (B) NotI digestion 3 hours – Lane 1: λ DNA/ HindIII
marker; Lane 2: NotI digestion pHIL-MDR1 (9233 bps) and smaller fragment (2880 bps).

After electroporation, the cells were incubated in 1M sorbitol at 28oC for 2 hours to recover.
They were plated on Minimal Dextrose (MD) and Minimal Methanol (MM) plates supplemented
with 1M sorbitol (MDS). After 5 days of incubation at 28oC, the resulting colonies were restreaked on fresh MD/MM plates to confirm the His+ phenotype. Control strains with cells
electroporated with no DNA insert were also streaked to differentiate between the Mut+ and Muts
phenotypes. The presence of the MDR1 gene was confirmed through PCR of cellular lysates
(figure 3.19 a).
Recombinants exhibiting the His+, Muts phenotype were selected, and small-scale cultures
were grown to test for P-gp expression. Integration of the MDR1 gene was confirmed in
transformed yeast strains, and its sequence was verified. Glycerol stocks were made from this
colony. 0.6% agarose gel of PCR products of genomic DNA from transformed Pichia GS115.
MDR1 internal primers were used to probe genomic DNA for the presence of the predicted 2842
bps PCR product (figure 3.19 a).
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Figure 3 19: MDR1 DNA and expression screening in Pichia pastoris GS115.
(A) MDR1 DNA sequence integration. Lane 1: PCR product of pHIL-MDR1 plasmid control;
Lane 2, GeneRulerTM 1 Kb DNA ladder; Lane 3, GS115 untransformed cells spiked with pHILMDR1 plasmid control; Lane 4, untransformed GS115 cells, negative control; Lane 5 GS115MDR1 transformant sample #22. (B) Immunoblot for P-gp expression from small-scale growth
with or without the presence of 500 nM Tariquidar. Duplicate blot – left: C219 anti-P-gp antibody,
right: anti-HIS antibody. Lane 1: MDR1 #22; Lane 2: MDR1 #22 + 500 nM Tariquidar (TRQ);
Lane 3: MDR1 #25; Lane 4: MDR1 #25 + 500 nM TRQ; Lane 5: Spectra Protein ladder 10-260
kDa; Lane 6: MDR1 Cl mini microsome control.

A small-scale growth was performed using glycerol stocks, and the cells were lysed with a
mini microsome preparation. The same pattern of expression observed on PichiaPink-MDR1 was
observed here with cross-reactivity of the C219 anti-P-gp antibody lower than the expected P-gp
size compared with the MDR1 CL control (figure 3.19 b). P-gp expression was not confirmed
through immunoblot analysis using the monoclonal antibody C219 – mouse anti-P-gp (Enzo Life
Sciences).

3.3 Methods and materials
3.3.1 E. coli strains:
Four (4) different strains of E. coli cells were used on this project:
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Table 3 1: Details of the E. coli strains used in the experiments.
Strain
CopyCutterTM

Genotype
EPI400TM F– mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 ∆lacX74

Electrocompetent E. coli recA1 endA1 araD139 ∆(ara, leu)7697 galU galK λ– rpsL nupG
(EPICENTRE)

tonA ∆pcnB dhfr

NEB® Stable competent E. F’ proA+B+ lacIq ∆(lacZ)M15 zzf::Tn10 (TetR) ∆(ara-leu) 7697
coli (High Efficiency)

araD139 fhuA ∆lacX74 galK16 galE15 e14- Φ80dlacZ∆M15
recA1 relA1 endA1 nupG rpsL (StrR) rph spoT1 ∆(mrr-hsdRMSmcrBC)

NEB® 5-alpha Competent fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96
E. coli (High Efficiency)

recA1 relA1 endA1 thi-1 hsdR17

SURE 2 Supercompetent e14-(McrA-) Δ(mcrCB-hsdSMR-mrr)171 endA1 gyrA96 thi-1
cells (Agilent)

supE44 relA1 lac recB recJ sbcC umuC::Tn5 (Kanr) uvrC [F´
proAB lacIqZΔM15 Tn10 (Tetr) Amy Camr]

3.3.2 Agarose gel electrophoresis:
0.6% agarose gels with 4.5 x 10-5% ethidium bromide were used and DNA visualization
was made under UV light.
3.3.3 Polymerase chain reaction (PCR):
The Taq DNA polymerase from New England Biolabs was gifted by Ms. Lynn McBee,
NEB. PCR reactions were performed as described in the manufacturer protocol. In short, Taq DNA
polymerase was added to 10X Standard Taq buffer, 10 mM dNTPs, 10 µM Forward Primer, 10
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µM Reverse Primer, template DNA, and nuclease-free water. 30-35 cycles were used on different
reactions and templates. Annealing temperatures were defined according to the primer set and
calculated by the NEB Tm calculator (http://tmcalculator.neb.com). The reactions ran on the MJ
Research PTC-200 Peltier Thermal Cycler.
3.3.4 Restriction enzyme digestions:
Reaction digestions were performed as directed in the manufacturer protocol (New
England Biolabs®). In short, 1 µg of DNA was incubated in 50 µL total volume with appropriate
enzyme units as listed in the protocol received with the enzyme. Reactions were incubated at 37oC
for 1-2 hours.
3.3.5 Vector Dephosphorylation:
New England Biolabs® Shrimp Alkaline Phosphatase (rSAP) dephosphorylated kit was
gifted by Lynn McBee. The dephosphorylation was performed as described in the protocol. The
linearized vector DNA, 10X CutSmart Buffer, 1 uni of rSAP, and deionized water up to 20 µL
were added. The mixture was incubated at 37oC for 30 min. The reaction was then heat-inactivated
at 65oC for 5 minutes.
3.3.6 Ligation:
The quick ligation kit from New England Biolabs® was kindly gifted by Lynn McBee. The
vector DNA was mixed with insert DNA at different molar ratios (1:1 up to 5:1), 2 µL of 2X Quick
Ligase Reaction Buffer added, water to a total volume of 19 µL, and 1µL of Quick Ligase. The
solution was mixed, centrifuged, and incubated at 25oC for 5 min. After a brief incubation on ice,
1-5 µL of this reaction was used in transformation experiments. NEBioCalculator was used to
calculate molar ratios (http://nebiocalculator.neb.com).
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3.3.7 Bacterial transformation
Competent cells were thawed on ice for 10 min. 1-5 µL of a ligation mixture was added to
50 µL of cells, and the tube was flicked to mix and incubated on ice for 30 min. A heat shock was
performed for 30 seconds in a water bath at 42oC before incubation on ice for 5 min. Then 950 µL
of SOC medium (0.5 % Yeast extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2,
10 mM MgSO4, 20 mM glucose) was added to the tube and incubated rotating or shaking for 60
min at 37oC. The tube was mixed and plated on LB plates with ampicillin. Plates were incubated
overnight at 37oC.
3.3.8 Mini plasmid preparations:
Zippy Plasmid Miniprep kits were obtained from Zymo Research, Inc. The provided
protocol was followed. Pelleted culture cells were added to 600 µL of deionized H2O and placed
in a 1.5 ml microfuge tube. 100 µL of 7x Lysis buffer was added, and the tube was inverted six
times. 350 µL of 4oC Neutralization Buffer was added immediately after, and the tube inverted
until the solution is all yellow and a precipitant is formed. The sample was centrifuged at 14,000
x g in a tabletop MR22 microfuge for 4 min. The supernatant was poured into a Zymo-Spin
column, placed in a collection tube, and centrifuged at the same speed for 15 seconds. The liquid
in the collection tube was discarded, and 200 ul of Endo-Wash Buffer was added to the column
and centrifuged for 30 seconds. 400 µL of Zippy Wash Buffer was added to the column and
centrifuged for 30 seconds. The column was then transferred to a new microfuge tube, and 30 µL
of deionized H2O was added to the column and incubated at room temperature for 1 min. The DNA
was then eluted by centrifugation for 30 seconds.
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3.3.9 Midi plasmid preparations:
ZymoPURETM Plasmid Midiprep kits were obtained from Zymo Research, Inc, and the
provided protocol was followed. Bacterial cells suspension was resuspended in ZymoPURE P1 on
a 50 mL conical tube (red solution). The ZymoPURE P2 solution was added to the mixture and
turned the solution dark purple. Indicating bacterial lysis was completed. ZymoPure P3 solution
was added to the mixture, and the solution turned yellow, indicating neutralization was complete.
The neutralized lysate was loaded into the ZymoPURE syringe filter and clarified into a new 50
mL conical tube. ZymoPure Binding Buffer was added to the cleared lysate and mixed. The
mixture was then loaded into the Zymo-Spin III-P Column, and a vacuum manifold was used to
clear and wash the column. Pure DNA was eluted from the Zymo-Spin III-P column using the
MR22 microfuge.
3.3.10 DNA purification:
DNA clean & concentratorTM-5 (Zymo Research) was used to purify and concentrate up to
5 µg of DNA using the protocol provided. DNA Binding Buffer was added to the DNA sample in
a 2:1 ratio for plasmid DNA or a 5:1 ratio for PCR products. The mixture was transferred to a
Zymo-SpinTM Column in a collection tube and centrifuged at 14,000 x g in the MR22 microfuge
for 30 seconds. 200 µL of DNA Wash Buffer was added to the column, and the centrifugation step
was repeated. The wash was also repeated. 6-10 µL deionized water was added to the column and
incubated at room temperature for 1 min. The column was placed in a new 1.5 ml microfuge tube
and centrifuged for 30 seconds at 14,000 x g to elute the DNA
3.3.11 DNA sequencing:
After purified, the DNA was sent to Lone Star Labs, Inc. in Houston, TX, for standard
Sanger sequencing. The electrophoretograms were then compared with the predicted plasmid
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sequence using the Basic Local Alignment Search Tool (BLAST) for nucleotides available from
the NIH (https://blast.ncbi.nlm.nih.gov/Blast.cgi)
3.3.12 Preparing electrocompetent Pichia pastoris cells:
Strains 1, 2, 3, and 4 of PichiaPink, were streaked onto YPD plates (1% yeast extract, 2%
bacto peptone, 2% dextrose, 1.5% agar) and incubated 28oC for up to 5 days. A single colony of
each was used to inoculate 10 ml YPD media to grow overnight at 28oC, shaking at 250 rpm. This
initial culture was used to inoculate 100 ml YPD media to a starting O.D. at 600 nm of ~0.2. This
culture was grown until it reached an O.D. at 600 nm between 1,2 and 1.5 (between 12.-16 hours).
The cells were harvested by centrifugation at 1,500 x g for 10 min at 4oC and resuspended in 250
ml of ice-cold sterile water. The cells were pelleted again, and the cells were resuspended in 10 ml
of ice bold 1 M Sorbitol. The centrifugation step was repeated, and the pellet was resuspended in
300 µL of ice-cold 1 M Sorbitol to a final volume of about 500 µL. The cells were kept on ice until
electroporation.
3.3.13 Integration of the MDR1 gene into PichiaPink/GS115 cells by electroporation:
100 µL of electrocompetent Pichia pastoris cells were added to a 0.2 cm cuvette (BioRad),
and 15 µg of linearized DNA was added in a volume of less than 25 µL. The cells and DNA were
incubated on ice for 5 min. Electroporation with 25 µF capacitance and 1.5 kV was performed
with a time constant between 4.68 and 4.8 msec on a BioRad Gene Pulser II. After that, 1 ml of
ice-cold YPDS media (YPD media + 1M Sorbitol) was added to the cuvette and mixed carefully
by pipetting. The cuvette was then incubated for 2 hours at 28oC without shaking. The samples
were then plated on PAD selection plates (PichiaPink cells) or MD/MM plates (GS115 cells) with
volumes of 100 µL, 200 µL, 300 µL, and 400 µL and incubated at 28oC for up to 5 days.
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3.3.14 Selection plates:
-

PAD selection plates: 13.4g/L Yeast Nitrogenous Base (YNB); 0.05 g/L Biotin; 20 g/L
Dextrose; 50 mg/L L-Arg HCl; 80 mg/L L-Asp acid; 20 mg/L L-His HCl; 50 mg/L LIso; 100 mg/L L-Leu; 50 mg/L L-Lys HCl ; 20 mg/L L-Met; 50 mg/L L-Phe; 100 mg/L
L-Thr; 50 mg/L L-Try; 50 mg/L L-Tyr; 20 mg/L Uracil; 140 mg/L L-Val; 20 g/L Agar

-

MD plates: 1.34% YNB; 4x10-5% Biotin; 2% Dextrose; 5% Agar (w/v)

-

MM plates: 1.34% YNB; 4x10-5% Biotin; 2%; 1% Methanol; 5% Agar (w/v)

3.3.15 Genomic DNA extraction:
Transformants colonies were inoculated in a 2 ml YPD medium, and the cultures were set at 28oC,
275 rpm for 24 hours on an incubator. After checking the successful growth in the cultures, each
one was transferred to a 2 ml centrifuge tube and centrifuged to 14,000 x g for 1 min (Beckman
22R Microfuge) to pellet the cells. The supernatant was discarded, and the cell lysis was made
according to the protocol described in

116

. Briefly, the pellets were resuspended in 300 µl of

breaking buffer (200 mM Lithium Acetate; 1% SDS), and the samples were incubated for 10 min
at 70oC. Regular ethanol precipitation protocol was followed: 1 ml 96-100% ethanol was added
for DNA precipitation, the samples were then centrifuged at 14,000 x g for 3 min. Pellet was
washed with 1.5 ml of 70% ethanol. The ethanol was dry using the Beckman tabletop vacufuge at
1.400 x g for 30 min. The pellet was resuspended in TE buffer, and the samples were centrifuged
again at 14,000 x g for 3 min. 1µl of the supernatant was used for PCR reaction.
3.3.16 Growth of Pichia pastoris GS115 strain
Cells were grown using the methods previously described in

70, 75, 76, 86

. In short, A single

colony from a Minimal Dextrose (MD) agar plate (1.34% Yeast Nitrogen Base (YNB), 4x10-5%
Biotin, 2% dextrose, 15g agar/L) was inoculated into 10 ml of liquid Minimal Glycerol (MG)
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medium (1.34% YNB, 1% glycerol, 4x10-5% Biotin) and incubated at 28oC with shaking to OD600
of ~2.0 (18h). After 16-18 hours, this 10 ml was added to 1 liter of MG medium in a 2-liter
Fernbach flask. Incubation at 28oC with shaking to OD600 of 2.0 to 4.0 was continued (~18h), then
the cultures were centrifuged in sterile bottles (4000 rpm for 20 min at 23oC). Protein production
was induced by switching the carbon source of the medium from glycerol to methanol. The cells
pellets were resuspended in 1 liter of Minimal Methanol (MM) medium (1.34% YNB, 4x10-5%
Biotin, 0,5% v/v methanol) in 2-liter Fernbach flasks covered with cheesecloth. Incubation
continued for 72h with the addition of methanol (1% v/v) at 24 and 48 hours. The pH correction
was adjusted to ~6.0 at these times. Cells were finally collected by centrifugation at 4000 rpm for
10 min at 4oC and resuspended in ice-cold “homogenization buffer” (0.33 M sucrose, 0.3 M TrisHCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 2 mM DTT, 100 mM 6-aminocaproic acid) at a
concentration of 1 g wet cells/ml buffer. The cells were stored at -80oC.
3.3.17 Growth of P. pastoris PichiaPinkTM:
Cells were grown using the methods previously described in Invitrogen for PichiaPinkTM
70, 75, 76, 86

. In short, A single colony from a YPD agar plate (1.34% Yeast Nitrogen Base (YNB),

4x10-5% Biotin, 2% dextrose, 15g agar/L) was inoculated into 10 ml of liquid Enriched Minimal
Glycerol (BMGY) medium (20% Yeast extract, 10% Bacto Peptone, 1.34% YNB, 1% glycerol,
4x10-5% Biotin, 100mM Potassium Phosphate) and incubated at 28oC with shaking to OD600 of
~2.0 (18h). After 16-18 hours, this 10 ml was added to 1 liter of BMGY medium in a 2-liter
Fernbach flask. Incubation at 28oC with shaking to OD600 of 2.0 to 4.0 was continued (~24h), then
the cultures were centrifuged in sterile bottles (6000 rpm for 7 min at 23oC). Protein production
was induced by switching the carbon source of the medium from glycerol to methanol. The cells
pellets were resuspended in 1 liter of enriched Minimal Methanol (BMMY) medium (20% Yeast
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extract, 10% Bacto Peptone, 1.34% YNB, 4x10-5% Biotin, 0,5% v/v methanol, 100mM Potassium
Phosphate) in 2-liter Fernbach flasks covered with cheesecloth. Incubation continued for 72h with
the addition of methanol (1% v/v) at 24 and 48 hours. The pH correction was adjusted to ~6.0 if
needed. Cells were finally collected by centrifugation at 6000 rpm for 7 min at 4 oC and
resuspended in ice-cold “homogenization buffer” (0.33 M sucrose, 0.3 M Tris-HCl, pH 7.4, 1 mM
EDTA, 1 mM EGTA, 2 mM DTT, 100 mM 6-aminocaproic acid) at a concentration of 1 g wet
cells/ml buffer. The cells were stored at -80oC.
3.3.18 Mini microsome preparations from small scale yeast cells growth:
Small scale growth of yeast follows the same procedures as the large scale but with smaller
volumes (10 ml). After the growth, the cells were pelleted by centrifugation (4,000 x g, for 10 min
at 4oC). Cell pellets were then resuspended in 500 µL-1 ml A1 buffer (30% v/v glycerol, 50mM
Tris-HCl, pH 8, 125mM NaCl, 10mM imidazole) supplemented with protease inhibitors (2 µg/ml
pepstatin A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 350 µg/ml PMSF and 10 µl/ml DTT). The
suspension and 1 ml of 0.5 mm glass beads (BioSpec) were added in a 2 ml cryovial tube, filled to
the top with buffer A1. The tube was subjected to 5-7 cycles of shaking on a mini bead beater
(BeadbugTM, Benchmark Scientific) to break the cells. The supernatant was then moved to a new
2 ml microfuge tube, and the beads were rinsed with 1 ml A1 supplemented with protease
inhibitors. The tubes were centrifuged at 14,000 x g for 30 min at 4oC. The supernatant was
collected into 15 ml polycarbonate tubes and subjected to another centrifugation at 45,000 rpm for
45 min at 4oC in a Ti 70.1 rotor in a Beckman Coulter Optima XPN-80 or LE-80K Ultracentrifuges.
The pellet was resuspended in 200 µL A1 with protease inhibitors referred above and stored at 20oC for analysis.
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3.3.19 Microsome preparation from yeast cells:
Microsomes were prepared essentially as described in 86, with the modifications made in
70, 75, 76

. Frozen cells were rapidly thawed by incubating bottles in a water bath set at 28-30oC for

~10 min, swirling the bottle's content to equilibrate the temperature. All further steps were
performed at 4oC or on ice. Protease inhibitors were added once the cell suspension was thawed
as follows: 2 µg/ml pepstatin A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 350 µg/ml PMSF, and
10 µl/ml DTT. All the cells were transferred to a chilled bead beater apparatus that was filled to
top with “buffer A1” (30% v/v glycerol, 50 mM Tris-HCl, pH 8, 125 mM NaCl, 10 mM imidazole)
supplemented with DTT (10µl/mL). Cells were mechanically disrupted by using 0.5 mm glass
beads in a bead-beater (BioSpec) for a total of 14 minutes. The bead-beater was attached to a
jacketed chamber filled with an ice-salt mixture that helped maintain the lower temperature. Cell
disruption was performed in 7 cycles of 2 minutes bead beating alternated with 6 minutes with the
bead-beater “off” to allow cells to cool down. This method helped solve the problem of overheated
samples due to the high heat output of the bead-beater motor. The homogenate was then
centrifuged for 30 minutes at 10,000 rpm (at Beckman J21-M equipped with a JA-20 rotor), and
the pellet was discarded. These steps removed unbroken cells, nuclei, and mitochondrial fractions.
The supernatant was centrifuged at 45,000 rpm (at Beckman Optima LE-80K equipped with Ti70
or Ti55.2) for 45 min at 4oC. After this ultracentrifugation, the supernatant contained cytoplasmic
protein and was discarded. The resulting pellet containing the microsomes was resuspended in
“wash buffer” (20% v/v glycerol, 50 mM Tris-Cl, pH 7.4 at 4oC, and protease inhibitors – 1 mM
PMSF, 1 mM DTT, Pepstatin A, Leupeptin, and Chymostatin as above). The microsomes were
recentrifuged at 45,000 rpm at Beckman Optima LE-80K equipped with Ti70 or Ti55.2) for 45
min at 4oC. The supernatant was discarded, and the pellet was resuspended initially using a
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paintbrush and then by 10 strokes by hand in a Potter-Elvehjem Teflon pestle homogenizer in 30
ml of “buffer A1” plus protease inhibitors as before). The microsomes were then frozen at -80oC.
3.3.20 Western Blot analysis:
Polyacrylamide gels at 6.5%, with a ratio of polyacrylamide to bis-polyacrylamide of 29:1,
were used. The gels were loaded with the samples (10-40 µg of protein) and ran for 1.5 h at 110
V before transferring to PVDF membrane (blot) for 100 min at 110V. The blot was incubated in
blocking buffer (TBS-t with 5% low fat dry milk) for 1 hour at room temperature or overnight at
4oC. After the incubation, the buffer was discarded, and the blot was washed 3 times with 5 min
in TBS-t (12 mM Tris-Cl pH 7.5; 0.5 M NaCl; 0.05% v/v Tween-20). Following the washes, the
blot was incubated in 1:1000 dilution in primary monoclonal antibody C219 – mouse anti-P-gp
(Enzo) for 1 hour at room temperature or overnight at 4oC in a rocking platform. Another set of 3
washes were applied to the blot. An incubation in 1:10,000 dilution secondary antibody goat antimouse IgG-HRP was applied to the blot for one hour at room temperature in a rocking platform.
The solution was discarded, and another set of washes were applied to the blot. For the
chemiluminescent development, an equal amount of Luminol Enhancer Buffer (Detection
Reagent 1) and the Peroxide Solution (Detection Reagent 2) (ThermoScientific) were mixed and
pipetted onto the membrane and allowed to incubate at room temperature for at least 1 min before
the development with chemiluminescent settings on a BioRad Chemidoc MP Imaging System.
3.4 Discussion
Several studies 82, 86 as well as our lab have reported on the expression of P-gp in the yeast
Pichia pastoris and purified the protein in what was assumed to be a fully biologically active form.
P. pastoris yeast grows to very high densities in fermenter cultures providing ample source
material. However, we experienced a modest expression level of the MDR1-clone available in our
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lab. The low protein yield during purification made it undesirable for further experimentation. Bai
et al. 82 suggested that codon usage bias may be one of the factors leading to inefficient translation
in Pichia, thereby limiting protein production. A codon usage adjusted sequence of mouse P-gpencoding mdr3 gene resulted in a significant increase in P-gp expression 82. We hypothesized that
a gene for human P-gp that has been optimized for translation in Pichia pastoris might allow higher
levels of protein expression than observed using human DNA sequences for P-gp.
The PichiaPinkTM system was also a promising approach to obtaining higher protein yield
besides the advantages provided by strains 1, 2, and 3 with knock-out of proteases, which would
make the purification process cheaper.
A new gene that encodes the human MDR1 P-gp was created that was optimized for
translation in Pichia pastoris. The DNA was commercially obtained and cloned into the pUC57
cloning vector and transformed in the CopyCutterTM EPI400TM Electrocompetent E. coli strain
115

. The DNA also included unique internal restriction sites for subcloning so that individual

sections of the MDR1 gene could be subcloned.
We observed difficulties in replication and maintenance of the MDR1 gene sequences in
E. coli strains. The great instability of the MDR1 gene made it hard to replicate DNA in E. coli
strains, and the desired amount of MDR1 insert was only achieved by PCR. Several attempts to
ligate the PCR product of MDR1-subsites2 insert into PichiaPinkTM high expression system
vectors pPinkHC and pPinkLC were made using different insert/vector ratios into different E. coli
strains and rearrangements were observed on most of our attempts.
Subclones of the five MDR1 subsections – EcoRI-PstI (A), PstI-XmaI (B), XmaI-ApaI (C),
ApaI-SalI (D), SalI-KnpI (E) - were made to identify which specific section of MDR1 DNA was
causing the counter-selection in E. coli. The cloning of subsections A, C, D, and E subsections
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were cloned without further problems on the E. coli strain DH5α. The section promoting
rearrangements was subsection B that could only grow successfully using the SURE® 2
Supercompetent cells (Agilent Technologies). According to the manufacturer, these cells lack
components of important pathways that catalyze rearrangements and present deletions of
nonstandard secondary and tertiary structures frequently found in eukaryotic DNA but impede
the cloning of conventional E. coli strains. The cells were also endonuclease (endA) and
recombination (recB recJ) deficient (Agilent). These features could present an important role in
the successful cloning of subsection B in this specific strain.
Once the subcloning was successfully made and all sequences were verified, we then
proceeded with the reassembly of the sections. Surprisingly, the assembly of the subsections of
MDR1 ABC and DE with the cloning vector pUC57 was easy to achieve, and the transformations
in the E. coli strain DH5α were successful (figure 3.9 d and e).
To prevent new rearrangements events, we decided to combine the MDR1 sections
ABC+DE and ligate them with the PichiaPink plasmids and transform them into the SURE 2
Supercompetent cells. The PCR product of the purified plasmid was finally sequence-verified,
and the plasmid pPinkHC-MDR1 was then prepared for electroporation into the PichiaPinkTM
strains.
The transformation was successful, and the sequence of MDR1 was found on the genomic
DNA of yeast.
Small scale expression growth was made, and the use of C219 antibody against P-gp
confirmed the presence of P-gp. Control MDR1-cysteine less presented a band slightly higher
than the ones seen on MDR1 WT.
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After confirming the expression, we decided to grow large-scale cultures (1L.) to perform
a full protein purification preparation. During the first step of breakage and formation of
microsomes, all the fractions were saved and aliquoted for analysis. The first clue that something
was not right was when the supernatant fractions from the ultracentrifugation - deemed to separate
soluble to insoluble proteins – presented “expression” of P-gp. Changes in glycerol content of the
medium were made with the same result.
Several questions about why P-gp would appear in solution and not pelleted or if we ever
had P-gp in the first place made us investigate the specificity of the C291 P-gp antibody. The
C219 antibody anti-P-gp (Enzo) used in our experiments was largely used over the years to
recognize different P-gp variants in our previous work from our lab. We found out that there was
cross-reactivity of the P-gp in Pichia cells, and the band we see on the expression test was not Pgp (figure 3.15).
The PCR from the genomic DNA was tested after transformation and digestions using
restriction enzymes to cut specifically at the MDR1 subsection’s restriction sites confirmed that
the DNA sequence of MDR1 was indeed present on the yeast (figure 3.12). Still, for some reason,
the protein was not being made.
Since the PichiaPinkTM is a new system optimized for secreted protein, the problem could
be on the membrane, not on the DNA. Multi copies of P-gp on membrane could not be supported
by the cells.
We still wished to take advantage of the codon-optimized MDR1 DNA sequence. We then
target to clone it into the Pichia pastoris GS115 strain, the host of other P-gp strains we have
available in our lab.

64

We had no difficulties on extract the MDR1 sequence from the pPinkHC-MDR1. The
cloning vector used on GS115 is pHIL. We needed to extract the pHIL cloning vector from the
pHIL-E556C-MDR1 plasmid containing another recombinant P-gp. The MDR1 sequence present
on the PichiaPink-MDR1 plasmid did not contain any specific sites similar to those found in the
pHIL-E566C plasmid. On this plasmid, the restriction sites SacII and XhoI were found before and
after the E566C-MDR1 sequence, respectively, making these two sites suitable to separate the
cloning vector pHIL and the E566C-MDR1 insert. We then developed adapter primers mdr1pink-to-hil for/mdr1-pink-to-hil-rev to include both restriction sites before and after the MDR1
sequence present on the PichiaPink-MDR1 plasmid. PCR successfully added both restriction sites
on the MDR1 sequence target on the PichiaPink-MDR1 plasmid. Digestions on both fragments,
plasmid, and optimized MDR1 insert, allowed later ligation, and the new plasmid pHIL-MDR1
with the confirmed correct MDR1 sequence was easily linearized for integration into Pichia
pastoris GS115 strain (figure 3.16).
Screenings on the new Pichia GS115 were successful, and we were able to find 2 (two)
transformants with the verified MDR1 sequence faster than the PichiaPinkTM screenings (figure
3.17 a). Unfortunately, the outcome of the expression was not different from what was observed
on the PichiaPinkTM strains. No expression was confirmed on both transformants. We should not
have as many multi copies of P-gp on the membrane as the previous strain to justify the lack of
expression. We hypothesize we would have a folding problem, and per Dr. David Clarke's
suggestions, we wanted to add tariquidar during the growth of the yeast somehow to orient the
folding of P-gp during its expression. The strategy also did not work, and we still did not confirm
the expression of P-gp (figure 3.17 b).
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We could try obtaining mRNA expression by qPCR to track that translation from the DNA
sequence and confirm the folding hypothesis. Still, after all the time and effort spent, we decided
to stop it here and proceed in a different direction using the clone provided by Dr. Ina Urbatsch
(Texas Tech University).
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CHAPTER 4
P-GLYCOPROTEIN WILD-TYPE PURIFICATION – INITIAL HITS AND LIPID CONTENT
EFFECT ON P-GP ACTIVITY

4.1 Introduction
A membrane protein-like P-gp has its activities affected by the molecular interactions
between the protein and the surrounded lipid composition, such as hydrophobic effects, hydrogen
bonding, or charge interactions. Lipid fluidity and membrane tension are also factors considered
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.
As described in chapter 1 and at 70, 80, the innovative approach from our group was to find

a molecule/compound that would target the P-gp power source to prevent the ATP binding on the
ATP binding domain – nucleotide-binding domain (NBD) – so the P-gp could not export the
chemotherapy drugs across the membrane.
From the high-throughput computational screens

72, 73

to identify the best predicted hit

compounds for the in silico docking experiments - as described on chapter 1, – Brewer et al70,
was able to test successfully the inhibitory effect of 4 (four) of those initial compounds (figure 4.1)
on the ATPase hydrolysis activity by purified mouse P-gp while three of them – compounds SMU
29[2-[(5-cyclopropyl-1H-1,2,4-triazol-3-yl)sulfanyl]-N-[2-phenyl-5-(2,4,5trimethylphenyl)pyrazol-3-yl]acetamide (ZINC 08767731, CID 17555821)], SMU 34 [2-[1-[4-(4methoxyphenyl)piperazin-1-yl]-1-oxobutan-2-yl]-4-methyl-[1]benzothiolo[2,3-d]pyridazin-1one (ZINC 09252021, CID 22514118)] and SMU 45 [ethyl 1-(1,3-benzodioxole-5-carbonyl)-3-

(3-phenylpropyl)piperidine-3-carboxylate (ZINC 15078148, ZINC 15078146, CID 26410703,
CID 45252040)] - showed the MDR-reversal in prostate cancer cell line 80, and ovarian cancer
cell line 1. More recently, computationally identified compounds were shown to reverse MDR in
cancer cells and needed to be biochemically tested on isolated human P-gp (McCormick et al.,
unpublished) – see chapter 5.

Figure 4. 1: The location of docked inhibitors in the human P-gp model from 70.
The nucleotide-binding domains (NBD) are represented in a silver-gray cartoon showing where
nucleotides (ATP and ADP) and compounds 19, 29, 34, and 45 were bound to this human P-gp
model.

For the initial biochemical analyses, mouse cysteine-less P-glycoprotein (mdr3-Cl) was
used70. Even though it is closely related to the human MDR1 P-gp, it still presented some important
differences that we wanted to explore. After the initial difficulties on the purification of the human
cysteine-less P-gp we had available in our lab and the failed attempts to clone the MDR1 gene into
high expression in yeast (chapter 3), we decided to made use of another KM71H Pichia pastoris
strain expressing human MDR1 wild -type that was kindly gifted by Dr. Ina Urbatsch (Texas Tech
University – Health Science Center, Lubbock, TX).
Previous works from this same group reported differences in P-gp ATPase hydrolysis
activity in the absence or the presence of lipids 86. One of our goals was to identify the best possible
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lipid environment condition to achieve the P-gp activity closer to its native state to test how our
compounds would affect the drug stimulated the activity of P-gp.
Here we report our P-gp purification attempts as well as the strategy to lipid-activate wildtype human P-gp as well as the use of P-gp reconstituted in nanodiscs and the evaluation of the
potential of our previously discovered drug-like compounds to serve as inhibitors of human P-gp
ATP hydrolysis activity.

4.2 Results
The Pichia pastoris expressing human MDR1 wild type was sent to us by our collaborator
and immediately aliquoted in bottles containing 80 mL of cells. Small aliquots of 500 μL of cells
were also saved for future attempts to grow these cells in our lab, while aliquots of 200 μL were
used for initial analysis. All aliquots, large and small, were stored at -80oC freezer for later usage.
Small scale cell breakage and western blot were made to check for human MDR1 expression. After
the confirmation of the P-gp expression, large-scale preparations were made.
Initial attempts to purify the human P-gp from these cells using the same protocol for the
mouse MDR3 cysteine-less

70, 86

resulted in an enriched protein with some contaminants. Small

changes on the affinity chromatography washes (including a second wash with a 40 mM Imidazole
buffer) yielded a successfully isolated P-gp, about 0.02 mg of P-gp/g Pichia pastoris cells (Figure
4.2 A, lane 8).
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Figure 4. 2: Human MDR1 P-gp purification steps and reconstitution into nanodiscs.
(a) Lane 1. Final microsome fraction; lane 2. Thermo Scientific Spectra Multicolor Broad Range
Protein Ladder (260-10 kDa); lane 3. Solubilization Pellet; lane 4. Solubilization Supernatant; lane
5. Ni-NTA Chromatography first fraction flow-through (FT); lane 6. Ni-NTA Chromatography
wash 1 fraction - 20 mM Imidazole (W1); lane 7. Ni-NTA Chromatography wash 2 fraction – 40
mM Imidazole; lane 8. Ni-NTA Chromatography final elution fraction – 300 mM Imidazole (Elu)
(~130 kDa). Top gel Coomassie blue staining. Bottom western blot image – C219 anti-P-gp
primary antibody (Enzo Life Sciences) – lanes 7 and 8 images were photobleached due to the high
amount of protein present. (b) Reconstitution of P-gp into nanodiscs: Lane 1: Color Prestained
Protein Standard, broad range (10-250 kDa) NEB®; Lane 2: MSP (~26 kDa); lane 3: P-gp in
micelles (~130 kDa); lane 4: P-gp reconstituted into nanodiscs.
From the initial cells that were saved, we prepared new cultures using Fernbach flasks for
culturing instead of the fermenter used by Dr. Urbatsch’s group on their preparations. We noticed
the initial cell growth took longer than the regular 24 hours in the glycerol-based medium. The
expression was not as good as the original cells, even after several attempts. We decided to use
enriched minimal glycerol (BMGY) medium (20% Yeast extract, 10% Bacto Peptone, 1.34%
YNB, 1% Glycerol, 4x10-5% Biotin, 100mM Potassium Phosphate) to increase the quality of the
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growth. Under these conditions, the cells grew faster, and after 24 hours in this medium, the OD600
was usually between 8 -14. After switching the medium from glycerol to methanol-based medium,
expression of P-gp was observed over the time between 24-72 hours after which the cultures were
harvested. Purification from this homegrown Pichia pastoris containing human P-gp presented
more challenges since we observed more contaminants in the final enriched P-gp fraction (figure
4.3 A, lane 8). When we tried to include more washes on the final steps of the chromatography
column, we ended up losing more P-gp, so we decided to keep only 2 washes: first wash buffer
containing 40 mM Imidazole and the second wash containing 60 mM Imidazole. Unfortunately,
these preparations yield 0.001 mg P-gp/g of cell – significantly lower than the original cells
provided from the Urbatsch group.
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Figure 4. 3: Homegrown human P-gp purification steps and reconstitution into nanodiscs
(a) Lane 1. Final microsome fraction; lane 2. Thermo Scientific Spectra Multicolor Broad Range
Protein Ladder (260-10 kDa); lane 3. Solubilization Pellet; lane 4. Solubilization Supernatant; lane
5. Ni-NTA Chromatography first fraction flow-through (FT); lane 6. Ni-NTA Chromatography
wash 1 fraction - 20 mM Imidazole (W1); lane 7. Ni-NTA Chromatography wash 2 fraction – 40
mM Imidazole; lane 8. Ni-NTA Chromatography final elution fraction – 300 mM Imidazole (Elu)
(~130 kDa). Top gel Coomassie blue staining. Bottom western blot image – C219 anti-P-gp
primary antibody (Enzo Life Sciences). (b) Reconstitution of Pgp into nanodiscs: Lane 1: Thermo
Scientific Spectra Multicolor Broad Range Protein Ladder (260-10 kDa); Lane 2: MSP (~26 kDa);
lane 3: P-gp in micelles (~130 kDa); lane 4: P-gp reconstituted into nanodiscs.
As other ABC transporters, P-glycoprotein has been reported to be activated in the presence
of lipids mimicking their natural cell membrane environment

86

. For this reason, attempts to

activate the enriched P-gp were made to achieve the best possible activation profile (figure 4.4).
Lipid activation was achieved after incubating the enriched P-gp with the lipid at room
temperature at different lipid to P-gp ratios in the presence of DTT, as described in 86. As observed
in figure 4.4, the lipid activated P-gp showed just a very slight difference in basal activity compared
with the non-activated P-gp. A larger difference was observed when drug stimulated the activity
of P-gp was measured with increasing lipid content. The added lipids seemed to affect the P-gp
72

response to verapamil in a concentration-dependent manner. The protein-lipid ratio of 1:100

Activity (nmol NADH/ min.mg of P-gp)

seemed to be the most suitable for the next tests.

P-gp activation: lipid ratio trials
140
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Figure 4. 4: Lipid activation using different P-gp: E. coli lipids weight ratio.
Samples were tested in duplicates in the presence of 5mM DTT and the assigned lipid amount
content.
As discussed earlier, nanodisc assembly of the mouse P-gp was successfully performed by
our group and resulted in a significant increase in P-gp ATP hydrolysis activity. In hopes of
achieving similar effects, we attempted to reconstitute the human P-gp into nanodiscs and compare
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the ATPase hydrolysis activity between P-gp in mixed micelles both in the absence (basal activity)
and presence (stimulated activity) of the transport substrate, verapamil. (figure 4.5).
A successful assembly of human P-gp into nanodiscs was achieved (figure 4.2 B lane 4
and 4.3 B lane 4) following the procedure described in

84, 93

, and its initial activity was assessed

(figure 4.5 B). Initial ATPase hydrolysis tests on P-gp reconstituted in nanodiscs showed low basal
activity (40 nmol NADH/min/mg of P-gp). Still, a good stimulated activity in the presence of
verapamil (100-118 nmol NADH/min/mg of P-gp), as well as some inhibitory effects of the drug,
stimulated activity by one of the previously discovered compounds, compound SMU 29 (95 nmol
NADH/min/mg of P-gp) that was also observed in activated P-gp (figure 4.5 A).
Comparing the performance of lipid-activated P-gp and P-gp reconstituted into nanodiscs
indicated a similar pattern in the response of drug stimulation activity and the inhibitory effect of
compound SMU 29 on the drug stimulated activity (figure 4.5).
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Figure 4. 5: Effect of different conditions on P-gp on P-gp ATPase hydrolysis.
(a) 1:100 protein: lipid ratio activated P-gp; (b) P-gp reconstituted into nanodiscs 1:500 protein:
lipid ratio.

While the ATP hydrolysis tests showed similar activities between activated P-gp and P-gp
in nanodiscs, there is better stability with the nanodisc preparations since its storage could keep
the activity constant for a longer time while lipid activated P-gp could only be used freshly made
as its activity would decrease dramatically after the freeze and thaw cycles. For this reason,
nanodiscs preparations were used in subsequent steps.
We also wanted to investigate if the ratio of protein:lipid would interfere with verapamil
stimulation of P-gp activity. To test that, we made nanodisc preparations using two different
protein:lipid molar ratios – 1:250 and 1:500. The differences in lipid content would make the
nanodiscs more or less compact, and this could interfere with the P-gp conformational changes
within the nanodiscs, affecting its activity.
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On this test (figure 4.6), we observed that nanodiscs with any lipid content tested would
improve the activation of P-gp in comparison with the P-gp in micelles only. The basal activity
was better in both conditions. Still, the 1:250 nanodisc presented a better outcome, possibly due to
the smaller size of the nanodiscs that would allow the nucleotide-binding sites to be closer,
facilitating the ATP hydrolysis of P-gp. The drug stimulation of P-gp by verapamil was improved
by the presence of lipid, observed both in lipid-activated P-gp and nanodisc preparations.
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Effect of lipids on P-gp activity
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Figure 4. 6: P-gp activity on different lipid environments.
P-gp ATPase hydrolysis activity on four different environments with or without the presence of
VPL: P-gp in micelles, P-gp in micelles activated by L-α Phosphatidylcholine (PC), P-gp
reconstituted in nanodiscs 1:250 P-gp:lipid ratio, P-gp reconstituted in nanodiscs 1:500 P-gp:lipid
ratio.
After the initial ATPase hydrolysis activity tests using compound SMU 29, we also tested
the effect of the other two initial hit compounds, SMU 34 and SMU 45, on the human P-gp
reconstituted in nanodiscs (using 1:500 Pgp:lipid ratio) to compare with the previous results
obtained with the mouse cysteine-less MDR3 P-gp 70 (figure 4.7).
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Figure 4. 7: Initial hit compounds effect in the human P-gp hydrolysis activity.
Activity with P-gp using Phosphatidyl Choline (PC) (Basal activity between 91-94 nmol
NADH/min.mg P-gp; stimulated activity between 91-123 nmol NADH/min.mg P-gp)
While the effect of compound 29 on the hydrolysis activity of the verapamil-stimulated Pgp was not as efficient on this test, a strong inhibition was observed when the compounds 34 and
45 were used in these tests (figure 4.7 B). Additional tests were made using compound 29 to
confirm its inhibitory effect on the ATPase hydrolysis of the drug-stimulated P-gp (see chapter 5).

4.3 Methods and materials
4.3.1 Growth of P. pastoris human MDR1 wild-type P-gp 70, 75, 76, 86, 98:
Cells were grown using the methods previously described in Invitrogen for PichiaPinkTM
70, 75, 76, 86

. In short, A single colony from a YPD agar plate (1.34% Yeast Nitrogen Base (YNB),

4x10-5% Biotin, 2% dextrose, 15g agar/L) was inoculated into 10 mL of liquid Enriched Minimal
Glycerol (BMGY) medium (20% Yeast extract, 10% Bacto Peptone, 1.34% YNB, 1% glycerol,
4x10-5% Biotin, 100mM Potassium Phosphate) and incubated at 28oC with shaking to an OD600 of
~2.0 (18h). After 16-18 hours, 10 mL of cells were added to 1 liter of BMGY medium in a 2-liter
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Fernbach flask. Incubation at 28oC with shaking to OD600 of 2.0 to 4.0 was continued (~24h), then
the cultures were centrifuged into sterile bottles (6000 rpm at JXN-16 centrifuge, JLA 8,100 rotor
for 7 min at 23oC). Protein production was induced by switching the carbon source of the medium
from glycerol to methanol. The cells pellets were resuspended in 1 liter of enriched Minimal
Methanol (BMMY) medium (20% Yeast extract, 10% Bacto Peptone, 1.34% YNB, 4x10-5%
Biotin, 0,5% v/v methanol, 100mM Potassium Phosphate) in 2-liter Fernbach flasks covered with
cheesecloth. Incubation continued for 72h with the addition of methanol (1% v/v) at 24 and 48
hours. The pH correction was adjusted to ~6.0 if needed. Cells were finally collected by
centrifugation at 6000 rpm for 7 min at 4oC and resuspended in ice-cold “homogenization buffer”
(0.33 M sucrose, 0.3 M Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 2 mM DTT, 100 mM 6aminocaproic acid) at a concentration of 1g wet cells/mL buffer. The cells were stored at -80oC
4.3.2 Microsome preparation from yeast cells:
Microsomes were prepared essentially as described in 86, with the modifications made in
70, 75, 76

. Frozen cells were rapidly thawed by incubating bottles in a water bath set at 28-30oC for

~10 min, swirling the bottle's content to equilibrate the temperature. Lysozyme from T. Harzanium
was added while the cells were thawing to improve the cell lysis. All further steps were performed
at 4oC or on ice. Protease inhibitors were added once the cell suspension was thawed as follow 2
µg/ml pepstatin A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 350 µg/ml PMSF, and 10 µl/ml
DTT. All the cells were transferred to a chilled bead beater apparatus that was filled to top with
“buffer A1” (30% v/v glycerol, 50 mM Tris-HCl, pH 8, 125 mM NaCl, 10 mM imidazole)
supplemented with DTT (10 µl/mL). Cells were mechanically disrupted by using 0.5 mm glass
beads in a bead-beater (BioSpec) for a total of 14 minutes. The bead-beater was attached to a
jacketed chamber filled with an ice-salt mixture that helped maintain the lower temperature. Cell
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disruption was performed in 7 cycles of 2 minutes bead beating alternated with 6 minutes with the
bead-beater “off” to allow cells to cool down. This method helped solve the problem of overheated
samples due to the high heat output of the bead-beater motor. The homogenate was then
centrifuged for 30 minutes at 10,000 rpm (at Beckman J21-M equipped with a JA-20 rotor), and
the pellet was discarded. These steps removed unbroken cells, nuclei, and mitochondrial fractions.
The supernatant was centrifuged at 45,000 rpm (at Beckman Optima LE-80K equipped with Ti70
or Ti55.2) for 45 min at 4oC. After this ultracentrifugation, the supernatant contained cytoplasmic
protein and was discarded. The resulting pellet containing the microsomes was resuspended in
“wash buffer” (20% v/v glycerol, 50 mM Tris-Cl, pH 7.4 at 4oC, and protease inhibitors – 1 mM
PMSF, 1 mM DTT, Pepstatin A, Leupeptin, and Chymostatin as above). The microsomes were
recentrifuged at 45,000 rpm at Beckman Optima LE-80K equipped with Ti70 or Ti55.2) for 45
min at 4oC. The supernatant was discarded, and the pellet was resuspended initially using a
paintbrush then by 10 strokes by hand in a Potter-Elvehjem Teflon pestle homogenizer in 30 mL
of “buffer A1” plus protease inhibitors as before). The microsomes were then frozen at -80oC.
4.3.3 P-gp Purification:
Purification of the transporter protein was performed essentially as described in 70, 75, 76, 86, which
successfully resulted in highly enriched mouse (MDR3) P-gp in mixed micelles. The microsomes
were quickly thawed in a circulating water bath set at 28-30oC and then eluted to a final
concentration of 4mg microsomal protein/ml with “buffer A2” (20% v/v glycerol, 50 mM TrisHCl, pH 8.0 at 4oC, 50 mM NaCl, 10 mM imidazole, plus protease inhibitors as follow: 2 µg/ml
pepstatin A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 1 mM PMSF). Further dilution of the
sample to a final concentration of 2 mg microsomal protein/mL was achieved by adding a
volume of buffer A2 equal to a total volume of the first dilution supplemented with 1.2%
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(w/v) n-dodecyl-β-D-maltoside, DDM (Inalco), and 0.02% (w/v) lyso-phosphatidylcholine, LysoPC (Lipoid GmbH). DDM and lyso-PC were added to facilitate micelle formation, providing a
more native environment during the purification process. Sonication of samples at 4oC for 4 cycles
of 5 minutes each in an ultrasonic bath filled with ice/water, interspersed with 5 minutes incubation
in an ice bucket on a rocking platform, was performed to allow protein solubilization. The
suspension was then centrifuged at 20,000 rpm for 30 min at 4oC (Beckman Optima LE-80K
equipped with Ti 70 or Ti 55.2 rotors) to remove insoluble material. The supernatant was then
applied to the pre-equilibrated Ni-NTA agarose resin (Qiagen) column at a ratio of 100 mg
microsomal protein per 1ml packing resin (one bed volume). The rest of the procedure was
performed at 4oC. The chromatography gel and solubilized protein solution were mixed and
incubated for 10 minutes before the column was poured. The flow-through was ~2ml/min. The
resin with bound P-gp was washed first with 20 bed-volumes of “Column wash buffer 1” (20 %
glycerol (v/v), 50 mM Tris-HCl, pH 7.5 @ 4 oC, 50mM NaCl, 20mM Imidazole, supplemented
with 5 µL 20% (w/v) DDM/mL buffer; 1µL 10 % (w/v) lyso-PC/mL buffer), followed by 10 bedvolume of “Column Wash buffer 2” (20 % glycerol (v/v), 50 mM Tris-HCl, pH 7.5 @ 4 oC, 50
mM NaCl, 40 mM Imidazole, supplemented with 5 µL 20% (w/v) DDM/mL buffer; 1µL 10 %
(w/v) lyso-PC/mL buffer). For both washes, the flow-through was ~1ml/min. P-gp was then eluted
with 3 bed-volumes of Elution buffer (20 % glycerol (v/v), 50 mM Tris-HCl, pH 7.5 @ 4oC, 50
mM NaCl, 300 mM Imidazole, supplemented with 5 µL 20% (w/v) DDM/mL buffer; 1µL 10 %
(w/v) lyso-PC/mL buffer) with a ~0.5 ml/min flow rate. All eluted protein was collected for the
next step. To obtain concentrated P-gp, the elution fraction from the Ni-NTA column was
concentrated 70- to 100-fold using Amicon centrifugal filters (Amicon/Millipore Corp., Billerica,
MA) with a molecular mass cutoff of 100,000 Da. This procedure enriches both protein and
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micelles and ensures retained solubilization of the membrane protein, resulting in concentrated,
enriched, and solubilized protein for use in nanodisc assembly. The protein was aliquoted in 40µl,
ready to be used in nanodisc assembly, and stored at -80oC.
4.3.4 Lipid activation:
Activation of P-gp was performed under varying conditions. As suggested by 70, 86, ~8 mM
Dithiothreitol (DTT) was added to purified P-gp with subsequent incubation on ice for 5 min.
Lipids were added at different concentrations and incubated at room temperature for 15 min. After
the incubation, the samples were sonicated at 4°C for 30 seconds and kept on ice until used in
ATPase assay. In separate experiments as described in 86, activation was performed in the absence
of DTT.
4.3.5 Nanodisc Assembly and Recovery 84, 85:
P-gp in mixed detergent micelles obtained during protein purification was assembled as
described in Chapter 2 – Material and Methods.
4.3.6 Assays of ATPase activity – Coupled-enzyme assay 70:
The activity assay for ATP hydrolyzing enzymes was developed by 74, as described in
Chapter 2 – Material and Methods.
4.3.7 Drug inhibition assays 70, 74-76:
A total volume of 5 ul containing 25 µM of experimental compounds dissolved in
dimethylsulfoxide (DMSO) was added to each well along with 45 ul of equilibration buffer (20%
glycerol, 50 mM Tris H-Cl, pH 7.5), in a 96-well plate. To each of these wells, 50 µl of the solution
containing 80-100 µg/ml concentrated P-gp incorporated into nanodiscs, in equilibration buffer in
the absence or presence of 300 µM verapamil. The plate was incubated at 37oC for 30 min before
adding 100 µl of prewarmed at 37oC coupled enzyme assay cocktail (as described on Assay of
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ATPase activity – Couples-enzyme assay). Immediately after addition, ATPase activity was
assayed for 20-30 min. ATP hydrolysis was recorded as absorbance decrease at 340 nm (ε=6300
M-1 cm-1), using a BioTek plate reader (BioTek, Winooski, VT). All tests were performed in
duplicate or triplicate and repeated at least two times using different P-gp preparations.

4.4 Discussion

To evaluate the mechanism of inhibition in the human P-gp, we have isolated human P-gp
from the yeast Pichia pastoris using mixed detergent micelles. The P. pastoris cells containing
human P-gp received from Dr. Urbatsch (Texas Tech University Health Science Center, Lubbock,
TX) was grown by a large fermenter, which resulted in cells with relatively high P-gp expression,
as was seen after purification and providing about 0.02 mg protein/g of cells of yield as well as
higher ATPase activities of P-gp both in micelles and nanodiscs. The final P-gp fraction presented
few or no contaminants, and a simple additional wash (40 mM imidazole buffer) was sufficient
during the purification using the chromatography resin Ni-NTA. Even though there were losses of
protein during each purification fraction, the high protein yield in the final fraction was sufficient
to proceed with our tests.
The same expression and yield were not observed in our attempts to grow the cells in-house
using the 2.8 liters Fernbach flasks at 28oC incubators. This observation made us modify our
washing steps during the purification process and attempts to ensure better expression and fewer
contaminants in the final P-gp fraction. Additional wash steps resulted in large losses of the protein
P-gp. Some changes in imidazole concentration present in the wash buffers allowed us to achieve
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somewhat better results. Using the first wash with 40mM imidazole buffer and a second wash with
a 60 mM imidazole buffer resulted in slightly more enriched protein.
As described by others 86, the presence of lipids is required to achieve higher P-gp ATPase
activity. On our initial tests, P-gp basal activity was slightly enhanced by the addition of lipids or
upon nanodisc assembly (figure 4.4). Nanodisc assembly showed better stability of P-gp and less
loss of activity than the lipid-activated samples after freezing. Verapamil-stimulated activity
increased both upon lipid-activation of P-gp and P-gp reconstitution into nanodiscs. As native
membrane proteins are found embedded in a lipid environment, this variation observed on the
ATPase activity of purified P-gp could be due to different intrinsic lipid content in the preparations.
P-gp reconstituted into nanodiscs was the lipid activation method used from here.
To investigate potential differences between the human and mouse versions of P-gp, we
replicated the tests' conditions with mouse MDR3 Cysteine-less P-gp using the human P-gp variant
reconstituted into nanodiscs. The results showed that the basal activity was slightly affected (range
activity in nmol NADH/ min.ng P-gp) by the compounds 29,34 and 45 (figure 4.7 A), similar to
what was found in 70. While the effect of compound 29 on the hydrolysis activity of the verapamilstimulated P-gp was not as strong in these initial tests, a strong inhibition was observed when the
compounds 34 and 45 were used (figure 4.7 B). Additional assays were made using compound 29
to confirm its inhibitory effect on the ATPase hydrolysis of the drug-stimulated P-gp (chapter 5).
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CHAPTER 5:
DRUG SCREENING FOR P-GLYCOPROTEIN INHIBITORS

5.1 Introduction
In 2021, the American Cancer Society estimated almost 2 million new cancer cases to be
diagnosed in the U.S and over 600,000 cancer deaths in the U.S. 118. Even though we are making
great progress in our understanding of the mechanisms of how cancer works, we still cannot
prevent it from happening. Improvement in cancer treatment might therefore be considered an
easier goal to achieve. Some of the main challenges for successful cancer treatment are related to
the variety of ways that cancer cells develop ways to evade therapy, i.e., ways to become resistant
to chemotherapy drugs.
As mentioned previously (see chapter 1), a great contributor to chemotherapy failure is
multidrug resistance (MDR) mediated by the overexpression of ATP-dependent efflux transporters
that prevent the drug accumulation inside the cell, promoting cancer survival

12

.

The search for inhibitors of P-glycoprotein – the most studied of these transporters - did
not bring much hope over the last decades 119. To date, most of the inhibitor candidates were found
to be substrates of P-gp. Since they work as competitive transport inhibitors, high concentrations
were necessary for the desirable inhibitory effect, leading to unacceptable toxicity. Another
concern is that such candidates competed with substrates of the cytochrome P450 isoenzyme 3A4,

causing drug-drug interactions 119, 120. Better methods to screen for good drug lead candidates to
overcome these limitations were addressed in recent studies performed by our group 2, 33, 70.
Crystal structures and homology models of P-gp allowed the utilization of targeted
screening and molecular dynamics simulations 31 for drug docking experiments 55, 56.
We have previously identified a group of compounds that were hypothesized to prevent
hydrolysis of ATP by P-gp but to not be substrates of P-gp 31 (see chapter 4), and several drug-like
compounds were discovered

33, 70, 80

(figure 1 a). We hypothesized that improving the binding

characteristics of a previously identified P-gp inhibitor would lead to a more successful drug

2

(figure 1 b).
Compound SMU-29, a P-gp inhibitor previously identified

70

, was predicted to bind to a

site on P-gp that is distinct from the ATP binding sites of the pump. This characteristic made the
compound an interesting candidate for further development since it lowered the likelihood of
negative effects on other ATP utilizing enzymes and lowered the chance for side effects of the
potential drug. Close inspection of the docking site of SMU-29 in the putative allosteric site on Pgp indicated that there was space available for additional interactions between the protein and
SMU-29. Modifications to SMU-29 that would fill this space and create additional
protein/compound interactions were hypothesized to increase the binding affinity of these SMU29 variants 2.
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Figure 5 1: Compound 29 and the rationale for its structure modification.
(A) Predicted binding site of compound SMU-29. Figure reproduced from70. Location of docked
inhibitors in the human P-gp model. On the left is the location where the nucleotides are bound.
On the right, the approximated location of the highest affinity interaction of P-gp inhibitors is
predicted by docking studies 70. SMU-29 (top right) is bound outside the nucleotide-binding sites
suggesting an allosteric effect causing inhibition of ATP hydrolysis likely by blocking
conformational transitions of the enzyme. (B) Schematic plan for the compound 29 modification:
structure of compound 29, the “Eastern” and “Western” portions of the molecule, the docking of
the potential allosteric site, and the possible modifications. Figure reproduced from 2.

Assessment of the docking profile indicated that “filling” additional space, especially
around the “Western” end of the compound, would create new and better protein-compound
interactions. (figure 5.1) 2. Experiments were designed to alter this specific part of the compound
for additional interactions with P-gp and binding affinity optimization. Using in silico medicinal
chemistry computational methods, where derivatives of SMU-29 were computationally designed,
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and binding affinities were predicted 2, several variants of SMU-29 were chosen for chemical
synthesis. In addition, close inspection of the binding interactions of SMU-29 with the binding site
on P-gp led to the synthesis of several more rational structure-based designed variants of hit
compound 29 2.

5.2 Results
5.2.1 Optimizing in silico identified targeted inhibitors of P-gp
The chosen variants of SMU-29 were synthesized by Dr. Maha Aljowni and Professor Alex
Lippert, Department of Chemistry, SMU. Cell culture experiments using the P-gp overexpressing
human prostate cancer cell line, DU145.TXR (19) indicated that all of these compounds reversed
multidrug resistance 2.
The effect of the SMU variants on ATP hydrolysis activity of P-gp was initially assessed
using the mouse cysteine-less P-gp 2, which had been found by our lab to be somewhat more stable
than the human homologous protein. The experiments suggested that one compound (-551) from
the computationally screening group may be a transport substrate because it stimulated the basal
P-gp ATPase activity,121, 122, while from the rationally designed group, only the compound -231
presented similar results.
To evaluate the effects of the 29 variants on ATPase activity of normal, cysteine-containing
human P-gp, P-gp was expressed in Pichia pastoris and reconstituted into membrane nanodiscs as
described in chapter 4. Fig. 5.2 shows the results of these experiments. ATP hydrolysis in the
presence of DMSO was the 100 % activity control. The specific basal activity of normal human
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MDR1 P-gp was between 123 and 193 nmol min-1g-1, and transport substrate (verapamil)
stimulated activity was between 193-263 nmol min-1mg-1.
The studies indicated that all SMU-29 variants inhibited verapamil-stimulated ATPase
activity (figure 5.2 and table 5.1). SMU-29 variants -216, -231, and -551 inhibited basal activity,
while the other compounds had no effect. None of the compounds were found to stimulate ATP
hydrolysis activity. It had been generally assumed that ATP hydrolysis is stimulated in the
presence of transport substrates 31, 123. The lack of stimulation of ATP activity by any of the SMU29 variants therefore tentatively suggested that none of these compounds were transport substrates
of the pump.

Figure 5 2: ATPase activity of nanodisc reconstituted P-gp after incubation with 29 variants.
(A) Effect of the 29 variants on basal activity P-gp. B. Effect of the 29 variants on verapamil
stimulated the activity of P-gp in nanodiscs. The data were normalized to vehicle (DMSO) only
activities (3 independent experiments with duplicate samples). (***, p < 0.001; **, p < 0.01; *, p
< 0.1; NS, not significant)
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Table 5 1Table 5.1: Summary of the effects of the compound 29 variants on ATP hydrolysis by
human P-glycoprotein 2

To test the hypothesis that the lack of stimulation of ATP hydrolysis activity by the 29variants indeed suggested that these compounds were not transport substrates, intracellular
accumulation of the 29 variants in P-gp overexpressing cancer cells was measured comparison
with the P-gp transport substrate, daunorubicin. In collaboration with Dr. Noelle Williams from
UTSW Preclinical Pharmacology Core, we used LC-MS/MS to quantify the intracellular
accumulation of the compounds in the absence or presence of the strong P-gp inhibitor tariquidar
(TQR) in the P-gp overexpressing prostate cancer cell line (DU145 TXR). These experiments
strongly suggested that none of the five SMU-29-variants that were computationally designed and
underwent computational docking routines were deemed transport substrates of P-gp 2. The five
90

compounds that were rationally designed with no computational pre-screening, three variants ( 238, -255, -286) were likely transport substrates of P-gp 2. This finding strongly indicated that
stimulation of P-gp ATPase activity is not a good indicator for a compound being a transport
substrate or not. Other types of experiments are needed to make that assumption. The studies also
showed that structure-based rational design without computational pre-screening using the
subtractive method first described in 70 does not result in reasonable predictions on whether or not
the variants will be transport substrates of the pump 2.

5.2.2 Biochemical and biophysical evaluation of in silico identified P-gp inhibitors.
From a total of 124 compounds that were computationally identified as potential P-gp
inhibitors and that were assessed in our lab, 16 compounds (57, 60, 61, 66, 68, 70, 71, 74, 78, 79,
96, 97, 101, 111, 114 and 124) were deemed to be the most promising hit compounds by their
ability to reverse multidrug resistance in various P-gp overexpressing cancer cell lines
(McCormick et al., unpublished) in addition to the three initially identified inhibitors SMU 29,
SMU34 and SMU 45

70

. These 16 compounds were further evaluated for their effect on ATP

hydrolysis activity by the purified human P-glycoprotein (similar to the 29 variants, see above)
(figure 5.3).
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Figure 5 3: Effect of the hit compounds on ATP Hydrolysis of Human MDR1 P-glycoprotein.
Results are presented compared to DMSO control ± standard deviation (2 independent experiments
with triplicate samples). The specific basal activity of normal human MDR1 P-gp was between
171 and 235 nmol NADH min-1 mg of P-gp -1, without a transport substrate. (***, p < 0.001; **,
p < 0.01; *, p < 0.1; NS, not significant)

The presence of DMSO carrier was used as 100 % activity, and the presence of SMU-45
70

was used as a positive control for P-gp ATPase inhibition. Compounds 57, 60, 68, 71, and 74

showed significant inhibition of ATP hydrolysis, while all other compounds either stimulated
ATPase or did not exhibit significant effects.
To evaluate whether the compounds that inhibited ATP hydrolysis indeed affected
nucleotide binding, electron spin resonance spectroscopy (ESR) using a spin-labeled ATP analog,
2’,3’-SL-ATP (SL-ATP) 79 was used.
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We have used ESR previously to evaluate the mechanism of inhibition of P-gp activity by
discovered inhibitors 70. Using SL-ATP, the number of accessible ATP binding sites on P-gp can
be assessed 70.
Using the normal human P-gp, titrations of P-gp with SL-ATP were performed, and the
binding of SL-ATP to P-gp was determined in the absence and presence of two of the most
promising P-gp inhibitors, compounds 70 and 111 (figure 5.4).

Figure 5 4: SL-ATP binding to human P-gp.
(A) P-gp SL-ATP titration. (B) SL-ATP titration in the presence of the compound 111 (top panel)
and compound 70 (bottom panel)

Interestingly, titration of the normal cysteine-containing human P-gp resulted in binding
curves that did not saturate at the expected 2 mol SL-ATP/mol of protein, unlike in previous
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experiments where the cysteine-less mutant of the mouse P-gp was used 2, 75. However, the binding
of SL-ATP was significantly reduced in the presence of inhibitors 70 and 111, indicating the direct
effect of these compounds on SL-ANP binding. The phenomenon of SL-ATP binding curves to Pgp that do not saturate at a maximum of 2 mol/mol has been observed previously when ATP
binding a normal, cysteine-containing mouse P-gp was evaluated. This phenomenon will be
discussed later.
5.2.3 Other inhibitors of P-glycoprotein
In collaboration with Amit Tiwari, College of Pharmacy and Pharmaceutical
Sciences, Department of Pharmacology and Experimental Therapeutics of the University of
Toledo, several compounds were tested for their effects on ATP hydrolysis. These compounds
were originally designed in the Tiwari lab as inhibitors of the second important multidrug
resistance protein, BCRP. They were shown in cell culture to cause cell death in BCRP,
overexpressing cancer cells in the absence of chemotherapeutics while not affecting non-cancerous
cells that do not overexpress BCRP (unpublished). While the compounds were designed to interact
with BCRP, it was interesting to investigate whether these compounds also interacted with Pglycoprotein.
Initial ATP hydrolysis assays using the normal, human P-glycoprotein indicated that all
experimental compounds affected ATPase activity (figure 5.5). These results are important
because they indicate cross reactivity of the compounds with P-gp and not only with BCRP.
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Figure 5 5: Effect of the Tiwari’s compounds on ATP Hydrolysis of Human P-glycoprotein.
Results are presented compared to DMSO control ± standard deviation The specific basal activity
of normal human MDR1 P-gp was between 171 and 235 nmol NADH min-1 mg of P-gp -1,
without the presence of a transport substrate. (n=4, two independent tests; ***, p < 0.001; **, p <
0.01; *, p < 0.1; NS, not significant).

5.3 Methods and materials
5.3.1 ATPase activity assay using activated P-gp in micelles and reconstituted P-gp into
nanodiscs:
ATP hydrolysis activity was measured using a Coupled Enzyme Assay (CEA) adapted to
a plate reader format 70, 74 as described earlier with the following modifications: To each well, 0.52 µg of P-gp incorporated into nanodiscs were added in the absence or presence of 100 µM
verapamil (VPL), and Tris-Cl buffer (50mM, pH 7.5) completed 100 µl volume.
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5.3.2 Drug inhibition assays:
As described in

70

, the effects of the in silico identified potential inhibitors and the

compounds from Dr. Tiwari’s group on P-gp were assessed at 25 µM of the experimental
compounds dissolved in dimethylsulfoxide (DMSO) in assays as described above. Vehicle DMSO
only was used as a control.
5.3.3 Electron spin resonance:
ESR measurements were performed using a Bruker EMX 6/1 ESR spectrometer operating
in the X-band mode, equipped with a high sensitivity cavity, essentially as described 75. Human Pgp was concentrated to 30 µL, and known amounts of SL-ATP were added to the protein sample
using a Hamilton syringe. After careful mixing, 30 µl of the sample was transferred to a 50 µl glass
capillary. The top of the glass tube was closed, and it was inserted into a quartz cuvette. The cuvette
was then placed in the ESR cavity, and the measurements were made at room temperature. The
measurements were made with constant parameters: microwave frequency 9.33 GHz, modulation
frequency 100 kHz, resolution 1024 points, microwave power 12.63 mW. The signal gain was
adjusted to the SL-ATP concentrations for better visualization. The buffer was the same as used
to elute P-gp from the chromatography column (see chapter 4, Material and methods section 4.3.3).
A standard curve was generated where known amounts of SL-ATP were added to the buffer that
was concentrated similarly to the protein sample to control for increased viscosity of the
detergent/mixed micelle solution. The signal amplitude of the high-field signal of the ESR spectra
was compared to the known amount of SL-ATP added. The moles of protein-bound ATP were
then determined as the difference of signal amplitude in the presence of a known amount of P-gp
compared to the signal amplitude in the absence of P-gp. The mol of protein-bound SL-ATP per
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mol of protein was plotted over the concentration of free SL-ATP present. Results were plotted
and calculated using Graphpad.

5.4 Discussion
We had previously used high-throughput in silico ligand docking studies and identified
drug-like compounds that reversed MDR in human cancer cells in cultures 1, 70, 80. The effects on
P-gp ATP hydrolysis activity were also assessed at that time. These results were used as an initial
biochemical evaluation of the mechanism of inhibition by these compounds. For these initial
experiments70, 124, a cysteine-less mutant of the mouse homolog of P-gp was used due to its
somewhat increased stability compared to the human protein. Interestingly, effects on ATP
hydrolysis did not always correlate well with the effects of the potential inhibitors in the cell culture
of human cancerous cells. One hypothesis was that the mouse protein, although 87% homology 45,
may be different enough to not be a good model for assessing inhibitor effects on the human
protein. To overcome the low stability of the human protein, the human P-gp was assembled into
nanodisc to provide a more nature-like membrane environment to maintain its active form for the
activity assays.
For the 29-variants biochemical assays using purified human P-gp reconstituted in
nanodiscs, compounds from both groups inhibited drug stimulated activity of P-gp (figure 5.3).
None of the new compounds stimulated the basal activity, suggesting no interaction with the drug
binding sites. Some of them inhibited P-gp basal activity, even though LC-MS/MS data (figure
5.4) indicated four of them to be transport substrates. These findings suggested that stimulation of
basal ATPase activity may not be a good predictor for compounds being transport substrates of Pgp.
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The experiments using LC-MS/MS to test for the quantitative cellular accumulation of the
29-variants in the presence of the P-gp inhibitor, tariquidar, indicated that none of the compounds
from the computationally screened group was a transport substrate. In contrast, from the rationally
designed/not computational screen group, 3 of the 5 compounds were likely P-gp transport
substrates 2.
Aside from the biochemical assays to measure ATPase activity, the results also indicate
the successful approach of the computational screening and analysis in optimizing P-gp inhibitors
2

.
Next, another set of compounds were screened for potential P-gp ATPase hydrolysis

inhibitors. Most of these compounds chosen for the biochemical assay affected the ATPase activity
of P-gp at some level (inhibition or stimulation), suggesting the successful approach to the
improved drug screening (figure 5.3). The next step would be to assess if they interact with the
nucleotide-binding domain using electron spin resonance.
ESR spectroscopy is a technique that detects unpaired electrons. Due to the low occurrence
of paramagnetic species in biological systems, spin-labeled nucleotides (SL-ATP) were introduced
78

.
In our experiments, it was not possible to determine the binding characteristics of SL-ATP

to the human cysteine-containing P-gp. As shown in figure 5.4 a, the binding curves of SL-ATP
to the human P-gp extrapolated significantly beyond the predicted maximum binding of 2 mol/mol.
A similar phenomenon was observed previously by our group when the wild-type, cysteinecontaining mouse P-gp variant was tested using ESR 75. In these experiments, the binding of SLATP also significantly exceeded the expected 2 mol/mol. The hypothesis at that time was that SLATP interacted directly with the cysteines in the Walker A motif (Cys-431 and Cys-1041). This
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interaction likely resulted in a chemical reduction of the radical 75, 87, leading to a decrease of the
signal amplitude of the ESR spectra mimicking binding of the SL-ATP to P-gp. This hypothesis
was then supported by experiments where a cysteine-less variant of the mouse P-gp was used. In
the absence of cysteines, maximum binding of SL-ATP of 2 mol/mol P-gp was observed.
In the presented experiments, the fact that the two P-gp inhibitors, compounds 70 and 111,
drastically decreased the binding of SL-ATP to P-gp strongly suggests that these compounds affect
nucleotide binding to P-gp. Repeating these experiments with a cysteine-less mutant of the human
P-gp will be needed for further confirmation.
Our collaborative work with the Tiwari lab (University of Toledo) indicated that
compounds designed and synthesized in their group that were supposed to specifically interact
with the breast cancer resistance protein (BCRP) also affected ATP hydrolysis of purified human
P-gp. These findings will be of importance for the design of future experiments and drug
development.
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CHAPTER 6:
THE CHALLENGES OF PRODUCTION AND PURIFICATION OF THE ABC
TRANSPORTER BREAST CANCER RESISTANCE PROTEIN (BCRP) ON LARGE SCALE
USING THE YEAST PICHA PASTORIS.

6.1 Introduction
One of the most studied ABC transporters, the Breast Cancer Resistance Protein (BCRP),
was first discovered by its expression in MCF7 breast cancer cells

125

. Since then, it was found

that BCRP is expressed in many tissues, including those with a barrier or detoxifying functions
such as placenta
intestine

128

126

, liver

, cerebral endothelium

129

, kidney

130

127

, apical membrane of the polar epithelial cells in

, and also blood-brain barrier

131, 132

. BCRP actively exports a

diverse range of chemicals and toxins from the cells, preventing chemotherapeutics from
accumulating to the concentration required to kill cancer cells. BCRP plays a protective role
against xenobiotics and their metabolites entering vital organs in the human body

130

. Besides its

known function in MDR, BCRP also exports steroids such as cholesterol, progesterone, and
testosterone 133-137.
The ABC transporter BCRP belongs to the ABCG subfamily. It is encoded by the ABCG2
gene located at chromosome 4q22. Expression results in a 2.4 kb mRNA encoding 655-amino acid,
72 kDa polypeptide localized to the plasma membrane 138, 139.
The BCRP is expressed as a single polypeptide containing only a single transmembrane
domain (TMD) with six transmembrane α-helices (TM1-6) and a nucleotide binding domain

(NBD) (figure 1)

140

. BCRP is considered a half transporter and needs to dimerize to gain full

functionality. The binding and hydrolysis of the two ATP molecules by two NBD in conjunction,
where both are using the missing structural elements from the opposing NBD in a complementary
fashion, induce the conformational change necessary for substrate transport TMD

141, 142

. BCRP

is mostly found as homodimers, but it may function as a homotetramer in the plasma membrane
143

. The NBD and the TMD are connected by two α-helices – connecting helix and coupling helix

141

. As a unique structural feature of BCRP, there is a longer extracellular loop (EL3) between

TM5 and TM6 that bears three cysteine residues that form an intramolecular (C592-C608) and an
intermolecular (C603-C603’of opposing monomers) disulfide bond that is important in the
stabilization of dimerization of BCRP 144, 145.

Figure 6 1: BCRP 3D structure and transport cycle of BCRP
Figure modified from Manolaridis et al (2018). The structure is showed as a dimer of two BCRP
protein chains (purple and green), substrate-bound (left) and ATP-bound (right)
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Given its role in MDR, inhibitors of BCRP have been studied for years12, 125, 126, 129, 131, 132.
To search for BCRP inhibitors as potential leads for developing co-therapeutics to combat
MDR, we used high-throughput in silico ligand docking similar to studies performed previously
in the search for inhibitors of the P-glycoprotein (P-gp)70, 80. Using molecular models of P-gp and
BCRP, we identified drug-like compounds that reversed MDR in human cancers

1, 70, 80

. Several

drug-like compounds were identified that reversed multidrug resistance in a BCRP-overexpressing
breast cancer cell line generated in our lab. Biochemical assays using purified BCRP would
provide important information regarding the mechanism of inhibition. Such assays have been
successfully used as primary screens in our P-gp drug finding process

70

. For these purposes,

relatively large amounts of protein are required to perform these assays. Expression of human
BCRP in Pichia pastoris in a biologically active form was previously reported

146

. In our group,

we decided to design a gene for human BCRP optimized for codon usage for translation in P.
pastoris, similar to the work done in 82 for P-gp expression.
Obtaining BCRP in a near native-like environment with high biological activity will be
necessary for the assessment of efficiency as well as the mechanism of BCRP inhibition of our
newly found drug-like compounds. In this chapter, strategies for cloning and expression of BCRP
on a large scale will be discussed.

6.2 Results
6.2.1 Cloning and expression in PichiaPinkTM and GS115 Pichia pastoris strains.
Following the same procedures applied for the P-gp codon-optimized cloning (see Chapter
3), a new BCRP clone optimized for translation in P. pastoris was synthesized and inserted in the
pUC57 vector by GenScript (Piscataway, NJ). The unique restriction sites, 5’EcoRI and 3’KpnI,
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were incorporated into the BCRP DNA sequence to allow cloning into pUC57 and PichiaPinkTM
vectors. The pUC57-BCRP was transformed into NEB 5-alphaTM to allow replication of the
multicopy vector. Both pUC57-BCRP and pPinkHC were double digested with the restriction
enzymes KpnI and EcoRI to generate complementary ends. This BCRP DNA sequence was
removed from the initial plasmids and then inserted into pPinkHC plasmids and transformed into
NEB 5-alphaTM. Plasmids were linearized by SpeI before integration into PichiaPinkTM strains 1
and 4 (see Chapter 3 for the methodology used on P-gp cloning). The PCR product of genomic
DNA from transformed PichiaPink™ Strain 4 yeast strains was observed in 0.6% agarose gels
(figure 6.2). AOX1 and CYC1 primers were used to probe genomic DNA for the presence of the
predicted 2.37 kb PCR product. The plasmid control was a PCR product using the same primers
to probe the pPinkHC-BCRP vector for the same insert size. Western blot confirmed protein
expression on mini microsome preparations from the pilot cultures prepared and from a large
microsome preparation (figure 6.2 b) using the B1 anti-BCRP antibody (Santa Cruz). The BCRP
cloning procedures into PichiaPinkTM cells and initial purification attempts were made previously
by Collette LaVigne (unpublished) (figure 6.2), and difficulties for the purification of BCRP were
reported. In these attempts, the final elution step during the purification preparation did not show
noticeable BCRP protein (figure not shown). Western blot analyses indicated a consistent loss of
BCRP protein during the purification procedure (figure 6.2 b). Some of the losses were observed
during the initial solubilization and before the affinity chromatography step. Attempts to solubilize
the sample were made using different concentrations of the detergents. Lyso-PC and DDM did not
provide improvements. The use of the detergent Fos-choline 16 only showed very slight
improvement during the solubilization (figure 6.2 c)
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Figure 6 2: BCRP gene in PichiaPink strain 4.
(A) Integration of BCRP gene in transformed PichiaPink strain 4. PCR product of genomic DNA
~2.2 kb. (B) Expression of BCRP confirmed during the growth in the methanol-based medium –
Western blot B1 anti-BCRP antibody – Data from Collete LaVigne M.S. dissertation thesis (2017).
Before optimizing protein purification, we accessed whether the BCRP expressed in
PichiaPink membranes was catalytically active, and initial ATPase hydrolysis activity tests were
performed (figure 6.3).
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Figure 6 3:Initial ATPase activity of BCRP on PichiaPink membranes.
ATPase activity assays were performed as described in 74. 0.2 mM EGTA and 8 mM NaN3 were
included in the ATPase cocktail mix to prevent activity from other ATPases.
The ATP hydrolysis activity of untransformed PichiaPink strain 4 (PPink4) in the absence
and presence of 1 µM Hoechst, as transport substrate of BCRP, are shown in panels 1 and 2. No
stimulation of ATPase activity in the presence of Hoechst was observed in the untransformed
strain. The ATP hydrolysis activity of the PichiaPink4-BCRP transformants (PPink4-BCRP) is
shown in panels 3 and 4, in the absence and presence of 1 µM Hoechst. Stimulation of ATP
hydrolysis is observed in the presence of Hoechst. The data are averages from three replicates per
sample. The results indicated that biologically active BCRP had been inserted into the PichiaPink
membranes.
Even though the PichiaPink expressed BCRP was biologically active, there still remained
the problem described above, that the membranes seemed very hard to solubilize. Most of the
BCRP remained in insolubilized form, making further purification problematic. We, therefore,
decided to also clone BCRP into the previously used Pichia pastoris GS115 strain
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Following the steps used for the MDR1 cloning into GS115, adapter primers bcrp-pink-tohil forward/reverse were designed to add the sequences for SacII and XhoI restriction before and
after the BCRP DNA sequence from the pPinkHC-BCRP plasmid (figure not shown). The BCRP
gene sequence with the complementary ends was then removed from the original plasmid. The
BCRP insert, and the plasmid pHIL-E556C were double digested with the restriction enzymes
SacII and XhoI to generate complementary ends. Both insert and vector were ligated and
transformed into NEB 5-alpha cells. Transformants were screened, and the one clone containing
the verified BCRP sequence was linearized with NotI and desalted. Integration into the GS115
cells was achieved by electroporation, and selection of the transformants was made by screening
for the Muts and His+ phenotype and PCR, as described in Chapter 3 – P-gp cloning
BCRP internal primers were used to confirm the presence of BCRP DNA in the
transformant, generating a PCR product of the size ~ 1564 bps, and pHIL primers to confirm the
complete BCRP DNA insert, resulting in a PCR product of the size ~ 2970 bps. Four different
colonies (#9-12) were evaluated (figure 6.4 a). Sample 12 presented the best outcome, the BCRP
sequence was verified, and BCRP expression was confirmed from the pilot cultures (figure not
shown).
To assess the best possible conditions for growth and expression, two cultures were
prepared with different culture media: the first followed the original protocol, and cells were grown
in minimal glycerol medium (MG – YNB, Biotin, Glycerol)/minimal methanol medium (MM –
YNB, Biotin, 0.5%$ methanol) while the second one was grown on enriched medium as suggested
for PichiaPinkTM cells (BMGY – 1% Yeast extract, 2% bacto peptone, 1mM Potassium Phosphate,
1.34% YNB, 0.0004% Biotin, 1% Glycerol/ BMMY - 1% Yeast extract, 2% bacto peptone, 1mM
Potassium Phosphate, 1.34% YNB, 0.0004% Biotin, 0.5% methanol). The cultures were grown
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for 24 hours in MG/BMGY. The medium was then replaced by MM/BMMY to induce protein
expression. Aliquots were taken at indicated time points for protein expression analysis (figure 6.4
b).

Figure 6 4: BCRP DNA screening and pilot expression tests in Pichia pastoris GS115.
(A) Integration of BCRP gene in transformed GS115 yeast strain. - Lanes 1 & 2: pHIL-BCRP
template controls; Lanes 3 & 5: colony #9; Lane 4: 1 kb GeneRuler DNA marker; Lanes 6 & 7:
colony #10; Lanes 8 & 9: GS115-BCRP #11; Lanes 10 & 11: GS115-BCRP #12. (B) Expression
of BCRP confirmed by Western blot analysis using B1 anti-BCRP - Lane 1: MG 24 hrs; Lane 2:
MM 24 hrs; MM 48 hrs; MM 72 hrs; Lane 5: PichiaPink-BCRP control; Lane 6: Protein ladder;
Lane 7: BMGY 24 hrs; Lane 8: BMMY 24 hrs; Lane 9: BMMY 48 hrs; Lane 10: BMMY 72 hrs.

After comparing the performance on the expression of BCRP using the regular MG/MM
medium and the enriched medium BMGY/BMMY recommended for the PichiaPinkTM, and we
noticed better results on expression from the enriched medium (figure 6.4 b, lane 10)
The time-course analysis was also made on PichiaPink-BCRP cells, and interestingly the
higher expression was achieved at 9 hours with a decrease of expression at 24 hours (figure 6.5 a).
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The culture b showed a recovery of expression at 33 hours to a second decrease at 48 hours (figure
6.5).

Figure 6 5: BCRP expression in PichiaPink- time course.
(A) Culture A – Cells were grown for a total of 24 hours after methanol induction (BMMY). Lane
1, microsome BCRP control. Lane 2, protein ladder. Lane 3, 24 hrs in BMGY. Lane 4-6, after
switching to BMMY. Lane 4, 6hrs. Lane 5, 9 hrs. Lane 6, red arrow shows a decrease of BCRP
expression at 24 hrs. (B) Culture B – Cells were grown for a total of 48 hours after methanol
induction (BMMY). Lane 1, microsome BCRP control. Lane 2, protein ladder. Lane 3, 24 hrs in
BMGY. Lane 4-9, after switching to BMMY. Lane 4, 6hrs. Lane 5, 9 hrs. Lane 6, red arrow shows
a decrease of BCRP expression at 24 hrs. Lane 7, 30 hrs. Lane 8, 33 hrs. Lane 9, 48 hrs, the red
arrow shows a decrease of expression at this time point. Both cultures were grown for 24 hours in
a BMGY medium. Then the medium was replaced by BMMY to induce protein expression.
Aliquots were taken at times indicated for protein expression analysis – 10 µg of lysates were
applied to each well.

One major concern during the first step of the purification preparation was the breakage of
the cells. The established method of breakage using glass beads and a bead beater seemed not to
be very effective. So, high-pressure cell rupture was carried out using an Avestin Emulsifle C-5
homogenizer (Avestin, Inc.). After three passages through the EmulsiFlex, we noticed relatively
good breakage of the cells on both P. pastoris strains (figure 6.6).
Cell breaking strategies that combined the use of Emulsiflex and glass beads/ bead beater
were also assessed (figure 6.6).
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Figure 6 6: Optimizing BCRP Preparation - Cell breakage.
Cell breakage after 3 passages of the Emulsiflex Homogenizer at a minimum of 5,000 psi. Arrows
in the image on the right indicate broken cells.
The next challenge was solubilization. We noticed that the way the cells were broken
directly influenced the results during the next steps of purification, i. e. membrane solubilization,
and affinity chromatography. The solubilization method was also crucial for the success of the
microsome solubilization. For P-glycoprotein (P-gp), the microsome fraction was first diluted to
2 mg/ml in low glycerol and low salt buffer containing protease inhibitors, 2-mercaptoethanol, and
0.6% of the non-ionic detergent n-dodecyl-β-d-maltoside (DDM). The suspension then undergoes
3-5 cycles of 5 min of sonication in an ice-cold water bath, alternated with 5 min of incubation on
the ice at the rocker platform. After this, the suspension is cleared by ultracentrifugation, and the
supernatant is loaded onto a pre-equilibrated Ni-NTA chromatography column. This procedure
worked fairly well for Pichia GS115 samples but failed on PichiaPinkTM membranes. Extra
sonication steps were added using a probe sonicator with 6 cycles of 60-70 watts for 30 seconds
before the water bath sonication. Prior to the sonication, the suspension was diluted to 2 mg/ml
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with the addition of Lyso-PC or E. coli lipids. This solution seemed to be sufficient to solubilize
the PichiaPinkTM microsome containing BCRP.
We still needed to test the combination of breakage and solubilization methods to achieve
the best possible results (figure 6.6 and 6.7).

Figure 6 7: Optimizing BCRP microsome solubilization – test 1
Three breakage strategies - (1) emulsiflex only; (2) glass beads only; (3) Glass beads + emulsiflex
- paired with four solubilization procedures - (A) Probe sonicator + water bath sonication + 1%
DDM + LysoPC; (B) Probe sonicator + water bath sonication + 1% DDM + E. coli lipids; (C)
water bath sonication + 1% DDM + LysoPC; (D) water bath sonication + 1% DDM + E. coli lipids.
The Emulsiflex breakage strategy showed the best results along with all solubilization
procedures. As we faced several technical difficulties keeping the system at 25 psi, we tested if the
passage samples on the emulsiflex at lower pressure before breakage by glass beads would work
better than the other conditions (figure 6.8). The strategy did not work and the emulsiflex only, but
it was acceptable over the other options.
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Figure 6 8: Optimizing BCRP microsome solubilization – test 2
(A) Emulsiflex only: Left, ladder. Middle, solubilization pellet. Right, solubilization supernatant.
(B) Emusiflex + Glass beads: Left, solubilization pellet. Right, solubilization supernatant.
We had previously optimized the purification protocol for the mouse P-gp (MDR3 Cl – see
chapter 2) in Pichia pastoris GS115. Later we made modifications for the human P-gp (MDR1
WT – see chapter 4). For BCRP purification, we improved the solubilization step presenting a
good amount of BCRP expressed on the supernatant fraction before its loading into the Ni-NTA
chromatography column (figure 6.9 a and b, lanes 4). We could still observe losses on the
following fractions, and even though the final elution fraction presented BCRP expression, the
isolation of the enzyme was not achieved.
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Figure 6 9: Solubilization and purification trials of BCRP expressed in Pichia pastoris.
(A) PichiaPink-BCRP - Lane 1: ladder; Lane 2: microsome (micros); Lane 3: solubilization pellet;
Lane 4: solubilization supernatant (super); Lane 5: chromatography column first flow-through
(FT); Lane 6: Chromatography column wash; Lane 7: Chromatography final fraction Elution. (B)
Pichia GS115-BCRP - Lane 1: microsome (micros); Lane 2: ladder; Lane 3: solubilization pellet;
Lane 4: solubilization supernatant (super); Lane 5: Chromatography column first flow-through
(FT); Lane 6: Chromatography column wash; Lane 7: Chromatography final fraction Elution.
Coomassie blue staining (top) and western blot (bottom) anti-BCRP (B1 antibody) - 10 µg loaded
in each well.
After the inclusion of a second wash with increased imidazole concentration (40 mM), we
observed that most of the BCRP previously on the elution fraction was then collected on the second
wash (figure 6.10 a and b, lanes 7).
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Figure 6 10: BCRP purification from Pichia pastoris cells.
(A)PichiaPink-BCRP - Lane 1: microsome; Lane 2: Color Prestained Protein Standard Broad
Range (10-250 kDa); Lane 3: solubilization pellet; Lane 4: solubilization supernatant; Lane 5:
chromatography column flow-through first fraction; Lane 6: chromatography column wash 1;
Lane 7: chromatography column wash 2; Lane 8: chromatography column final elution fraction.
(B) Pichia GS115: Lane 1: microsome; Lane 2: solubilization pellet; Lane 3: solubilization
supernatant; Lane 4: Spectra Multicolor Broad Range Protein Ladder (10-260 kDa); Lane 5:
chromatography column flow-through first fraction; Lane 6: chromatography column wash 1;
Lane 7: chromatography column wash 2; Lane 8: chromatography column final elution fraction.
Since BCRP purification could not be achieved using any of the attempted methods, we
decided to assess whether the ATP hydrolysis activity of BCRP containing membranes could
potentially be used to assess the BCRP inhibition mechanism by the discovered small-molecule
BCRP inhibitors (fig 6.11)
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Figure 6 11: BCRP activity in PichiaPink membranes.
Ppink: PichiaPink cells only; PpinkHC: PPink+ pPinkHC vector; PpinkHC-BCRP: PichiaPinkBCRP; MNT: mitoxantrone.
Since the PichiaPink-BCRP strain showed better overall BCRP expression in crude
microsome preparations, we used this strain to obtain BCRP containing membrane vesicles
bypassing the microsome suspension 20 times through a 26G 3/5-gauge syringe. We repeat the
same procedure with the untransformed PichiaPink and the PichiaPink cells transformed with the
pPinkHC vector to compare the background activity. Stimulation of BCRP ATPase activity by the
transport mitoxantrone (MNT) was also assessed.
Vector alone membranes (Ppink and Ppink HC) showed only very weak ATPase activity
that was not significantly affected by MNT, while BCRP containing membranes (PpinkHC-BCRP)
indicated higher ATPase activity that was significantly activated in the presence of the transport
substrate mitoxantrone (figure 6.11).
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These results opened the possibilities to assess the inhibitory mechanism of potential BCRP
inhibitors found in cell culture assays.

6.2.2 BCRP expression in Pichia SDM 1163
The difficulties in purifying BCRP from the two strains of Pichia pastoris we had in our
lab made us look for other options that would give more possibilities to isolate BCRP.
We received the Pichia SDM1163 strain containing BCRP from Dr. Mark Rosenberg
(Oxford University). The advantage of this clone is the presence of the GFP and FLAG tags and
the usual HIS tag to facilitate the purification in case we faced similar difficulties as observed for
the PichiaPinkTM and GS115 cells.
Dr. Rosenberg advised the use of zeocin for clone selection. The colonies grew faster in
plates than the other Pichia strains, so the plates required an exhaustive streak pattern to produce
single colonies. The SDM1163 cells grew well on the regular MG/MM medium and presented the
expected BCRP expression after 72 hours of induction in the methanol-based medium.
From this step forward, the same difficulties presented by PichiaPink and Pichia GS115
were met on the Pichia SDM1163 to purify BCRP. The additional tags on this particular clone
will allow a different approach to achieve BCRP isolation.
We wanted to test if the enriched BCRP found in the elution fraction was active for further
experiments. Initial assays in comparison with the activity of BCRP on the microsomal fraction,
the other fractions from the chromatography column presented a BCRP that was catalytically
active and presented higher ATPase activity (figure 6.12).
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Figure 6 12: Enriched BCRP Activity Assays.
Comparison of ATPase hydrolysis activity from BCRP in membrane microsome and Ni-NTA
chromatography fractions – initial flow-through (FT), wash 1 – W1 (20 mM imidazole), wash 2 –
W2 (50 mM imidazole), final fraction elution – Elu (200 mM imidazole).

6.3 Methods and materials
6.3.1 E. coli strains:
NEB®

5-alpha

Competent

E.

coli (High

Efficiency)

genotype:

F’ proA+B+

lacIq ∆(lacZ)M15 zzf::Tn10 (TetR) ∆(ara-leu) 7697 araD139 fhuA ∆lacX74 galK16 galE15
e14- Φ80dlacZ∆M15 recA1 relA1 endA1 nupG rpsL (StrR) rph spoT1 ∆(mrr-hsdRMS-mcrBC)
6.3.2 Agarose gel electrophoresis:
Same as described in chapter 3 –Methods and Materials
6.3.3 Polymerase chain reaction (PCR):
Same as described in chapter 3 – Methods and Materials
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6.3.4 Restriction enzyme digestions:
Same as described in chapter 3 – Methods and Materials
6.3.5 Vector Dephosphorylation:
Same as described in chapter 3 – Methods and Materials
6.3.6 Ligation:
Same as described in chapter 3 – Methods and Materials
6.3.7 Bacterial transformation
Same as described in chapter 3 – Methods and Materials
6.3.8 Mini plasmid preparations:
Same as described in chapter 3 – Methods and Materials
6.3.9 Midi plasmid preparations:
Same as described in chapter 3 – Methods and Materials
6.3.10 DNA purification:
Same as described in chapter 3 – Methods and Materials
6.3.11 DNA sequencing:
Same as described in chapter 3 – Methods and Materials
6.3.12 Integration of the BCRP gene into GS115 cells by electroporation:
100 µL of electrocompetent Pichia pastoris cells were added to a 0.2 cm cuvette (BioRad)
and 15 µg of linearized DNA was added in a volume of less than 25 µL. The cells and DNA were
incubated on ice for 5 min. Electroporation with 25 µF capacitance and 1.5 kV was performed
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with a time constant between 4.68 and 4.8 msec on a BioRad Gene Pulser II. After that, 1 ml of
ice-cold YPDS media (YPD media + 1M Sorbitol) was added to the cuvette and mixed carefully
by pipetting. The cuvette was then incubated for 2 hours at 28oC without shaking. The samples
were then plated on MD/MM plates with volumes of 100 µL, 200 µL, 300 µL, and 400 µL and
incubated at 28oC for up to 5 days.
6.3.13 Selection plates:
6.3.13.1

MD plates: 1.34% YNB; 4x10-5% Biotin; 2% Dextrose; 5% Agar

6.3.13.2

MM plates: 1.34% YNB; 4x10-5% Biotin; 2%; 1% Methanol; 5% Agar

6.3.14 Genomic DNA extraction:
Same as described in chapter 3 – Methods and Materials
6.3.15 Growth of Pichia pastoris GS115 strain
Cells were grown initially using the methods previously described for GS115 cells in
chapter 3. Later, a single colony from a YPD plate (1% Yeast extract, 2% bacto-peptone, 1%
dextrose, 15g agar/L) was inoculated into 10 ml of YPD medium (1% Yeast extract, 2% bactopeptone, 2% dextrose) and incubated at 28oC with shaking to OD600 of ~2.0 (18h). The growth
proceeded as described on PichiaPinkTM cells with 72 hours methanol induction.
6.3.16 Growth of PichiaPinkTM:
Cells were grown using the methods previously described in Invitrogen for PichiaPinkTM
70, 75, 76, 86

, and in chapter 3. In sHORT, A single colony from a YPD agar plate (1.34% Yeast Nitrogen

Base (YNB), 4x10-5% Biotin, 2% dextrose, 15g agar/L) was inoculated into 10 ml of liquid
Enriched Minimal Glycerol (BMGY) medium (20% Yeast extract, 10% Bacto Peptone, 1.34%
YNB, 1% glycerol, 4x10-5% Biotin, 100mM Potassium Phosphate) and incubated at 28oC with
shaking to OD600 of ~2.0 (18h). After 16-18 hours, this 10 ml was added to 1 liter of BMGY
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medium in a 2-liter Fernbach flask. Incubation at 28oC with shaking to OD600 of 2.0 to 4.0 was
continued (~24h), then the cultures were centrifuged in sterile bottles (6000 rpm for 7 min at 23oC).
Protein production was induced by switching the carbon source of the medium from glycerol to
methanol. The cells pellets were resuspended in 1 liter of enriched Minimal Methanol (BMMY)
medium (20% Yeast extract, 10% Bacto Peptone, 1.34% YNB, 4x10-5% Biotin, 0,5% v/v
methanol, 100mM Potassium Phosphate) in 2-liter Fernbach flasks covered with cheesecloth.
Incubation continued for 72h with the addition of methanol (1% v/v) at 24 and 48 hours. The pH
correction was adjusted to ~6.0 if needed. Cells were finally collected by centrifugation at 6000
rpm for 7 min at 4oC and resuspended in ice-cold “homogenization buffer” (0.33 M sucrose, 0.3
M Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 2 mM DTT, 100 mM 6-aminocaproic acid) at a
concentration of 1g wet cells/ml buffer. The cells were stored at -80oC.
6.3.17 Growth of Pichia pastoris SMD1163
After receiving Pichia Pastoris SMD1163 from Dr. Mark F. Rosenberg, Oxford Protein
Production Factory, Oxford University, cultures were grown first on YPD plates (1% yeast extract,
2% bacto-peptone, and 1% dextrose). We added a single colony to 10ml of glycerol-based media,
BMGY (1.34% yeast nitrogen base, 0.00004% biotin, 1% glycerol, 100 mM potassium phosphate,
1% yeast extract, 2% bacto-peptone, 1mg/mL Zeocin), in a 125ml Erlenmeyer flask for the
overnight cultures. The initial cultures were transferred to larger flasks containing the same
glycerol-based medium for 24 hours incubation. We then switched the media from the glycerolbased media to a methanol-based media, BMMY (1.34% yeast nitrogen base, 0.00004% Biotin,
0.5% methanol, 100 mM potassium phosphate, 1% yeast extract, 2% bacto-peptone. This was
followed by 5% methanol feedings at 24 and 48 hours. Finally, we harvested the yeast cells after
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72 hours of methanol induction by spinning down the samples in a table-top centrifuge to remove
the cells from the media.
6.3.18 Mini microsome preparations from small scale yeast cells growth:
Same as described in chapter 3 – Methods and Materials
6.3.19 Microsome preparation from large flasks of yeast cells:
Microsomes were prepared essentially as described in 86, with the modifications made in
70, 75, 76

. Yeast cultures were grown on a 1–6-liter scale. Sample concentration was diluted using

A1 Buffer (5% glycerol, 50 mM Tris-HCl, 125 mM NaCl, 10 mM imidazole, 5 mM EDTA, 1 mM
EGTA, 1 µg/ml Deoxyribonuclease I (DNAse I – Sigma Aldrich) and lysing enzyme (from
Trichoderma harzianum – Sigma Aldrich). Cell membranes were disrupted using 3 passages
through an Emulsiflex Homogenizer at 5,000 psi and 10 cycles of glass bead homogenization in a
bead beater. Cycles alternated between 2 minutes with the bead beater ‘on’ and 6 minutes with it
‘off.’ The sample was then subjected to differential centrifugation. One low-speed centrifugation
and two high-speed ultracentrifugations were used to isolate the microsomal membranes (for a
detailed procedure, see materials and methods in Chapter 3). The microsomes were then frozen at
-80oC.
6.3.20 Solubilization of BCRP from Pichia Pastoris GS115 and PichiaPinkTM
The microsomes were quickly thawed in a circulating water bath set at 28-30oC and then
eluted to a final concentration of 2 mg microsomal protein/ml with “buffer A2” (20% v/v glycerol,
50 mM Tris-HCl, pH 8.0 at 4oC, 50 mM NaCl, plus protease inhibitors as follow: 2 µg/ml pepstatin
A, 4 µg/ml leupeptin, 0.5 µg/ml chymostatin, 1 mM PMSF, 1 mM of 2-Mercaptoethanol and 0.01
mM TCEP. To solubilize the Pichia GS115, 0.6% of DDM (n-Dodecyl ß-D-maltoside) was added
to the suspension. In comparison, for membranes from PichiaPinkTM, we added 1% DDM (n120

Dodecyl ß-D-maltoside), and a 0.2% PC (phosphotidylcholine) was added initially removed from
the dilution on later preparations. We also used a probe sonicator (Branson Ultrasonics Sonifier
250 – Analog Ultrasonic Cell Disruptor/Homogenizer) – 6 cycles of 60-70 watts for 30 seconds at
4oC (temperatures checked before starting the sonication) prior water-bath sonication for improved
PichiaPinkTM membrane solubilization. Once the solubilization was achieved, insoluble fractions
were removed by centrifugation, and the supernatant was applied to a 100 ml Ni-NTA (Qiagen©)
column for purification using affinity chromatography.
6.3.21 Solubilization of BCRP from Pichia Pastoris SMD1163
Pichia SMD1163 membranes were easily solubilized by water-bath sonication. This was
done through the addition of 1% DDM, 0.01% LysoPC, and protease inhibitors (2 μg/ml Pepstatin
A, 4 μg/ml Leupeptin, 0.5 μg/ml Chymostatin, 2mM PMSF, 2mM DTT) to Buffer A (20%
glycerol, 50mM Tris-HCl, pH 8) followed by four cycles of 4 water bath sonication with time in
between to rest. Once the solubilization was achieved, insoluble fractions were removed by
centrifugation, and the supernatant was applied to an affinity chromatography column with NiNTA resin (Qiagen) after overnight incubation.
6.3.22 BCRP Purification from Pichia GS115 and PichiaPinkTM membranes
The suspension resultant from the solubilization procedures was centrifuged at 20,000 rpm
for 30 min at 4oC (Beckman Optima LE-80K equipped with Ti 70 or Ti 55.2 rotors) to remove
insoluble material. The supernatant was then applied to the pre-equilibrated Ni-NTA agarose resin
(Qiagen) column at a ratio of 100 mg microsomal protein per 1ml packing resin (one bed volume).
The rest of the procedure was performed at 4oC. The chromatography gel and solubilized protein
solution were mixed and incubated for 10 minutes before the column was poured (overnight
incubations were also tested, but no differences were noted). The flow-through was ~2 ml/min.
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The resin with bound P-gp was washed first with 20 bed-volumes of “Column wash buffer 1” (20
% glycerol (v/v), 50 mM Tris-HCl, pH 7.5 @ 4 oC, 50 mM NaCl, 10 mM Imidazole, supplemented
with 5 µL 20% (w/v) DDM/mL buffer; 1µL 10 % (w/v) lyso-PC/mL buffer), followed by 10 bedvolume of “Column Wash buffer 2” (20 % glycerol (v/v), 50 mM Tris-HCl, pH 7.5 @ 4 oC, 50
mM NaCl, 20mM-40mM Imidazole, supplemented with 5 µL 20% (w/v) DDM/mL buffer; 1µL
10 % (w/v) lyso-PC/mL buffer). For both washes, the flow-through was ~1 ml/min. BCRP was
then eluted with 5 bed-volumes of Elution buffer (20 % glycerol (v/v), 50 mM Tris-HCl, pH 7.5
@ 4 oC, 50 mM NaCl, 300 mM Imidazole, supplemented with 5 µL 20% (w/v) DDM/mL buffer)
with a ~0.5 ml/min flow rate. All eluted protein was collected for the next step. To obtain
concentrated BCRP, the elution fraction from the Ni-NTA column was concentrated 70- to 100fold using Amicon centrifugal filters (Amicon/Millipore Corp., Billerica, MA) with a molecular
mass cutoff of 50,000 Da. The protein was stored at -80oC.
6.3.23 BCRP Purification from Pichia SMD1163 membranes
After the solubilization, the resulting supernatant from the ultracentrifugation was applied to a
column with Ni-NTA resin (Qiagen) and allowed to incubate overnight before the slurry was
applied column and let sit for 10 min and allowed to flow through at 2ml/min. Next, the first wash
(Buffer A, 20mM imidazole, 50mM NaCl) was applied, incubated, and allowed to flow through at
a slower rate. This was followed by a second wash (Buffer A, 50 mM imidazole, 50 mM NaCl)
and finally the elution (Buffer A, 250 mM imidazole, 50 mM NaCl). All fractions were
concentrated in 50 kDa Amicon filters, and the protein was stored at -80oC.
6.3.24 ATPase activity assay using P. pastoris membranes:
Same as described in chapter 5 – Materials and Methods
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6.3.25 Western Blot analysis:
Same as described in chapter 3 – Materials and Methods, with the following modification:
1:1000 dilution in primary monoclonal antibody B1 – mouse anti-ABCG2 (sc-377176, Santa Cruz
Biotechnology) for 1 hour at room temperature or overnight at 4oC in a rocking platform.

6.4 Discussion
Relatively large quantities of purified BCRP are desirable to perform biochemical, kinetic,
and biophysical analyses of inhibitors of BCRP for the evaluation of the inhibition mechanism of
the new drug-like compounds we wanted to test in our lab.
A new human BCRP clone was designed with optimized codon usage for translation and
expression in P. pastoris. It was successfully integrated into two strains of Pichia pastoris,
PichiaPinkTM and GS115, and BCRP expression was observed in both strains (figures 6.2 and 6.4).
Expression of BCRP was significantly higher in PichiaPinkTM at nine hours after induction. Initial
ATP hydrolysis assays on PichiaPink-BCRP membranes (figure 6.3) indicated that the protein
expressed was catalytically active and that ATP hydrolysis activity could be stimulated by the
known BCRP transport substrate Hoechst 33342 140, 147.
Challenges to purify BCRP from heterologous membranes were previously reported

148

.

Optimization of the expression system PichiaPinkTM was required in each step of the purification,
including the cell growth. Most of the modifications made for PichiaPink-BCRP cells improved
GS115-BCRP and KM71H-MDR1 (P-gp) purification conditions.
As seen in figure 6.4, BCRP expression in PichiaPink cells was highest at 6-9 hours after
induction with methanol. After 9 hours, expression began to decrease. This decrease in expression
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may be due to the high alcohol oxidase production and depletion of the nutrients of the media. We
tried to “feed” the cells with additional methanol at different time intervals before 24 hours, but
the cells continued to die (data not shown). We determine the optimal time to harvest the
PichiaPink cells to be at 9 hours after induction with methanol, suggesting a surprisingly fast onset
of protein production in the PichiaPinkTM strains. Protein expression was confirmed by Western
blot analysis using both anti-BCRP and anti-His antibodies. ATP hydrolysis assays indicated that
the protein expressed was catalytically active and that the ATP hydrolysis activity could be
stimulated by the BCRP transport substrate, Hoechst 33342 (figure 6.11).
Pichia GS115 required less optimization on the steps before the purification. Large scale
cultures using the enriched medium recommended for PichiaPinkTM growth resulted in a better
BCRP expression at 72 hours after methanol induction than the previous recommenced minimal
glycerol/methanol medium (figure 6.4 b). We decided to also use the enriched culture medium on
the next grows of GS115-BCRP. Even though the expression levels of BCRP in GS115 had
improved, it was still lower than what was achieved by PichiaPink-BCRP. As we were still facing
difficulties in isolating BCRP from PichiaPink membranes, we decided to try and optimize
conditions for both strains, hoping that GS115 membranes would be easier to work with. While
solubilization for GS115 membranes was deemed adequate, optimization efforts were needed for
better protein expression and higher yields during purification.
Microsome and purification protocols as originally described by Bai et al.
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for P-

glycoprotein in Pichia pastoris were initially used for BCRP purification from PichiaPinkTM and
Pichia GS115. We noticed some difficulties from the beginning: the cells were not well broken.
The microsome yield was low compared with the regular preparations made with P-gp, where the
cells were successfully broken using 0.5 mm glass beads on 7 cycles at the bead beater at high
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intensity. Unfortunately, the same strategy did not seem to work well in our attempts for BCRP
membranes. In addition to that, the final microsomal fraction was also not well solubilized in the
first step of protein purification. We thought both steps could be related, so we ran trials of each
condition independently.
We improved the breakage by changing the volume of the beads added and the ratio mass
of cells/total volume. We also added deoxyribonuclease I (DNAse I) to reduce sample viscosity
due to the release of nucleic acids and the lysing enzyme from Trichoderma harzianum to
hydrolyze yeast cells wall oligosaccharides. We increased the breakage cycles from 7 to 9 cycles
of 2 minutes of breakage and 2 minutes resting on ice. These changes improved the overall cell
breakage and the microsome yield, but we still faced poor solubilization in later stages (figure 6.7).
We hypothesized that the breakage using glass beads could break the membrane so that they would
form sheets that would stack together, preventing the solubilization from working properly. To test
this hypothesis, we used an Emulsiflex – Avestin C5 High-Pressure Homogenizer (Avestin, Inc.)
to produce membrane vesicles instead of membrane sheets. It has an additional advantage over the
well-known French press. It can hold large sample volumes, process samples in continuous passes,
achieve higher pressure, and process relatively viscous samples. The recommended pressure
reported for Pichia was 22000-25000 psi with multiple passages. We tested the system comparing
samples with one, two, and three passages, with the latter being the most successful on cells
breakage (figure 6.6). When the system worked properly, it resulted in three times better cell
breakage than glass beads and bead beaters.

However, after only very few uses of the

homogenizer, the system clogged and did not reach the pressure needed to disrupt the cells.
As membrane solubilization is a critical step for protein purification, we also tested
different solubilization conditions. During the previous attempt to solubilize PichiaPink-BCRP,
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the addition of lyso-PC and the DDM to dilute the samples, the method of choice for the P-gp
purification, was not successful. Fos-choline-16 was reported to facilitate the solubilization of
insect cells containing BCRP

148-151

. Most of those studies aimed to isolate BCRP for structural

studies, so protein activity was a secondary concern. Telbizs et al. (2013)152 described a successful
Sf9 cells solubilization using a lipid/detergent mixture (1% DDM and 0.4% E. coli lipid extract).
They found that BCRP was inactive in detergent-solubilized form using different detergents. Still,
the ATPase activity could be preserved when lipids were used together with DDM in the
solubilization except when the detergent used was Fos-choline-16, when the ATPase activity was
abolished possibly for irreversible dissociation of the homodimers. With this information in mind,
we decided not to go further with any tests using Fos-choline-16 but try E. coli lipid extract
compared to the Lyso-PC already established in our methods.
Initially, we start increasing the DDM concentration and added extra cycles of sonication
at the water bath with no success on the solubilization. We then thought about increase the
sonication strength by using a sonicator with a probe (see Material and Methods, section 6.3.21)
before the water bath sonication. We noticed clearance of the suspension after each cycle. We
combined this new sonication procedure with different combination of lipid/detergent usage
(DDM, E. coli lipid extract and Lyso-PC) and cells breakage methods: (A) Probe sonicator + water
bath sonication + 1% DDM + LysoPC; (B) Probe sonicator + water bath sonication + 1% DDM +
E. coli lipids; (C) water bath sonication + 1% DDM + LysoPC; (D) water bath sonication + 1%
DDM + E. coli lipids.
For all conditions tested, using only the Emulsiflex for cell breakage was better for the
subsequent solubilization step, as shown in figure 6.7. Moreover, the solubilization was
successfully achieved using DDM and Lyso-PC combination working even better than the
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combination DDM + E. coli lipids. Combining techniques, including cell breakage and
solubilization conditions, achieved a consistent 60% membrane solubilization of PichiaPinkBCRP microsomes. However, using only the Emulsiflex as a cell breakage method required
excessive time as it suffered from some technical difficulties (i.e., achieving necessary pressures
was difficult), which made it hard to maintain the quality and reproducibility of the method. The
time involved was problematic for protein stability. As the pressures were hard to maintain
consistently at 25,000 psi, we decided to run 3 cycles at 5,000 psi on the Emulsiflex followed by
glass bead breakage. Subjecting the cells to the Emulsiflex homogenization before glass bead
breakage allowed significant improvements in the purification of BCRP. When we compared the
solubilization results of this combined with the performance of the Emulsiflex only (figure 6.8),
the adjustment was somewhat satisfactory. Still, it worked better than the option of glass beads or
glass beads + Emulsiflex (figure 6.7).
Once the successful microsomal solubilization was established, the next step was to
optimize the conditions for purification on the Ni-NTA affinity chromatography. Insoluble
fractions from solubilization were removed by centrifugation, and the supernatant was applied to
a Ni-NTA column for purification.
In our first attempt, we observed loss of BCRP in each fraction of the purification. Even
though we were able to collect some BCRP from the final elution, it was not purified as we could
see many contaminants on the final fraction (figure 6.9). Changes in imidazole concentration in
the binding buffer and changes in pH as well as including more wash steps did not improve the
outcome significantly
McDevitt et al.

148, 149

reported difficulties in isolating detergent solubilized protein

complexes due to low binding affinity for the immobilized metal affinity chromatography (IMAC).
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The suggestion was that the histidine-tag of BCRP might be partially occluded since
immunoblotting confirmed the tags were intact.
In summary, microsome preparations with high expression of BCRP in PichiaPink and
GS115 cells were achieved. Solubilization was also improved, however, and BCRP purification
proved challenging. For this reason, crude microsome preparations were formed into vesicles and
used for activity assays (figure 6.11). We wanted to know if we could still use the membranes for
activity assays and test the effects of the new drug-like compounds on BCRP ATPase hydrolysis
activity.
ATPase activity of BCRP expressed in membranes has been largely performed by others
146, 153, 154

. As PichiaPink-BCRP cells presented higher protein expression, we decided to start our

trials with these membranes to analyze if the BCRP was catalytically active. We compared
PichiaPink-BCRP membranes with PichiaPink membranes in different backgrounds: PichiaPink
cells only and PichiaPink-pPinkHC (integration of the cloning vector) (figure 6.11). We also
wanted to verify if the BCRP ATPase activity could be stimulated by the substrate mitoxantrone
(MNT).
Since the activity of the PichiaPink-BCRP was increased when compared with both
backgrounds and was stimulated by a transport substrate, we assume biologically active BCRP
was present. With these results, we were optimistic that we would be able to use membrane assays
to further tests of drug inhibition in the future.
For some mechanistic studies, for example, evaluating the effect of the potential inhibitor
on ATP binding using electron spin resonance spectroscopy, purified protein in mixed micelles or
nanodisc assembled proteins is required. To date, all efforts to purify BCRP to a level that allows
these experiments have not been successful, despite using different strains of yeast.
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However, the presence of different tags on the SDM1163-BCRP that we received in
collaboration with Mark Rosenberg (Oxford University) may present other alternatives to the
purification procedures describe here.
Much effort was put into this project as we still could not test any of the potential BCRP
inhibitors to corroborate the cell culture findings. We hope that optimizing the conditions and the
advances made up to now will allow for a better outcome in the near future.

129

REFERENCES

1. Nanayakkara AK, Follit CA, Chen G, Williams NS, Vogel PD, Wise JG. Targeted inhibitors of
P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor
cells. Sci Rep. 2018;8(1):967. Epub 2018/01/19. doi: 10.1038/s41598-018-19325-x.
PubMed PMID: 29343829; PMCID: PMC5772368.
2. Wise JG, Nanayakkara AK, Aljowni M, Chen G, De Oliveira MC, Ammerman L, Olengue K,
Lippert AR, Vogel PD. Optimizing Targeted Inhibitors of P-Glycoprotein Using
Computational and Structure-Guided Approaches. J Med Chem. 2019;62(23):10645-63.
Epub 2019/11/09. doi: 10.1021/acs.jmedchem.9b00966. PubMed PMID: 31702922;
PMCID: PMC7031812.
3. Binkhathlan Z, Lavasanifar A. P-gp Inhibition as a Therapeutic Approach for Overcoming
Multidrug Resistance in Cancer: Current Status and Future Perspectives. Current Cancer
Drug Target. 2013;13:326-46; PMCID: 23369096.
4. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, Buchner T.
Management of acute myeloid leukemia in elderly patients. J Clin Oncol.
1999;17(11):3569-76. Epub 1999/11/05. PubMed PMID: 10550156.
5. Jamroziak K, Robak T. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and
clinical outcome of haematological malignancies. Hematology. 2004;9(2):91-105. Epub
2004/06/19. doi: 10.1080/10245330310001638974. PubMed PMID: 15203864.
6. Leighton JC, Jr., Goldstein LJ. P-glycoprotein in adult solid tumors. Expression and prognostic
significance. Hematol Oncol Clin North Am. 1995;9(2):251-73. Epub 1995/04/01. PubMed
PMID: 7642464.
7. Zhang D, Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing
therapeutic challenges. Expert Rev Anticancer Ther. 2007;7(10):1369-78. Epub
2007/10/20. doi: 10.1586/14737140.7.10.1369. PubMed PMID: 17944563.
8. Nooter K, Herweijer H. Multidrug resistance mdr genes in human cancer. Br J Cancer.
1991;63:663-9.
9. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer.
Pharmacological reviews. 1990;42(3):155-99. Epub 1990/09/01. PubMed PMID: 2217530.
10. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta
oncologica. 1992;31(2):205-13. doi: 10.3109/02841869209088904. PubMed PMID:
1352455.
11. Chin JE, Soffir R, Noonan K, Choi K, Roninson IB. Structure and expression of the human
MDR (P-glycoprotein) gene family. Mol Cell Biol. 1989;9(9):3808-20.

130

12. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent
transporters. Nat Rev Cancer. 2002;2(1):48-58. doi: 10.1038/nrc706. PubMed PMID:
11902585.
13. Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance
gene. Advances in cancer research. 1993;60:157-80. Epub 1993/01/01. PubMed PMID:
8417499.
14. Kartner N, Ling V. Multidrug resistance in cancer. Sci Am. 1989;260(3):44-51. Epub
1989/03/01. PubMed PMID: 2564696.
15. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical
strategy of inhibiting p-glycoprotein. Cancer control : journal of the Moffitt Cancer Center.
2003;10(2):159-65. Epub 2003/04/25. PubMed PMID: 12712010.
16. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using
modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics
of anticancer drugs. European journal of pharmaceutical sciences : official journal of the
European Federation for Pharmaceutical Sciences. 2000;11(4):265-83. Epub 2000/10/18.
PubMed PMID: 11033070.
17. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the
cytotoxicity of anticancer agents. Cell. 1993;74(6):957-67. Epub 1993/09/24. PubMed
PMID: 8402885.
18. Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, White E. Hypoxia and defective
apoptosis drive genomic instability and tumorigenesis. Genes & development.
2004;18(17):2095-107. Epub 2004/08/18. doi: 10.1101/gad.1204904. PubMed PMID:
15314031; PMCID: PMC515288.
19. Ambdukar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical,
cellular and pharmacological aspects of the multidrug transporters. Annu Rev Pharmacol
Toxicol. 1999;39:361-98.
20. Croop JM, Guild BC, Gros P, Housman DE. Genetics of multidrug resistance: relationship of
a cloned gene to the complete multidrug resistant phenotype. Cancer Res.
1987;47(22):5982-8. Epub 1987/11/15. PubMed PMID: 3664502.
21. Gros P, Ben Neriah YB, Croop JM, Housman DE. Isolation and expression of a complementary
DNA that confers multidrug resistance. Nature. 1986;323(6090):728-31. Epub 1986/10/23.
doi: 10.1038/323728a0. PubMed PMID: 3022150.
22. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug
transporter. Annu Rev Biochem. 1993;62:385-427; PMCID: 8102521.
23. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular
localization of the multidrug-resistance gene product P-glycoprotein in normal human
tissues. Proc Natl Acad Sci U S A. 1987;84(21):7735-8. Epub 1987/11/01. PubMed PMID:
2444983; PMCID: PMC299375.
24. Kane SE, Pastan I, Gottesman MM. Genetic basis of multidrug resistance of tumor cells. J
Bioenerg Biomembr. 1990;22(4):593-618. Epub 1990/08/01. PubMed PMID: 1977744.
25. Pastan I, Gottesman MM. Multidrug resistance. Annu Rev Med. 1991;42:277-86. Epub
1991/01/01. doi: 10.1146/annurev.me.42.020191.001425. PubMed PMID: 2035973.
26. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. Expression of the human
multidrug resistance cDNA in insect cells generates a high activity drug-stimulated
membrane ATPase. J Biol Chem. 1992;267(7):4854-8. Epub 1992/03/05. PubMed PMID:
1347044.
131

27. Sharom FJ, Yu X, Doige CA. Functional reconstitution of drug transport and ATPase activity
in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem.
1993;268(32):24197-202. Epub 1993/11/15. PubMed PMID: 7901214.
28. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications.
Clinical pharmacokinetics. 2003;42(1):59-98. Epub 2002/12/20. doi: 10.2165/00003088200342010-00003. PubMed PMID: 12489979.
29. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Seminars in
cancer biology. 1997;8(3):161-70. Epub 1997/06/01. doi: 10.1006/scbi.1997.0068. PubMed
PMID: 9441946.
30. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster
ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152-62. Epub 1976/11/11. PubMed
PMID: 990323.
31. McCormick JW, Vogel PD, Wise JG. Multiple Drug Transport Pathways through Human PGlycoprotein. Biochemistry. 2015;54(28):4374-90. doi: 10.1021/acs.biochem.5b00018.
PubMed PMID: 26125482; PMCID: PMC4527178.
32. Chen C, Chin JE, Ueda K, Clark DP, Pastan I. Internal duplication and homology with bacterial
transport protein in mdr1 pgp gene from MDR human cells. Cell. 1986;47:361-89.
33. Wise JG. Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites.
Biochemistry. 2012;51(25):5125-41. Epub 2012/06/01. doi: 10.1021/bi300299z. PubMed
PMID: 22647192; PMCID: PMC3383123.
34. Shustik C, Dalton W, Gros P. P-glycoprotein-mediated multidrug resistance in tumor cells:
biochemistry, clinical relevance and modulation. Molecular aspects of medicine.
1995;16(1):1-78. Epub 1995/01/01. PubMed PMID: 7783568.
35. Sato T, Kodan A, Kimura Y, Ueda K, Nakatsu T, Kato H. Functional role of the linker region
in purified human P-glycoprotein. The FEBS journal. 2009;276(13):3504-16. Epub
2009/06/06. doi: 10.1111/j.1742-4658.2009.07072.x. PubMed PMID: 19490125.
36. Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem. 2011;50(1):161-78.
doi: 10.1042/bse0500161. PubMed PMID: 21967057.
37. Bruggemann EP, Currier SJ, Gottesman MM, Pastan I. Characterization of the azidopine and
vinblastine binding site of P-glycoprotein. J Biol Chem. 1992;267(29):21020-6. Epub
1992/10/15. PubMed PMID: 1356986.
38. Demeule M, Laplante A, Murphy GF, Wenger RM, Beliveau R. Identification of the
cyclosporin-binding site in P-glycoprotein. Biochemistry. 1998;37(51):18110-8. Epub
1999/01/28. PubMed PMID: 9922180.
39. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV. Evidence for two
nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A.
1997;94(20):10594-9. Epub 1997/10/06. PubMed PMID: 9380680; PMCID: PMC23414.
40. Loo TW, Bartlett MC, Clarke DM. Transmembrane segment 7 of human P-glycoprotein forms
part of the drug-binding pocket. Biochem J. 2006;399(2):351-9. Epub 2006/07/04. doi:
10.1042/bj20060715. PubMed PMID: 16813563; PMCID: PMC1609921.
41. Loo TW, Clarke DM. Location of the rhodamine-binding site in the human multidrug
resistance P-glycoprotein. J Biol Chem. 2002;277(46):44332-8. Epub 2002/09/12. doi:
10.1074/jbc.M208433200. PubMed PMID: 12223492.
42. Loo TW, Clarke DM. Recent progress in understanding the mechanism of P-glycoproteinmediated drug efflux. The Journal of membrane biology. 2005;206(3):173-85. Epub
2006/02/04. doi: 10.1007/s00232-005-0792-1. PubMed PMID: 16456713.
132

43. Zhang X, Collins KI, Greenberger LM. Functional evidence that transmembrane 12 and the
loop between transmembrane 11 and 12 form part of the drug-binding domain in Pglycoprotein encoded by MDR1. J Biol Chem. 1995;270(10):5441-8. Epub 1995/03/10.
PubMed PMID: 7890659.
44. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication
between multiple drug binding sites on P-glycoprotein. Mol Pharmacol. 2000;58(3):624-32.
Epub 2000/08/23. PubMed PMID: 10953057.
45. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q,
Urbatsch IL, Chang G. Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding. Science. 2009 Mar 27:1718-22.
46. Hollenstein K, Dawson RJ, Locher KP. Structure and mechanism of ABC transporter proteins.
Curr Opin Struct Biol. 2007;17(4):412-8. Epub 2007/08/29. doi: 10.1016/j.sbi.2007.07.003.
PubMed PMID: 17723295.
47. Lee JY, Urbatsch IL, Senior AE, Wilkens S. Nucleotide-induced structural changes in Pglycoprotein observed by electron microscopy. J Biol Chem. 2008;283(9):5769-79. Epub
2007/12/21. doi: 10.1074/jbc.M707028200. PubMed PMID: 18093977.
48. Li J, Jaimes KF, Aller SG. Refined structures of mouse P-glycoprotein. Protein science : a
publication of the Protein Society. 2014;23(1):34-46. Epub 2013/10/25. doi:
10.1002/pro.2387. PubMed PMID: 24155053; PMCID: PMC3892297.
49. Verhalen B, Ernst S, Borsch M, Wilkens S. Dynamic ligand-induced conformational
rearrangements in P-glycoprotein as probed by fluorescence resonance energy transfer
spectroscopy. J Biol Chem. 2012;287(2):1112-27. Epub 2011/11/17. doi:
10.1074/jbc.M111.301192. PubMed PMID: 22086917; PMCID: PMC3256922.
50. Verhalen B, Wilkens S. P-glycoprotein retains drug-stimulated ATPase activity upon covalent
linkage of the two nucleotide binding domains at their C-terminal ends. J Biol Chem.
2011;286(12):10476-82. Epub 2011/02/01. doi: 10.1074/jbc.M110.193151. PubMed
PMID: 21278250; PMCID: PMC3060501.
51. Zoghbi ME, Altenberg GA. Hydrolysis at one of the two nucleotide-binding sites drives the
dissociation of ATP-binding cassette nucleotide-binding domain dimers. J Biol Chem.
2013;288(47):34259-65. Epub 2013/10/17. doi: 10.1074/jbc.M113.500371. PubMed
PMID: 24129575; PMCID: PMC3837166.
52. Zoghbi ME, Altenberg GA. ATP binding to two sites is necessary for dimerization of
nucleotide-binding domains of ABC proteins. Biochemical and biophysical research
communications. 2014;443(1):97-102. Epub 2013/11/26. doi: 10.1016/j.bbrc.2013.11.050.
PubMed PMID: 24269240; PMCID: PMC3901029.
53. Jin MS, Oldham ML, Zhang Q, Chen J. Crystal structure of the multidrug transporter Pglycoprotein from Caenorhabditis elegans. Nature. 2012;490(7421):566-9. Epub
2012/09/25. doi: 10.1038/nature11448. PubMed PMID: 23000902; PMCID: PMC3482266.
54. Dawson RJ, Locher KP. Structure of the multidrug ABC transporter Sav1866 from
Staphylococcus aureus in complex with AMP-PNP. FEBS Lett. 2007;581(5):935-8. Epub
2007/02/17. doi: 10.1016/j.febslet.2007.01.073. PubMed PMID: 17303126.
55. Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature.
2006;443(7108):180-5. Epub 2006/09/01. doi: 10.1038/nature05155. PubMed PMID:
16943773.
56. Ward A, Reyes CL, Yu J, Roth CB, Chang G. Flexibility in the ABC transporter MsbA:
Alternating access with a twist. Proc Natl Acad Sci U S A. 2007;104(48):19005-10. Epub
133

2007/11/21. doi: 10.1073/pnas.0709388104. PubMed PMID: 18024585; PMCID:
PMC2141898.
57. Senior AE, Bhagat S. P-glycoprotein shows strong catalytic cooperativity between the two
nucleotide sites. Biochemistry. 1998;37(3):831-6. Epub 1998/02/10. doi:
10.1021/bi9719962. PubMed PMID: 9454572.
58. Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S, Gottesman MM, Pastan I.
Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition
state. Biochemistry. 1998;37(14):5010-9. Epub 1998/05/16. doi: 10.1021/bi973045u.
PubMed PMID: 9538020.
59. Sauna ZE, Ambudkar SV. Evidence for a requirement for ATP hydrolysis at two distinct steps
during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci
U S A. 2000;97(6):2515-20. Epub 2000/03/16. PubMed PMID: 10716986; PMCID:
PMC15960.
60. Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat Rev Mol Cell
Biol. 2009;10(3):218-27. doi: 10.1038/nrm2646. PubMed PMID: 19234479; PMCID:
PMC2830722.
61. Urbatsch IL, Tyndall GA, Tombline G, Senior AE. P-glycoprotein catalytic mechanism:
studies of the ADP-vanadate inhibited state. J Biol Chem. 2003;278(25):23171-9. doi:
10.1074/jbc.M301957200. PubMed PMID: 12670938.
62. Tanford C. Mechanism of free energy coupling in active transport. Annual review of
biochemistry.
1983;52:379-409.
Epub
1983/01/01.
doi:
10.1146/annurev.bi.52.070183.002115. PubMed PMID: 6311079.
63. Urbatsch IL, Beaudet L, Carrier I, Gros P. Mutations in either nucleotide-binding site of Pglycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites. Biochemistry.
1998;37(13):4592-602. Epub 1998/04/29. doi: 10.1021/bi9728001. PubMed PMID:
9521779.
64. Senior AE, M.K. a-S, Urbatsch IL. The Catalytic cycle of P-glycoprotein. FEBS Letters.
1995;377(Dec 27):285-9; PMCID: 8549739.
65. Urbatsch IL, Sankaran B, Bhagat S, Senior AE. Both P-glycoprotein nucleotide-binding sites
are catalytically active. J Biol Chem. 1995;270(45):26956-61. Epub 1995/11/10. PubMed
PMID: 7592942.
66. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: The early years
of
P-glycoprotein
research.
FEBS
Letters.
2006;580(4):998-1009.
doi:
10.1016/j.febslet.2005.12.060.
67. Seelig A, Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and
modifiers. European journal of pharmaceutical sciences : official journal of the European
Federation for Pharmaceutical Sciences. 2000;12(1):31-40. Epub 2000/12/21. PubMed
PMID: 11121731.
68. Baguley BC. Multiple drug resistance mechanisms in cancer. Molecular biotechnology.
2010;46(3):308-16. Epub 2010/08/19. doi: 10.1007/s12033-010-9321-2. PubMed PMID:
20717753.
69. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and
drug disposition. Clinical pharmacokinetics. 1999;37(6):485-505. Epub 2000/01/11. doi:
10.2165/00003088-199937060-00004. PubMed PMID: 10628899.
70. Brewer FK, Follit CA, Vogel PD, Wise JG. In silico screening for inhibitors of p-glycoprotein
that target the nucleotide binding domains. Mol Pharmacol. 2014;86(6):716-26. Epub
134

2014/10/02. doi: 10.1124/mol.114.095414. PubMed PMID: 25270578; PMCID:
PMC4244591.
71. Morris GM, Goodsell DS, Huey R, Olson AJ. Distributed automated docking of flexible
ligands to proteins: parallel applications of AutoDock 2.4. Journal of computer-aided
molecular design. 1996;10(4):293-304. Epub 1996/08/01. PubMed PMID: 8877701.
72. Irwin JJ, Shoichet BK. ZINC--a free database of commercially available compounds for virtual
screening. J Chem Inf Model. 2005;45(1):177-82. Epub 2005/01/26. doi:
10.1021/ci049714+. PubMed PMID: 15667143; PMCID: PMC1360656.
73. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover
chemistry for biology. J Chem Inf Model. 2012;52(7):1757-68. Epub 2012/05/17. doi:
10.1021/ci3001277. PubMed PMID: 22587354; PMCID: PMC3402020.
74. Vogel G, Steinhart R. ATPase of Escherichia coli: purification, dissociation, and reconstitution
of the active complex from the isolated subunits. Biochemistry. 1976;15(1):208-16. Epub
1976/01/13. PubMed PMID: 2281.
75. Delannoy S, Urbatsch IL, Tombline G, Senior AE, Vogel PD. Nucleotide binding to the
multidrug resistance P-glycoprotein as studied by ESR spectroscopy. Biochemistry.
2005;44(42):14010-9. Epub 2005/10/19. doi: 10.1021/bi0512445. PubMed PMID:
16229490.
76. Hoffman AD, Urbatsch IL, Vogel PD. Nucleotide binding to the human multidrug resistance
protein 3, MRP3. Protein J. 2010;29(5):373-9. Epub 2010/06/22. doi: 10.1007/s10930-0109262-4. PubMed PMID: 20563633.
77. Biswas R, Kuhne H, Brudvig GW, Gopalan V. Use of EPR spectroscopy to study
macromolecular structure and function. Science progress. 2001;84(Pt 1):45-67. Epub
2001/05/31. PubMed PMID: 11382137.
78. Hubbell WL, Cafiso DS, Altenbach C. Identifying conformational changes with site-directed
spin labeling. Nat Struct Biol. 2000;7(9):735-9. Epub 2000/08/31. doi: 10.1038/78956.
PubMed PMID: 10966640.
79. Streckenbach B, Schwarz D, Repke KR. Analysis of phosphoryl transfer mechanism and
catalytic centre geometries of transport ATPase by means of spin-labelled ATP. Biochim
Biophys Acta. 1980;601(1):34-46. Epub 1980/09/02. PubMed PMID: 6250610.
80. Follit CA, Brewer FK, Wise JG, Vogel PD. In silico identified targeted inhibitors of Pglycoprotein overcome multidrug resistance in human cancer cells in culture. Pharmacol
Res Perspect. 2015;3(5):e00170. Epub 2015/10/31. doi: 10.1002/prp2.170. PubMed PMID:
26516582; PMCID: PMC4618641.
81. Tombline G, Urbatsch IL, Virk N, Muharemagic A, White LB, Senior AE. Expression,
purification, and characterization of cysteine-free mouse P-glycoprotein. Arch Biochem
Biophys. 2006;445(1):124-8. doi: 10.1016/j.abb.2005.11.004. PubMed PMID: 16343415.
82. Bai J, Swartz DJ, Protasevich, II, Brouillette CG, Harrell PM, Hildebrandt E, Gasser B,
Mattanovich D, Ward A, Chang G, Urbatsch IL. A gene optimization strategy that enhances
production of fully functional P-glycoprotein in Pichia pastoris. PLoS One.
2011;6(8):e22577. Epub 2011/08/10. doi: 10.1371/journal.pone.0022577. PubMed PMID:
21826197; PMCID: PMC3149604.
83. Peterson GL. A simplification of the protein assay method of Lowry et al. which is more
generally applicable. Analytical biochemistry. 1977;83(2):346-56. Epub 1977/12/01.
PubMed PMID: 603028.

135

84. Alvarez FJ, Orelle C, Davidson AL. Functional reconstitution of an ABC transporter in
nanodiscs for use in electron paramagnetic resonance spectroscopy. J Am Chem Soc.
2010;132(28):9513-5. Epub 2010/06/29. doi: 10.1021/ja104047c. PubMed PMID:
20578693; PMCID: PMC2927203.
85. Bayburt TH, Sligar SG. Membrane protein assembly into Nanodiscs. FEBS Lett.
2010;584(9):1721-7. doi: 10.1016/j.febslet.2009.10.024. PubMed PMID: 19836392;
PMCID: PMC4758813.
86. Lerner-Marmarosh N, Gimi K, Urbatsch IL, Gros P, Senior AE. Large scale purification of
detergent-soluble P-glycoprotein from Pichia pastoris cells and characterization of
nucleotide binding properties of wild-type, Walker A, and Walker B mutant proteins. J Biol
Chem. 1999;274(49):34711-8. Epub 1999/11/27. PubMed PMID: 10574938.
87. Urbatsch IL, Gimi K, Wilke-Mounts S, Lerner-Marmarosh N, Rousseau ME, Gros P, Senior
AE. Cysteines 431 and 1074 are responsible for inhibitory disulfide cross-linking between
the two nucleotide-binding sites in human P-glycoprotein. J Biol Chem.
2001;276(29):26980-7. Epub 2001/05/18. doi: 10.1074/jbc.M010829200. PubMed PMID:
11356825.
88. Borch J, Hamann T. The nanodisc: a novel tool for membrane protein studies. Biol Chem.
2009;390(8):805-14. Epub 2009/05/21. doi: 10.1515/bc.2009.091. PubMed PMID:
19453280.
89. Bayburt TH, Grinkova YV, Sligar SG. Self-Assembly of discolidal phospholipid bilayer
nanoparticles with membrane scaffold proteins. Nano Lett. 2002;2:853-6.
90. White GF, Racher KI, Lipski A, Hallett FR, Wood JM. Physical properties of liposomes and
proteoliposomes prepared from Escherichia coli polar lipids. Biochim Biophys Acta.
2000;1468(1-2):175-86. doi: 10.1016/s0005-2736(00)00255-8. PubMed PMID: 11018662.
91. Goluch ED, Shaw AW, Sligar SG, Liu C. Microfluidic patterning of nanodisc lipid bilayers
and multiplexed analysis of protein interaction. Lab on a chip. 2008;8(10):1723-8. Epub
2008/09/25. doi: 10.1039/b806733c. PubMed PMID: 18813396.
92. Mitra N. Nanodiscs: Membrane Protein Research in Near-Native conditions. MATER
METHODS. 2013;3. Epub 03/14/2013. doi: http://dx.doi.org/10.13070/mm.en.3.177.
93. Denisov IG, Grinkova YV, Lazarides AA, Sligar SG. Directed self-assembly of monodisperse
phospholipid bilayer Nanodiscs with controlled size. J Am Chem Soc. 2004;126(11):347787. Epub 2004/03/18. doi: 10.1021/ja0393574. PubMed PMID: 15025475.
94. Li B, Cao Y, Zhou L, Liang C, Sun F. A novel protein expression system-PichiaPink™- and a
protocol for fast and efficient recombinant protein expression. African Journal of
Biotechnology. 2011;10(83). doi: 10.5897/ajb11.1513.
95. Cereghino GP, Cereghino JL, Ilgen C, Cregg JM. Production of recombinant proteins in
fermenter cultures of the yeast Pichia pastoris. Curr Opin Biotechnol. 2002;13(4):329-32.
Epub 2002/09/27. doi: 10.1016/s0958-1669(02)00330-0. PubMed PMID: 12323354.
96. Cereghino JL, Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia
pastoris. FEMS Microbiol Rev. 2000;24(1):45-66. Epub 2000/01/21. doi: 10.1111/j.15746976.2000.tb00532.x. PubMed PMID: 10640598.
97. Cregg JM, Cereghino JL, Shi J, Higgins DR. Recombinant protein expression in Pichia
pastoris. Mol Biotechnol. 2000;16(1):23-52. Epub 2000/12/01. doi: 10.1385/mb:16:1:23.
PubMed PMID: 11098467.
98. Invitrogen. PichiaPink Expression system - For high-level and large-scale expression and
secretion of bioactive revcombinant proteins in Pichia pastoris. User guide2014.
136

99. Invitrogen. Pichia Expression kit - For expression of recombinant proteins in Pichia pastoris.
User guide. 2014.
100. Brzobohatý B, Kovác L. Factors enhancing genetic transformation of intact yeast cells modify
cell wall porosity. J Gen Microbiol. 1986;132(11):3089-93. Epub 1986/11/01. doi:
10.1099/00221287-132-11-3089. PubMed PMID: 3040893.
101. Gietz RD, Woods RA. Genetic transformation of yeast. Biotechniques. 2001;30(4):816-20,
22-6, 28 passim. Epub 2001/04/21. doi: 10.2144/01304rv02. PubMed PMID: 11314265.
102. Kobayashi K, Kuwae S, Ohya T, Ohda T, Ohyama M, Ohi H, Tomomitsu K, Ohmura T.
High-level expression of recombinant human serum albumin from the methylotrophic yeast
Pichia pastoris with minimal protease production and activation. J Biosci Bioeng.
2000;89(1):55-61. Epub 2005/10/20. doi: 10.1016/s1389-1723(00)88050-0. PubMed
PMID: 16232698.
103. Thompson JR, Register E, Curotto J, Kurtz M, Kelly R. An improved protocol for the
preparation of yeast cells for transformation by electroporation. Yeast. 1998;14(6):565-71.
Epub
1998/05/30.
doi:
10.1002/(sici)1097-0061(19980430)14:6<565::aidyea251>3.0.co;2-b. PubMed PMID: 9605506.
104. Ohi H, Miura M, Hiramatsu R, Ohmura T. The positive and negative cis-acting elements for
methanol regulation in the Pichia pastoris AOX2 gene. Mol Gen Genet. 1994;243(5):48999. Epub 1994/06/03. doi: 10.1007/bf00284196. PubMed PMID: 8208240.
105. Koutz P, Davis GR, Stillman C, Barringer K, Cregg J, Thill G. Structural comparison of the
Pichia pastoris alcohol oxidase genes. Yeast. 1989;5(3):167-77. Epub 1989/05/01. doi:
10.1002/yea.320050306. PubMed PMID: 2660463.
106. Tschopp JF, Brust PF, Cregg JM, Stillman CA, Gingeras TR. Expression of the lacZ gene
from two methanol-regulated promoters in Pichia pastoris. Nucleic Acids Res.
1987;15(9):3859-76. Epub 1987/05/11. doi: 10.1093/nar/15.9.3859. PubMed PMID:
3108861; PMCID: PMC340787.
107. Gedvilaite A, Sasnauskas K. Control of the expression of the ADE2 gene of the yeast
Saccharomyces cerevisiae. Current genetics. 1994;25(6):475-9. Epub 1994/06/01. PubMed
PMID: 8082196.
108. Som I, Mitsch RN, Urbanowski JL, Rolfes RJ. DNA-bound Bas1 recruits Pho2 to activate
ADE genes in Saccharomyces cerevisiae. Eukaryotic cell. 2005;4(10):1725-35. Epub
2005/10/11. doi: 10.1128/ec.4.10.1725-1735.2005. PubMed PMID: 16215179; PMCID:
PMC1265903.
109. Stotz A, Muller PP, Linder P. Regulation of the ADE2 gene from Saccharomyces cerevisiae.
Current genetics. 1993;24(6):472-80. Epub 1993/12/01. PubMed PMID: 8299166.
110. Jones EW, Fink GR. Regulation of amino acid and nucleotide biosynthesis in Yeast. The
Molecular Biology of the Yeast Saccharomyces: Metabolism and Gene Expression.
1982:181-299.
111. Zonneveld BJ, van der Zanden AL. The red ade mutants of Kluyveromyces lactis and their
classification by complementation with cloned ADE1 or ADE2 genes from Saccharomyces
cerevisiae. Yeast. 1995;11(9):823-7. Epub 1995/07/01. doi: 10.1002/yea.320110904.
PubMed PMID: 7483846.
112. Gleeson MA, White CE, Meininger DP, Komives EA. Generation of protease-deficient
strains and their use in heterologous protein expression. Methods Mol Biol. 1998;103:8194. Epub 1998/07/29. doi: 10.1385/0-89603-421-6:81. PubMed PMID: 9680635.

137

113. Cregg JM, Barringer KJ, Hessler AY, Madden KR. Pichia pastoris as a host system for
transformations. Mol Cell Biol. 1985;5(12):3376-85. Epub 1985/12/01. doi:
10.1128/mcb.5.12.3376-3385.1985. PubMed PMID: 3915774; PMCID: PMC369166.
114. Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA, 3rd, Smith HO. Enzymatic
assembly of DNA molecules up to several hundred kilobases. Nature methods.
2009;6(5):343-5. Epub 2009/04/14. doi: 10.1038/nmeth.1318. PubMed PMID: 19363495.
115. company E-aI. CopyCutter™ EPI400™ Electrocompetent E. coli, CopyCutter™ EPI400™
Chemically Competent E. coli, CopyCutter™ Induction Solution. User guide. 2012.
116. Lõoke M, Kristjuhan K, Kristjuhan A. Extraction of genomic DNA from yeasts for PCRbased applications. Biotechniques. 2011;50(5):325-8. Epub 2011/05/10. doi:
10.2144/000113672. PubMed PMID: 21548894; PMCID: PMC3182553.
117. Lee AG. How lipids affect the activities of integral membrane proteins. Biochim Biophys
Acta. 2004;1666(1-2):62-87. Epub 2004/11/03. doi: 10.1016/j.bbamem.2004.05.012.
PubMed PMID: 15519309.
118. Society AC. Cancer Facts and Figures 2021.
119. Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three decades of P-gp inhibitors:
skimming through several generations and scaffolds. Curr Med Chem. 2012;19(13):19462025. doi: 10.2174/092986712800167392. PubMed PMID: 22257057.
120. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG. Interaction of
cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther.
2002;303(1):323-32. doi: 10.1124/jpet.102.037549. PubMed PMID: 12235267.
121. Orlowski S, Mir LM, Belehradek J, Jr., Garrigos M. Effects of steroids and verapamil on Pglycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and
verapamil are mutually non-exclusive modulators. Biochem J. 1996;317 ( Pt 2)(Pt 2):51522. doi: 10.1042/bj3170515. PubMed PMID: 8713080; PMCID: PMC1217517.
122. Sachs CW, Safa AR, Harrison SD, Fine RL. Partial inhibition of multidrug resistance by
safingol is independent of modulation of P-glycoprotein substrate activities and correlated
with inhibition of protein kinase C. J Biol Chem. 1995;270(44):26639-48. doi:
10.1074/jbc.270.44.26639. PubMed PMID: 7592889.
123. Loo TW, Bartlett MC, Detty MR, Clarke DM. The ATPase activity of the P-glycoprotein
drug pump is highly activated when the N-terminal and central regions of the nucleotidebinding domains are linked closely together. J Biol Chem. 2012;287(32):26806-16. Epub
20120614. doi: 10.1074/jbc.M112.376202. PubMed PMID: 22700974; PMCID:
PMC3411018.
124. Chen G. "Mechanistic Studies of Drug-Like Inhibitors of P-glycoprotein Using ATPase
Assays, Electron Spin Resonance Spectroscopy and Cancer Cell Models" Biological
Sciences Thesis and Dissertations 102021.
125. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug
resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A.
1998;95(26):15665-70. doi: 10.1073/pnas.95.26.15665. PubMed PMID: 9861027; PMCID:
PMC28101.
126. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placentaspecific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in
multidrug resistance. Cancer Res. 1998;58(23):5337-9. PubMed PMID: 9850061.
127. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB. The
expression and functional characterization of ABCG2 in brain endothelial cells and vessels.
138

Faseb j. 2003;17(14):2085-7. Epub 20030904. doi: 10.1096/fj.02-1131fje. PubMed PMID:
12958161.
128. Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J. Distribution of breast cancer
resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem
Pharmacol. 2005;70(5):695-9. doi: 10.1016/j.bcp.2005.05.031. PubMed PMID: 15998509.
129. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH,
van De Vijver MJ, Scheper RJ, Schellens JH. Subcellular localization and distribution of
the breast cancer resistance protein transporter in normal human tissues. Cancer Res.
2001;61(8):3458-64. PubMed PMID: 11309308.
130. Woodward OM, Köttgen A, Coresh J, Boerwinkle E, Guggino WB, Köttgen M. Identification
of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc
Natl Acad Sci U S A. 2009;106(25):10338-42. Epub 20090608. doi:
10.1073/pnas.0901249106. PubMed PMID: 19506252; PMCID: PMC2700910.
131. Cooray HC, Blackmore CG, Maskell L, Barrand MA. Localisation of breast cancer resistance
protein in microvessel endothelium of human brain. Neuroreport. 2002;13(16):2059-63.
doi: 10.1097/00001756-200211150-00014. PubMed PMID: 12438926.
132. Garg P, Dhakne R, Belekar V. Role of breast cancer resistance protein (BCRP) as active
efflux transporter on blood-brain barrier (BBB) permeability. Mol Divers. 2015;19(1):16372. Epub 20141214. doi: 10.1007/s11030-014-9562-2. PubMed PMID: 25502234.
133. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y. Estrone and 17beta-estradiol
reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res.
2002;93(3):231-5. doi: 10.1111/j.1349-7006.2002.tb02162.x. PubMed PMID: 11927002;
PMCID: PMC5926974.
134. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW. Sterol transport by
the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol
Chem. 2003;278(23):20645-51. Epub 20030328. doi: 10.1074/jbc.M301358200. PubMed
PMID: 12668685.
135. Tanaka Y, Slitt AL, Leazer TM, Maher JM, Klaassen CD. Tissue distribution and hormonal
regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem
Biophys Res Commun. 2005;326(1):181-7. doi: 10.1016/j.bbrc.2004.11.012. PubMed
PMID: 15567169.
136. Wang H, Zhou L, Gupta A, Vethanayagam RR, Zhang Y, Unadkat JD, Mao Q. Regulation
of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental
BeWo cells. Am J Physiol Endocrinol Metab. 2006;290(5):E798-807. Epub 20051213. doi:
10.1152/ajpendo.00397.2005. PubMed PMID: 16352672.
137. Telbisz Á, Hegedüs C, Váradi A, Sarkadi B, Özvegy-Laczka C. Regulation of the function of
the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations
in potential substrate and steroid binding sites. Drug Metab Dispos. 2014;42(4):575-85.
Epub 20140102. doi: 10.1124/dmd.113.055731. PubMed PMID: 24384916; PMCID:
PMC3965895.
138. Jani M, Ambrus C, Magnan R, Jakab KT, Beéry E, Zolnerciks JK, Krajcsi P. Structure and
function of BCRP, a broad specificity transporter of xenobiotics and endobiotics. Arch
Toxicol. 2014;88(6):1205-48. Epub 20140429. doi: 10.1007/s00204-014-1224-8. PubMed
PMID: 24777822.

139

139. Nakanishi T, Ross DD. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug
resistance and regulation of its gene expression. Chin J Cancer. 2012;31(2):73-99. Epub
20111118. doi: 10.5732/cjc.011.10320. PubMed PMID: 22098950; PMCID: PMC3777471.
140. Doyle L, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein
BCRP (ABCG2). Oncogene. 2003;22(47):7340-58. doi: 10.1038/sj.onc.1206938. PubMed
PMID: 14576842.
141. Manolaridis I, Jackson SM, Taylor NMI, Kowal J, Stahlberg H, Locher KP. Cryo-EM
structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states.
Nature. 2018;563(7731):426-30. Epub 20181107. doi: 10.1038/s41586-018-0680-3.
PubMed PMID: 30405239; PMCID: PMC6379061.
142. Eckenstaler R, Benndorf RA. 3D structure of the transporter ABCG2-What's new? Br J
Pharmacol. 2020;177(7):1485-96. Epub 20200211. doi: 10.1111/bph.14991. PubMed
PMID: 31985041; PMCID: PMC7060357.
143. Xu J, Liu Y, Yang Y, Bates S, Zhang JT. Characterization of oligomeric human half-ABC
transporter ATP-binding cassette G2. J Biol Chem. 2004;279(19):19781-9. Epub 20040304.
doi: 10.1074/jbc.M310785200. PubMed PMID: 15001581.
144. Henriksen U, Fog JU, Litman T, Gether U. Identification of intra- and intermolecular disulfide
bridges in the multidrug resistance transporter ABCG2. J Biol Chem. 2005;280(44):3692634. Epub 20050817. doi: 10.1074/jbc.M502937200. PubMed PMID: 16107343.
145. Kage K, Fujita T, Sugimoto Y. Role of Cys-603 in dimer/oligomer formation of the breast
cancer resistance protein BCRP/ABCG2. Cancer Sci. 2005;96(12):866-72. doi:
10.1111/j.1349-7006.2005.00126.x. PubMed PMID: 16367905.
146. Mao Q, Conseil G, Gupta A, Cole SP, Unadkat JD. Functional expression of the human breast
cancer resistance protein in Pichia pastoris. Biochem Biophys Res Commun.
2004;320(3):730-7. doi: 10.1016/j.bbrc.2004.06.012. PubMed PMID: 15240109.
147. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient
Hoechst 33342 efflux pump and is preferentially expressed by immature human
hematopoietic progenitors. Blood. 2002;99(2):507-12. doi: 10.1182/blood.v99.2.507.
PubMed PMID: 11781231.
148. McDevitt CA, Collins R, Kerr ID, Callaghan R. Purification and structural analyses of
ABCG2. Adv Drug Deliv Rev. 2009;61(1):57-65. Epub 20081213. doi:
10.1016/j.addr.2008.07.004. PubMed PMID: 19124053.
149. McDevitt CA, Collins RF, Conway M, Modok S, Storm J, Kerr ID, Ford RC, Callaghan R.
Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2.
Structure. 2006;14(11):1623-32. doi: 10.1016/j.str.2006.08.014. PubMed PMID: 17098188.
150. Pozza A, Pérez-Victoria JM, Di Pietro A. Overexpression of homogeneous and active
ABCG2 in insect cells. Protein Expr Purif. 2009;63(2):75-83. Epub 20081021. doi:
10.1016/j.pep.2008.09.021. PubMed PMID: 18977303.
151. Dezi M, Fribourg PF, Di Cicco A, Arnaud O, Marco S, Falson P, Di Pietro A, Lévy D. The
multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective
extraction from membranes. Biochim Biophys Acta. 2010;1798(11):2094-101. Epub
20100804. doi: 10.1016/j.bbamem.2010.07.034. PubMed PMID: 20691149.
152. Telbisz Á, Özvegy-Laczka C, Hegedűs T, Váradi A, Sarkadi B. Effects of the lipid
environment, cholesterol and bile acids on the function of the purified and reconstituted
human ABCG2 protein. Biochem J. 2013;450(2):387-95. doi: 10.1042/bj20121485.
PubMed PMID: 23205634.
140

153. Ozvegy-Laczka C, Köblös G, Sarkadi B, Váradi A. Single amino acid (482) variants of the
ABCG2 multidrug transporter: major differences in transport capacity and substrate
recognition.
Biochim
Biophys
Acta.
2005;1668(1):53-63.
doi:
10.1016/j.bbamem.2004.11.005. PubMed PMID: 15670731.
154. Kannan P, Telu S, Shukla S, Ambudkar SV, Pike VW, Halldin C, Gottesman MM, Innis RB,
Hall MD. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an
inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci.
2011;2(2):82-9. Epub 20101021. doi: 10.1021/cn100078a. PubMed PMID: 22778859;
PMCID: PMC3369725.

141

